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1. INTRODUCTION 
For many decades treatment of an acute disease or a chronic illness has been 
mostly accomplished by delivery of drugs to patients using various pharmaceutical 
dosage forms, including tablets, capsules, pills, suppositories, creams, ointments, 
liquids, aerosols and injectables as drug carriers. Even these conventional drug 
delivery systems are the primary pharmaceutical products commonly seen in the 
prescription and over- the - counter drug market place, they known to provide a 
prompt release of drug. Therefore to achieve as well as to maintain the drug 
concentration within the therapeutically effective range needed for treatment, it is 
often necessary to take this type of drug delivery system several times a day.
1
 
Limitations associated with conventional dosage form:
2
 
 Poor patient compliance – increased chances of missing the dose of a drug 
with short half- life for which frequent administration is necessary. 
 A typical peak – valley plasma concentration-time profile is obtained which 
makes attainment of steady-state condition difficult. 
 The unavoidable fluctuations in the drug concentration may lead to under –
medication or over- medication as the Css values fall are rise beyond the 
therapeutic range. 
 The fluctuating drug levels may lead to precipitation of adverse – effects 
especially of a drug with small therapeutic index whenever over-medication 
occurs. 
In recent years to solve the above mentioned limitations considerable attention 
has been focused on the development of new techniques and drug delivery systems.
3 
These are capable of controlling the rate of drug delivery, sustaining the duration of 
therapeutic activity and targeting the delivery of drug to tissue.
1 
 
1.1. CONTROLLED RELEASE SYSTEMS 
Controlled release systems provide drug release in an amount sufficient to 
maintain the therapeutic drug level over extended period of time with the release 
profiles of predominantly controlled by the special technological construction and 
design of the system itself. The release of active constituent is therefore, ideally 
independent of exterior factors.
4 
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1.1.1. Advantages of controlled release preparations: 
The controlled release dosage form have the important advantages over 
conventional formulations have been summarizes as follows:
5,6,7,8.
 
 Decreased the intensity of adverse effects and toxicity for highly toxic 
substances. 
 Reduction of dosage frequency and extension of duration of activity for an 
equal level of active agent. 
 Protection against environmental degradation. 
 Increased convenience of use by conversion of liquid material into solids and 
flowable powders. 
 Control the release of active agents. 
 More uniform blood concentration and reduced fluctuation. 
 Decreased the cost of treatment as less active material is needed. 
1.1.2. Classification of controlled release systems: 
Controlled drug delivery system may be classified on the basis of their nature, 
mechanism of drug release and nature of the drug incorporation.
9 
Based on these the 
controlled release products that exist include:
4,9. 
 Diffusion controlled systems. 
o Matrix controlled systems. 
 Reservoir controlled systems. 
 Dissolution controlled systems. 
o Matrix dissolution controlled systems. 
o Reservoir dissolution controlled systems. 
 Dissolution and diffusion controlled release systems. 
 Erosion products. 
 Water penetration controlled systems. 
o Swelling controlled system. 
o Osmotic controlled system. 
 Drug` covalently linked to the polymer. 
 Ion exchange resin controlled release systems. 
 Responsive drug delivery systems. 
o Open loop systems. 
o Closed loop systems. 
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1.2 NOVEL DRUG DELIVERY SYSTEM 
The novel drug delivery systems are the carriers which maintain the drug 
concentration in therapeutic range for longer period of time and also, in addition, may 
deliver the content to the site of action if so desired as per requirements.
9 
1.2.1. Advantages of novel drug delivery system:
9 
 Optimum therapeutic drug concentration in the blood or in tissue may be 
maintained over a prolonged period of time. 
 Pre determined release rates for an extended period of time may be achieved. 
 Duration for short half-life drugs may be increased. 
 By targeting the site of action, side effects may be eliminated. 
 Frequent dosing and wastage of the drug may be reduced or excluded. 
 Better patient compliance may be ensured. 
1.2.2. Categories of novel drug delivery system:
10
 
 Sustained or controlled drug delivery systems. 
These drug delivery systems provide drug action at a predetermined rate by 
providing a prolonged or constant release, respectively at therapeutically 
effective levels in the circulation. 
 Localized drug delivery devices. 
These drug delivery devices provide drug action through spatial or temporal 
control of drug release in the vicinity of the target. 
 Rate programmed drug delivery systems. 
These systems provide drug action by manipulating the release of drug 
molecules by system design, which controls the molecular diffusion of drug 
molecule. 
 Targeted drug delivery systems. 
These systems provides the drug action by using carriers either for passive or 
active targeting or one based on self programmed approach, usually anchored 
with suitable sensory devices, which recognize their receptor at the target. 
1.3 TARGETED DRUG DELIVERY 
Targeted drug delivery implies for selective and effective localization of 
pharmacologically active moiety at pre-identified targets in the therapeutic 
concentration, while restricting its access to non-target normal cellular linings, thus 
minimizing toxic effects and maximizing therapeutic index.
10
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The objective of drug targeting is to achieve a desired pharmacological response at a 
selected site without undesirable interaction at other sites.
 10
 
1.3.1. Rationale of drug targeting:
 10.
 
 The site specific targeted drug delivery negotiates an exclusive delivery to 
specific pre-identified compartments with maximum intrinsic activity of drugs 
and concomitantly reduced access of irrelevant non-target cells. 
 The targeted delivery to previously in-accessible domains, e.g., intracellular 
sites, virus, bacteria and parasites offers distinctive therapeutic benefits. 
 The controlled rate and mode of delivery to pharmacological receptor and 
specific binding with target cells; as well as bioenvironmental protection of the 
drug en route to the site of action are specific features of targeting. 
 Contributes to higher drug concentration at the site of action and resultant lower 
concentration at non target tissue where toxicity might crop-up. 
 The high drug concentration at the target site is a result of the relative cellular 
uptake of the drug vesicle, liberation of drug and efflux of free drug from the 
target site. 
At present drug targeting is achieved by one of two approaches, to direct the drug 
to its site of action.
3
 
1. Chemical modification of the parent compound to a derivative which is 
activated only at the target site. 
2. Utilizes carriers such as liposomes, microspheres, nanoparticles, antibodies, 
cellular carriers, macromolecules. 
1.3.1.1 Chemical modification: 
There are a variety of strategies to modify the chemical structure of drug molecules, 
they are: 
 Prodrug approach 
A prodrug is an inactive chemical derivative of a parent compound that is 
activated predictably in vivo to the active drug species.
3 
They are designed to 
maximize the amount of active drug that reaches the site of action, through 
manipulation of physicochemical, biopharmaceutical or pharmacokinetic 
properties of the drug.
8 
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 Chemical delivery system approaches. 
These approaches signify the systematic techniques that incorporate structure–
activity along with structure–metabolism rapports and are intended to design 
harmless, locally active composites with a superior therapeutic index.
12
 
1.3.1.2 Carriers: 
Carriers are drug vectors, which sequester, transport and retain drug en route 
while elute or deliver it within or in the vicinity of target.
10 
An ideal drug carrier 
engineered as a targetable device should have the following features:
 10.
 
 It must be able to cross anatomical barriers. 
 It must be recognized specifically and selectively by the target cells and must 
maintain the avidity and specificity of the surface ligands. 
 The linkage of the drug and the directing unit should be stable in plasma, 
intestinal and other biofluids. 
 Carrier should be non toxic, non immunogenic and biodegradable particulate or 
macromolecule and after recognition and internalization, the carrier system 
should release the drug moiety inside the target organs, tissue or cells. 
 The biomolecule used for carrier navigation and site recognition should not be 
ubiquitous otherwise it may cross over the sites, defeating the concept of 
targeting. 
Types of carriers in targeted drug delivery: 
Several carriers appended as pilot molecules to selectively deliver the drug to 
the intended cell lines have been reported (table: 1.3.1).
10 
Table: 1.3.1.Carriers in targeted drug delivery 
Types of carriers Examples 
Colloidal Carriers 
 
Vesicular systems 
Liposomes, niosomes, 
pharmacosomes,virosomes, 
immunoliposomes. 
Microparticulate 
systems 
Microparticles, nano particles, magnetic 
microspheres, albumin 
microspheres,nanocapsules. 
Cellular carriers 
Resealed erythrocytes, serum albumin, 
antibodies, platelets, leukocytes. 
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Supramolecular 
delivery   systems 
Micelles, reverse micelles, mixed 
micelles, polymeric micelles, liquid 
crystals, lipoproteins. 
Synthetic LDL mimicking particles. 
Polymer based systems 
Signal sensitive, muco-adhesive, 
biodegradable, bioerodible, soluble 
synthetic polymeric carriers. 
Macromolecular carriers 
Proteins, glycoproteins, neo glycoproteins 
and artificial viral envelopes. 
Glycosylated water soluble polymers 
(poly-L-lysine) 
Mabs, immunological Fab fragments, 
antibody enzyme complex and bispecific 
Abs. 
Toxins, immunotoxin and rCD4 toxin 
conjugates. 
Lectins and polysaccharides. 
 
Based on the nature of the origin of carrier they are categorized as,
 10
 
a. Endogenous: Low density lipoprotein, high density lipoprotein, chylomicrons, 
serum albumin, erythrocytes. 
b. Exogenous: Microparticulates, soluble polymeric and biodegradable polymeric 
drug carriers. 
1.3.2. Levels of drug targeting:
 10
 
The various approaches of vectoring the drug to the target site can be broadly 
classified as: 
 Passive targeting 
 Inverse targeting 
 Active targeting 
 Dual targeting 
 Double targeting 
 Combination targeting 
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1.3.2.1. Passive targeting:
 9,10
 
Passive targeting occurs because of the body’s natural response to the 
physiochemical characteristics of the drug or drug –carrier system. It is a sort of 
passive process that utilizes the natural course of biodistribution of the carrier system; 
through which it eventually accumulate in the organ compartments of body. This 
sensing behavior is exploited to target macrophage associated diseased cell lines are 
shown in the table 1.3.2. 
Table: 1.3.2. Passive hepatic targeting for macrophage associated diseases. 
Drugs proposed for encapsulation Macrophage associated infected cell lines 
Antimalarial and anti-infective Leishmaniasis, brucellosis,  
Antifungal (Amphotericin B) Candidiasis, intracellular fungal infection, 
histoplasmosis, systemic mycoses 
Cytotoxic drug Histiocytes medullar reticulosis, monocyte 
and hairy cell leukemia, hodgkin’s disease. 
Antiviral drugs Viral infected diseases, hepatitis 
Glucocerebroside and other 
enzymes 
Enzyme storage diseases, gaucher’s disease, 
mucoliposes type II&III 
 
1.3.2.2. Inverse targeting: 
Inverse targeting is a result of the avoidance of passive uptake of colloidal 
carriers by the reticuloendothelial system. This process leads to the reversion of bio 
distribution trend of carrier and hence the process is referred to as inverse 
targeting.
10,13
. 
The possible strategies applied to achieve inverse targeting are,
10
 
a. Suppress the function of reticuloendothelial system by a pre injection of a large 
amount of blank colloidal carriers or macromolecules like dextran sulphate. 
b. Modification of the size, surface charge, composition, surface rigidity and 
hydrophilicity of carriers for desirable biofate. 
1.3.2.3. Active targeting: 
Active targeting refers to alteration of the natural disposition of the drug 
carriers directing it to specific cells, tissue or organs.
13  
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The natural distribution pattern of the drug carrier composites is enhanced 
using chemical, biological and physical means, so that it approaches and identified by 
particular biosites.
 10
 
The active targeting can be achieved by ligand mediated targeting and 
physical targeting. 
1.3.2.3.1.Ligand mediated active targeting: 
All the carrier systems, explored so far, in general are colloidal in nature. They 
can be specifically functionalized using various biologically relevant molecular 
ligands including antibodies, polypeptides, oligosaccharides, viral proteins and 
fusogenic residues. The ligands afford specific avidity to drug carrier. The engineered 
carrier constructs selectively deliver the drug to the cell or group of cells generally 
referred to as target.
10 
1.3.2.3.2. Physical targeting (Triggered Release): 
The selective drug delivery programmed and monitored at the external level 
(ex vivo) with the help of physical means is referred to as physical targeting. In this 
mode of targeting some characteristics of the bioenvironment are used either to direct 
the carrier to a particular location or to cause selective release of its contents.
10
Active 
targeting can affected at different levels and accordingly refered to as first order 
targeting(organ compartmentalization), second order targeting (celluar targeting) and 
third order targeting(intracellular  organelles targeting).
 13
 
First order targeting: 
It refers to DDS that restrictedly delivers the drug to capillary bed or active 
site.
13
 Compartmental targeting in lymphatics, peritoneal cavity, plural cavity, 
cerebral ventricles, lungs, joints, eyes etc. represents first order targeting.
 10
 
The ability of liposomes to extravasate and penetrate into diseased states other than 
mononuclear phagocyte system (MPS) is directly related to their size. 
10
 
 Large liposomes (10µ or above) are rapidly removed via mechanical filtration 
of lungs. 
 The size ranges from 10µ to 150 nm are removed by tissue macrophages 
originated in the liver and spleen, which are the natural target for these vesicles. 
 Liposomes of smaller (≤100 nm) with a homogenous distribution have been 
developed to achieve significant levels in other tissues. 
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Second order targeting: 
The selective delivery of drugs to a special cell type not to the normal cells is 
referred as second order drug targeting.
 10,13.
 
Third order targeting: 
The third order targeting is defined as drug delivery specifically to the 
intracellular site of target cells.
10,13.
 
1.3.2.4. Dual targeting: 
This classical approach of drug targeting employs carrier molecule which have 
their own intrinsic biological effect, thereby synergizing with the effect of the loaded 
active drug.
9
 
1.3.2.5. Double targeting: 
This combination of drug targeting is made between spatial control and 
temporal control of drug delivery.
9
 
The temporal control of drug delivery has been developed in terms of control 
drug release prior to the development of drug targeting. If spatial targeting combined 
with temporal control release results in an improved therapeutic index by the 
following two effects.
10
 
 If the drug release or activation is occurred locally at therapeutic sites, 
selectivity is increased by multiplication of the special selectivity with the local 
release/activation. 
 The improvement in the therapeutic index by a combination of a spatially 
selective delivery and a preferable release pattern for a drug, such as zero order 
release for a longer time period of the drugs. 
1.3.2.6. Combination targeting: 
These targeting systems are equipped with carriers, polymers and homing 
devices of molecular specificity that could provide a direct access to target site. 
Modification of proteins and peptides with natural polymers such as polysaccharides 
or synthetic polymers such as polyethylene glycol may alter their physical 
characteristics and favor targeting the specific compartment, organs or their tissues 
within the vasculature. Further vectorization of these modified proteins and peptides 
into vesicular or microparticulate carriers may take advantage of the intrinsic or 
inherited properties of carrier to achieve a site specific active targeting of 
encapsulated contents.
10 
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1.4 VESICULAR SYSTEM 
Vesicles are hollow colloidalelementsinwhichaconcentric dual layer fabricated 
by amphiphilicparticles. These amphiphilic molecules consist of a polar hydrophilic 
head group and an apolar hydrophobic tail. Due to their amphiphilic properties these 
molecules can form unilamellar or multilamellar vesicles. They are a helpful carrier 
for drug release of both hydrophobic medicaments, which unite with the lipid double 
layer and hydrophilic medicaments, which are enclosed in the internal aqueous 
region.
14,15
 
Encapsulation of medicaments in vesicular organization can be expected to 
prolong the availability of the medicaments in the systemic circulation and hence 
augment penetration into objective tissue and diminish toxicity.
16 
The constituents of vesicles influence their physicochemical properties such as 
their charge, elasticity, size, lamellarity, and thermodynamic phase. The vesicular 
construction can also be altered to afford controlled or sustained drug delivery for 
extended periods.
17 
The rationale for using vesicular drug delivery is manifold,
15
 
a. Vesicles might act as drug carriers to deliver entrapped drug molecules. 
b. Vesicles might act as penetration enhancers. 
c. Vesicles might serve as a depot for sustained release. 
d. Vesicles might serve as a rate limiting membrane barrier for the modulation of 
systemic absorption. 
e. The individual components of vesicles might have additional useful properties. 
f. Vesicles are biodegradable, minimally toxic and relatively nonimmunogenic. 
Vesicular drug transporters showing very hopeful role are listed as follows,
 
1. Liposomes 
2. Niosomes 
3. Virosomes 
4. Transferosomes 
5. Proteasomes 
6. Archaesome 
7. Sphingosomes 
8. Phamacosomes 
9. Ethosomes 
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1.4.1. Liposomes: 
 
Figure: 1.4.1. Structure of liposomes 
Liposomes are artificially prepared spherical microscopic vesicles composed 
of a bilayer of lipids with an aqueous cavity at their centre. These can be used as a 
vehicle for administration of nutrients and pharmaceutical drugs. The drug molecules 
can either be encapsulatd in aqueous space or intercalated into the lipid bilayer. They 
are composed of natural phospholipids and may also contain mixed lipid chains with 
surfactant properties.
18,19,20.
 
Liposomes form when the lipids are exposed to aqueous environment. Under 
appropriate lipid- to- water ratio and temperature, the lipids will arrange into bilayer 
vesicles.
21 
Liposomes were first described by British haematologist Dr Alec D Bangham 
FRS in 1961 (published 1964), at the Babraham Institute, in Cambridge.
22 
By 1970, 
their structure and physical chemical characteristics had led researchers in a number 
of fields to investigate the potential of liposomes as carriers of therapeutical active 
ingredients.
19 
Liposomes are able to carry both water soluble and lipophilic moieties, with 
the water soluble drugs being incorporated within the aqueous compartments and 
lipid-soluble drugs incorporated within the bilayer. In addition, some drugs and 
molecules can be adsorbed onto the surface of the liposomes through electrostatic 
interactions, e.g. nucleic acid and many proteins are anionic in nature and can be 
electrostatically bound to the surface of the cationic liposome.
21 
Liposomes can be formulated in a range of diameters from around 30 nm up to 
several micrometers, therefore they can be considered as nanotechnology.
21 
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1.4.1.1.Advantages of liposomes:
22,23,24. 
 Liposomes are biocompatible, completely biodegradable, non-toxic in nature.  
 It reduces exposure of sensitive tissue to toxic drugs. 
 Increased stability and they protect the encapsulated drug from external 
environment.  
 They are suitable for delivery of hydrophobic, amphipathic and hydrophilic 
drugs without chemical modification. 
 They reduce toxicity and reduce deleterious effects that are observed at 
concentration similar to or lower than those required for maximum therapeutic 
activity.  
 Liposome encapsulated drug are delivered intact to various tissues and cells and 
can be released when liposome is destroyed, enabling site specific and targeted 
drug delivery. 
1.4.1.2.Structural Composition: 
There are number of components for liposomes however phospholipids and 
cholesterol are considered the most important primary materials for liposome 
vesicular delivery systems.
19,20. 
Phospholipids: 
In liposome formulation phospholipids are major principle component of the 
biological membranes. Some commonly used phospholipids for preparing liposomes 
are from natural and synthetic origin. 
Example:
8 
Natural phospholipids: phosphatidyl choline, phosphatidyl ethanolamine, 
phosphotidyl serine. 
Synthetic phospholipids: dioleoyl phosphatidylcholine, distearoyl 
phosphatidylcholine, dioleoyl phosphatidyl ethanolamine and distearoylphosphatidyl 
ethanolamine. 
Most clinically approved products use phosphatidyl cholines as the lipid 
within the formulation. It is used to give a structural framework in the liposome 
bilayers. By varying the structure of the lipid fatty acid tails the characteristics of the 
liposomes can be manipulated. By increasing the length of the carbon tails and the 
degree of saturation of the lipids the liposomes can be designed to have a more rigid 
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and less permeable bilayer. This is useful for improving drug retention and avoiding 
opsonization.
21
 
Cholesterols:
 
Cholesterol is also a common component o the liposome formulations. 
Incorporation of cholesterol in liposome bilayer brings about major changes in the 
preparation of these membranes. Cholesterol does not by itself form bilayer structure, 
but can be incorporated into phospholipid membranes in very high concentration upto 
1:1 or even 2:1 molar ratios of cholesterol to phosphotidyl choline. Cholesterol inserts 
into the membrane with its hydroxyl group oriented towards the aqueous surface and 
aliphatic chain aligned parallel to the acyl chains in the centre of the bilayer.
20 
The 
presence of cholesterol in the bilayer can reduce the bilayer permeability of the 
liposomes and thus impove drug retention within liposomes. This has been attributed 
to the ability of cholesterol to reduce the mobility of the phospholipids and improve 
lipid packing within the bilayer.
21
 
1.4.1.3. Classes of liposomes: 
Liposomes are classified based on their size and number of lamellae. 
Small unilamellar vesicles (SUV): 
8,21. 
 
Figure: 1.4.2.Structure ofSmall unilamellar vesicles 
 These are single bilayer vesicles, around 30 to 100 nm in size. 
 They are generally easier to prepare in homogenous size range compared to 
other types of vesicles and are most commonly used in clinically approved 
products. 
 Due to their small size there is low ratio of internal aqueous volume per mole of 
lipid. 
Large unilamellar vesicles (LUV):
8,21. 
 
Figure: 1.4.3. Structure of large unilamellar vesicles 
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 These are large single – bilayer vesicles of 100 nm and greater. 
 These vesicles offer a large aqueous compartment compared with SUVs 
Multilamellar vesicles (MLV):
8,21.
 
 
Figure: 1.4.4. Structure of multilamellar vesicles 
 These vesicles have multiple concentric bilayers and are 100 nm to several 
micrometers in size depending on their composition and their method of 
preparation. 
 Their low aqueous volume (due to multiple bilayers) reduces their capacity for 
carrying water- soluble dugs.   
Multivesicular vesicles (MVV):
 8,21. 
 
Figure:1.4.5. Structure of multivesicular vesicles 
 MVV are of similar size to MLVs, however rather than multiple concentric 
bilayers, they have vesicles within vesicles. 
1.4.1.4. Disadvantages of liposomes:  
 Less chemical stability.25,26 The phospholipids used are more prone to oxidative 
drgradation and hence they must be handled and stored in nitrogen atmosphere.
27
 
 The phospholipids used will interact with the serum components, the high 
density lipoprotein in particular.
 27
 
 High density lipoproteins remove phospholipid molecules from lipid bilayer 
structure, an event which allegedly leads to their destruction resulting in the 
leakage of the entrapped drugs.
 27
 
 The production cost is high 28 and there complex method for routine and large 
scale production.
 25,26.
 
 Leakage and fusion of encapsulated drug/molecules can occur. 28 
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  It has short half life-in reticuloendothelial system, particularly the kupffer cells 
in the liver remove liposomes from the circulation.
 28
 
 Difficulties in sterilization.25,26. 
 Degradation of liposome due to hydrolysis. 25,26. 
 Sedimentation, aggregation and fusion are possible during storage of 
liposome.
25,26.
 
1.4.2. Niosomes: 
 
Figure: 1.4.6. Structure of niosomes 
Niosomes are unilamellar or multilamellar microscopic vesicles, formed on 
admixtures of nonionic surfactant and cholesterol with subsequent hydration in 
aqueous media can entrap both hydrophilic and lipophilic drugs, either in aqueous 
region or in vesicular membrane made of lipid materials.
27,29,30
The noisome vesicles 
are  ranging from 10 to 1000 nm in size.
109
 
1.4.2.1. Advantages of niosomes: 
 Better stability than liposomes and it is a chemically stable alternative to 
liposome.
27,29.
 
 As compared to liposomes, about 50% of phospholipids can be replaced with 
nonionic surfactant in case of noisome preparation.
27
 
 It can prolong the circulation of entrapped drug and altering its organ 
distribution and metabolic stability.
27
 
 Flexibility in their structural constitution. 109 
 Reduce the systemic toxicity of many drugs.27 
 The handling and storage of the surfactants require no special conditions.27 
 Because of the presence of nonionic surfactant with the lipid, there is better 
targeting of drugs to tumour, liver and brain.
27
 
 It is very useful for targeting the drug for treating cancer, parasitic, viral and 
other microbial diseases effectively.
27
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 Liver can act as depot for many drugs where niosomes containing drugs may be 
taken up and broken down by lysosomal lipase slowly to release the free drug 
and re-enter the circulation. Hence niosomes are slowly degraded providing a 
more sustained effect.
27
 
1.4.2.2.Types of Niosomes: 
Based on the size: 
Niosomes can be characterized by their size distribution studies as follows, 
27 
Small niosomes: 100 nm to 200 nm.
 
 
Large niosomes: 800 nm to 900 nm.
 
 
Big niosomes: 2 µm – 4 µm.  
Based on the composition:
14
 
Many types of niosomes are mentioned in the literature including discomes, 
proniosomes, elasticniosomes and surfactant ethosomes. 
Proniosomes: 
Proniosomes are water soluble carrier particles containing dry niosomes,  
which  are hydrated immediately before use to yield an aqueous noisome dispersion. 
Surfactantethosomes: 
Surfactant ethosomes contain non ionic surfactants, a high concentration of 
ethanol or isopropyl alcohol and water. 
Elastic niosomes: 
Elastic niosomes are composed of nonionic surfactants, ethanol and water. 
Discomes: 
These are the large discoid structures, which exist under certain conditions of 
the phase diagram of nonionic surfactant vesicles. 
1.4.2.3.Methods of preparation: 
Niosomes can be formulated by following methods,
27,33,35
 
 Ether injection method. 
 Hand shaking method. 
 Reverse phase evaporation technique. 
 Trans membrane pH gradient method. 
 The Bubble Method. 
 Sonication. 
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 Microfluidization. 
 Enzymatic method. 
1.4.2.4. Disadvantages of niosomes:
 27
 
 Niosomes  are associated with problems related to physical stability such as 
fusion, aggregation, sedimentation and leakage on storage.
37
 
 Hydrolysis of encapsulated drugs which limiting the shelf life of the 
dispersion.
38
 
 Simple addition of aqueous phase to a dry powder of the nonionic surfactant is 
an inefficient and irreproducible method of making hydrated niosomes.
39
 
 The material tends to clump together and extensive agitation or other treatment 
is required to disperse the aggregates into a niosome suspension.
40
 
1.4.3. Virosomes: 
A virosome is a drug or vaccine delivery system consisting of unilamellar 
phospholipid membrane vesicle incorporating virus derived proteins to allow the 
virosomes to fuse with target cells. Virosomes are not able to replicate but are pure 
fusion-active vesicles.
41
 
1.4.4.Transferosomes: 
Transfersomes are a form of elastic or deformable artificial vesicle designed to 
be such as a cell vesicle vesicle, can carry water as well as fat-soluble agent. 
Transfersomes were first introduced in the early 1990s.
42 
1.4.5. Proteasomes: 
Proteasomes are cytoplasmic organelle, composed of a cylindric core particle 
bound by two regulatory particles at each end, responsible for degrading endogenous 
proteins. Proteins to be destroyed are recognized by proteasomes because of the 
presence of ubiquitin conjugated to the targeted protein's lysine residue.
43,44.
 
1.4.6. Sphingosomes: 
Sphingosomes is bilayered vesicles in which an aqueous volume is entirely 
enclosed by membrane lipid bilayer mainly composed of natural or synthetic 
sphingolipid.
145
 
1.4.7. Archaesome: 
Archaeosomes are liposomes made from the polar ether lipids of Archaea. 
These lipids are unique and distinct in structure from the ester lipids found in Eukarya 
and Bacteria.
 46
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1.4.8. Ethosomes: 
The ethosomes are vesicular carrier consisting of hydroalcoholic or 
hydro/alcoholic/glycolic phospholipids in which the concentration of alcohols or their 
combination is relatively high. The ethosomes may contain phospholipids with 
various chemical structures like phosphatidylcholine (PC), hydrogenated PC, 
phosphatidic acid (PA), phosphatidylserine (PS), phosphatidylethanolamine (PE), 
phosphatidylglycerol (PPG), phosphatidylinositol (PI), hydrogenated PC, alcohol 
(ethanol or isopropyl alcohol), water and propylene glycol (or other glycols).
47
 
1.4.9. Phamacosomes: 
Pharmacosomes are zwitterionic, amphiphilic, stoichiometric complexes of 
polyphenolic compounds with phospholipids. 
48 
1.4.10. Problems of vesicular system:
49
 
 High manufacturing cost. 
 Fusion and leakageof entrapped medicament from the vesicles. 
 Lowsolubility and short half life. 
 Less stability (physical and chemical instability). 
 Sometimes phospholipid undergoes oxidation and hydrolysis. 
1.5 PRONIOSOME 
Proniosomes are dry pharmaceutical formulation of water-soluble drug carrier 
substances that are encrusted with surface active agent and can be measured out as 
desired and hydrated to form niosomal suspension immediately prior to use on brief 
agitation in warm aqueous media within minutes.
50
 The resultant niosomes are very 
similar to conventional niosomes and more homogeneous in size.
51
 
1.5.1. Structure:
43 
 
Figure 1.5.1. Structure of proniosome derived niosomes 
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Proniosome formulations are minute lamellar arrangements of alkyl or dialkyl 
polyglycerolnon-ionic surfactant, cholesterol and hydrophilic carrier molecule. On 
hydrolysis they generate unilamellar or multi-lamellar noisome vesicles. In noisome 
vesicle hydrophilic ends of surfactant exposed towards outsideandhydrophobic chains 
face each otherwithin the bilayer.Therefore the noisome vesicle seizes hydrophilic 
drugs within the gap enfolded in the vesicle and the hydrophobic drugs are entrenched 
within the bilayer. 
1.5.2. Advantages of proniosomes:
49,52,53,54.
 
 Proniosomes have power for entrapping wide range of active pharmaceutical 
ingredients. 
 Superior in bioavailability. 
 Used for the targeted release of pharmaceutical substances. 
 Diminution in drug toxicity due to the nonionic character of the surfactant. 
 Used for sustained and controlled drug delivery system. 
 More stability while compared to niosomes.  
 Osmotically stable. 
 In release studies proniosome formulations appear to be alike to conventional 
noisome formulations. 
 The quantity of carrier necessary to hold up the surfactant could be simply 
adjusted. 
 Uses pharmaceutically acceptable solvents in the preparation. 
 Requires no extraordinary circumstances for storage and handling. 
 Economical whilecompared to niosomes. 
 Show improved purity than liposomes. 
 Uncomplicated to scale up as no long-lasting process is utilized.  
 Proniosomes are dry granules or powders, which makes additional processing 
and packaging feasible. 
 Ease for carrying, shipping,distribution, storing and dosing. 
 The powder formulationaffords best possible flexibility in unit dosing as tablets 
or capsules. 
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1.5.3. Comparison with niosomes:
55,56.
  
Table: 1.5.1. Comparison between proniosomes and niosomes 
S.No Niosomes Proniosomes 
1 
Niosomes are in aqueous 
solution 
Proniosomes are in dry 
condition, can be hydrated 
instantly before use. 
2 
Special equipments are 
necessary for 
manufacturing. 
Not require special 
equipments. 
3 
Less stable than 
proniosomes. 
More stable than niosomes. 
4 
Expensive formulation 
than proniosomes. 
Cheap as compared to 
niosomes. 
5 
Further processing and 
packing are difficulty. 
Further processing and 
packing are probable as it is 
dry powder. 
6 
Difficult to transportation, 
storage and dosing. 
Convenient to transportation, 
storage and dosing. 
 
1.5.4. Types of proniosomes: 
Based on the type of carrier utilized and the method of preparation, the 
proniosomes can be divided into two types.
43
 
1. Dry granular proniosome: 
 Sorbitol based proniosomes 
             Sorbitol based proniosome is a dried out formulation that consistsof sorbitol 
powder as a carrier.These are made by spraying surfactant mixture containing organic 
solvent onto the dried sorbitol powder along with evaporating the solvent.
36 
These can 
be bring into noisome within short moment of time by adding  hot water along with 
subsequent agitation.
43 
It is very useful for fear that the active ingredient is sensible to 
hydrolysis. 
 Maltodextrin based proniosomes: 
             Maltodextrin based proniosomes can be prepared by quick slurry method 
using maltodextrin as a carrier.It is a polysaccharide soluble in water and not as much 
of soluble in organic solvent. The higher surface area of maltodextrin leads to thinner 
surfactant covering, which makes the rehydration procedure more proficient.
59 
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2.Liquid crystalline proniosomes 
  These are semisolid liquid crystal proniosome gel formulated  by dissolving 
the surfactant, drug and lipid  in a smallest amount of pharmaceutically acceptable 
solvent like ethanol, furthermore hydrating with minimal amount of water to form a 
gel. These formulations are usually available as translucent, transparent or white 
semisolid gel texture. Also these are physically stable during transport as well as 
storage and used for the transdermal delivery of the drugs.
58. 
When the surfactant 
molecules are contact withwater, there are three following means  through which lipid 
soluble chains of surfactant can be changed into order less, liquid state called 
lyotropic liquid crystals. 
59,60.
 
 Rising temperature on kraft point (Tc),  
 Incorporation of solvent which liquefy lipids,  
 Use of both solvent and temperature. 
1.5.5 Composition of dry granular proniosomes: 
Dry granular proniosome formulation comprises of various ingredients such as 
drug, surfactants, carrier materials, membrane stabilizers and charge inducers.
25,36,49. 
Table :1.5.2. Composition of proniosome 
S.No. Ingredients Examples 
1 Surfactants 
Fatty alcohol – Oleyl alcohol, 
Cetostearyl alcohol, stearyl alcohol, 
Cetyl alcohol. Ehers – Nonoxynol-9,  
Octyl glucoside, Lauryl glucoside, 
Decyl glucoside, Brij,Triton X -100. 
Esters – Spans, Polysorbates, Glyceryl 
laurate. Black copolymers – 
Poloxamers.     
2 Carrier materials 
Sorbitol, Maltodextrin, Spray dried 
lactose, magnesium aluminium silicate, 
Mannitol, Sucrose stearate, 
microcrystalline cellulose, Glucose 
monohydrate, Lactose monohydrate. 
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1.5.5.1. Drug: 
Various classes of drugs selections for proniosomes formation based upon the 
below mentioned assumptions;
38,59. 
 Least aqueous solubility drugs. 
 High dosage frequency drugs. 
 Low half-life. 
 Suitable for Controlled drug delivery. 
 Drugs with more adverse drug reactions. 
1.5.5.2. Surfactants: 
Surfactants are the surface active components, generally organic composites 
that are amphiphilic in property. Therefore, a surfactant molecule includes both a 
lipophilic and a hydrophilic component.
59
 
The presence of variable length of ethylene oxide chains build the hydrophilic 
part of surfactants and long chain linear alcohols, fatty acids, alkylated phenol 
derivatives etc. assemble the hydrophobic portion of the surfactant.
25
 
The majority of non-ionic amphiphiles utilized for vesicle formation are 
shown in table 1.5.2. The selection of surfactant for proniosome formulation should 
be done on the basis of hydrophilc lipophilic balance, phase transition temperature, 
Chemical structure, critical packing parameter and solubility of drug.
32
 
The HLB value in between 4 and 8 are excellent candidates for noisome 
vesicle formation. Elevated HLB value diminishes the surface free energy and let 
vesicle formation of big size.
61 
Phase Transition Temperature of surfactantis an important parameter forthe 
entrapment efficiency of active pharmaceutical ingredient in vesicle. If the phase 
3 
Membrane 
stabilizers 
Cholesterol, Lecithin, mystryl alcohol. 
4 Charge inducers 
Dicetyl Phosphate, stearylamine, 
Solulan C24. 
5 
Hydration 
medium 
Phosphate buffer pH 7.4, Hot water 
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transition temperatureof surfactants enhance it leads to augment in the entrapment 
efficiency of drug and reduce in the permeability. 
62
 
Chemical structure of surfactants shows the impact on drug entrapment 
efficiency. Increasing the length of alkyl chain is leading to good entrapment 
efficiency. 
25
 
The geometry of proniosome derived vesicle to be formed by means of 
surfactants is affected by its critical packing parameters.It can be defined using 
subsequent equation. 
  Critical packing parameter (CPP) = Hydrophobic group volume/(Critical 
hydrophobic group lengthX area of hydrophilic head group).
60
 
A CPP between 0.5 and 1 specifies that the surfactant is liable to form vesicles. A 
CPP value below 0.5 point out a major role from the hydrophilic head group region 
and is said to offer spherical micelles and the value is above 1 indicates a large 
involvement from the hydrophobic group capacity should generate inverted 
micelles.
63
 
1.5.5.3. Carrier materials: 
Carrier used for proniosomes formulation should have the properties like non-
toxicity, free flowing ability, poor solubility in organic solvent and high aqueous 
solubility for uncomplicated hydration.
64 
The carriers used for the proniosome 
formulations are given in the table 1.5.2. The utility of maltodextrin in proniosomes 
allowed flexibility in the fraction of surfactant as well as other components which can 
be included.
54
 
1.5.5.4. Membrane stabilizers: 
Steroids are essential components of cell membrane and their occurrence in 
membrane brings about significance modification with regard to bilayer fluidity, 
stability, and permeability. Cholesterol is a naturally synthesizing steroid used as 
membrane stabilizer and it controls aggregation of molecules so as to stabilize the 
system against the generation of aggregate by electrostatic or repulsive steric effects. 
It leads conversion from the gel phase to liquid state in vesicular system.
59 
But 
addition of cholesterol away from a certain limit starts distracting the expected bi-
layered configuration leading to failure of drug entrapment.
17  
Phosphatidylcholine is a chief constituent of lecithin. It proceeds as membrane 
stabilizer in addition to penetration enhancer 
59 
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1.5.5.5. Charge inducers: 
Stearyl amine and dicetyl phosphate are charged lipids employed to impart 
charges on proniosome derived niosomal vesicles.
32 
Dicetyl phosphate impart 
negative charge and Stearylamine induces positive charge to vesicles.
25,61. 
Solutan 
C24 used to get homogeneous nature and reduces aggregates.
25 
1.5.6. Preparation methods of proniosomes: 
Proniosomal formulations may be formulated by following three methods,
17 
1. Slurry method.  
2. Slow spray coating method.  
3. Coacervation phase separation method. 
1.5.6.1.Slurry method: 
 
Figures 1.5.2: proniosome preparation by slurry method 
Almir and Blazek et al., 2001 developed this method to manufacture 
proniosomes utilizing  maltodextrin as acarrier. In this  method, the whole volume 
ofsurfactant and lipid mixture was added into the rotary evaporator containingdry 
maltodextrin and vacuum was applied till the content to be dry and free 
flowing.
36,65,66. 
1.5.6.2.Coacervation phase separation method: 
 
Figure1.5.3: Proniosome preparation by coacervation phase separation method 
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This is broadly adopted method to prepare proniosomal gel.Bhavana Vora 
et.al. 1998 developed this method for the transdermal delivery of proniosomal gel.
 
Exactlyweighed amounts oflipid, surfactantand drug were taken ina dry and clean 
broad mouthed glass vial of 5mlcapacity and added 0.5ml of alcohol to it. Subsequent 
to warming, all the contents are mixed properly with a glass rod. The open end of the 
bottle is covered by means of a lidto avoid the loss of solvent from it and heated 
overwater bath at 60as 70°C for about 5 min till the complete dissolution of 
surfactantmixture. Then the aqueous phase was incorporated and heated on a 
waterbath untill a clear solution was produced which was thenchanged into 
proniosomal gel on cooling.
31,67. 
1.5.6.3.Slow spray coating method: 
 
Figure 1.5.4: Proniosome preparation by slow spray coating method 
 
H u and Rhodes et al. formulated proniosomes by spraying the surfactant 
dissolved organicsolvent onto sorbitol powder followed by evaporatingthe 
solvent.Throughout the spraying phase, the speed of application should be controlled 
in order that the sorbitol powder bed does not turn into overly wet.This procedure has 
to be repeated till all of the surfactant mixture had been applied and the evaporation 
process should be continued till the powder becomes entirely dry.
57
 
1.5.7. Alteration of proniosomes into niosomes: 
The noisome vesicles can be got from the proniosomes via the addition the 
aqueous phasewith the proniosomes along with brief shaking at a temperature more 
than the transition phase temperature of the added surfactant (Temperature>mean 
phasetransition temperature).
31
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Figure 1.5.5: Alteration of proniosomes into niosomes 
 
1.5.8.Characterization of proniosomes: 
(1)Vesicle size determination and size distribution: 
a)  Malvern Mastersizer: 
The proniosomal formulations were hydrated with phosphate buffer 
and sonicated for 3 minutes using bath sonicator. The mean vesicle size, 
distribution of size and zeta potential of formulations were determined by 
photon correlation spectroscopy with Zetasizer Nano ZS90.
69,70. 
 b) Optical microscopy.
 
A drop of hydrated formulation was observed under optical 
microscope at 45X,
40
 100X
74
 magnification and 200-300 vesicles sizes were 
measured.
71,72 
(2)Shape and surface morphological characterization:  
a) Scanning electron microscopy:
 
One drop of reconstituted suspension of proniosomewas placed on 
clear glass slab,
73
 aluminum stub,
74
 air dried along with sputter-coated with 
palladium/gold  by means of a vacuum `evaporator  and observed using 
ascanning electron microscope fixed with a digital camera, at specified 
accelerating voltage.
40,52. 
b) Transmission electron microscopy: 
  A drop of reconstituted proniosome formulation was spread to a 
carbon-coated mesh copper grid and allowed to stick on the carbon substrate. 
The residual dispersion was cleaned by a bit of filter paper and stained with 
uranyl acetate followed by examined under the transmission electron 
microscope
74
. 
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(3) Aerodynamic behavior by twin-Stage Impinger: 
The aerodynamic behavior should be evaluated for the proniosome 
formulations to be used as aerosols using the twin-stage impinge (TSI). The 
formulation was filled into the nebulizer and its mouth piece was fixed to the TSI. By 
applying the vacuumaerodynamic behavior of the proniosomes were estimated by 
applying the formula.
75 
(4) Flow property: 
a) Angle of reposeby Funnel method: 
The angle of repose was determined by using usual fixed funnel 
method.Briefly, proniosome powder was poured into afunnel which was 
placed at a height of 2.5 cmfromblackhorizontalsurface. The powders were 
flowed down from the funnel to form a cone shape on the horizontal surface. 
The angle of repose was determined by measuring the elevationof the cone (h) 
and the diameter of its base (d). The angle of repose (ѳ) was calculated from 
the subsequent equation:Tan ѳ = 2h/d. 76,77 
b) Carr’s compressibility index and Hausner’s ratio: 
The Carr’s compressibility index and Hausner’s ratio were calculated 
from the bulk and tapped density of the proniosome powders.
78 
(5) Spontaneity:
 
Spontaneity of proniosomes formation is illustrated as number of niosomes 
generated following hydration of proniosomes. The small amount of formulation was 
shifted to the base of a little stoppered glass container and spread uniformly. One ml 
of phosphate saline was incorporated carefully through the walls of the container and 
set aside without agitation. Fifteen minutes later a drop of sample was withdrawn and 
mounted on Neubaur’s chamber. The numbers of vesicles eluted from proniosome 
formulations were counted. 
40,55,67,79. 
(6) Zeta potential determination by Zetasizer: 
Colloidal properties of formulation can be estimated by determining zeta 
potential.Diluted vesicle dispersion was transferred into quartz cuvettes and the zeta 
potential was measured by zeta sizer.  
(7) Separation of unentrapped drug: 
The removal of unencapsulated drug from the proniosome derived niosomes 
can be accomplished by diverse techniques, which include – 
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a) By centrifugation: 
The non-encapsulated active moiety was separated by centrifugation of 
the dispersion at 15,000 rpm at 4°C for one hour using a cooling centrifuge.  
The supernatant was separated and the residue was resuspended in saline. This 
procedure was repeated two times to ensure that unencapsulated drug was 
fully removed. 
68,75,82,83. 
b) Through Dialysis bag: 
The reconstituted proniosomes were placed in the dialysis bag and 
unentrapped API was dialyzed for half an hour in 100 ml of phosphate buffer 
saline. The dialysis of unentrapped drug was fulfilled after 12-15 changes.
76,84 
c) Through cellophane membrane attached glass tube: 
Free drug was removed from dispersion by placing 1ml of the 
niosomal dispersion into a cellophane membraneattached glass tube and 
dialyzed carefully for one hour every time against 100 ml of phosphate buffer 
until free drug was completely removed. 
85 
 d) Minicolumn centrifugation method using swollen sephadex: 
Sephadex G 50 was allowed to swell for 5 hours in water and 
carefullyadded into whatman filter padinserted1 ml syringe. Excessive water 
present in the columnwas removed by spinning at 300 rpm for 3 minutes using 
centrifuge to avoid air entrapment. The reconstituted formulation (100μl) was 
addedslowlyon the column along with centrifuged at 500 rpm for 3 minutes. 
Then this same process was repeated after adding 100μl of water and 
unentraped drug can be removed through triple washing along with 
centrifugation. 
86 
 
Figure1.5.6: Filter pad inserted minicolumn 
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(8) Determination of entrapment efficiency:  
The vesicles gained after the separation of unentrapped drug are fused by 
using suitable solvents and evaluated for drug content. The entrapmentefficiency 
percentage is calculated by the following formula, 
29,76 
Entrapment efficiency percent = (entrapped drug/theoretical drug concentration) X100 
 (9)Osmotic Shock: 
The consequence of osmotic shock on proniosome formulations derived 
noisomeswere evaluated by incubating of niosomal suspensions in media of diverse 
tonicities. The formulations were incubated with hypotonic (0.5%NaCl), isotonic 
(0.9%NaCl), and hypertonic solutions (1mol/L sodium iodide solution) for 3 hours. 
Then the changes in the vesicle size in the formulations were observed. 
83 
(10)In viro drug release from proniosomal vesicles: 
In vitro drug release studies for proniosome formulations are determined by 
various techniques like 
Franz diffusion cell: 
Cellophane membrane placed in between the donor and receptor compartment 
of diffusion cell. Phosphate buffer was filledin the receptor sector and maintained at 
37±1°C with constant stirring by using a magnetic bar at specified rpm. Weighed 
quantity of proniosome formulation was kept on the cellophane membrane and the top 
portion of the diffusion cell was closedwith paraffin paper. At fixed time intervals 
small volume of medium from receptor compartment were collected and instantly 
replaced withan equal volume of fresh medium to uphold the sink conditions. The 
samples were investigated by a validated spectrophotometric estimation method.  
40,71,73,87. 
 
Figure1.5.7: Franz diffusion cell 
 
CHAPTER 1                                                                                                                                    INTRODUCTION 
 
J.K.K.NATTRAJA COLLEGE OF PHARMACY Page 30 
 
Cellophane dialyzing membrane: 
One gram of proniosomal formulationwas placed on glass circular disk and 
cellophane dialyzing membrane was placed over it with the help of rubber band. The 
disk was mounted on the base of a glass tubeand 50 ml of phosphate buffer was 
transferred onto the membrane surface. The temperature was maintained to 37°C 
using water bath and the buffer solution was constantly circulated over the 
membranewith the help of peristaltic pump. The rate of drug release was monitored 
by utilizing monitoring system. 
52,87 
Dialysis bag:
 
The required size of dialysis bags was immersed in the aqueous solution for 12 
hours before use. Specified volume of reconstituted pronoisome suspension was taken 
into the dialysis bag and tied at both ends using thread. 
90
 The bag was then placed 
into the receptor and the release study was carried out.
74,88,89 
 
Figure1.5.8: Invitro release assembly by dialysis bag
 
USP Dissolution apparatus Type I: 
The proniosome formulation was placed in molecular porous membrane fixed 
glass cylindrical tubes and other end of the tube was attached with the USP 
Dissolution test apparatus in the place of basket. The dissolution study was carried out 
utilizing suitable medium and rpm at 37±0.5°C.
75 
USP Dissolution apparatus Type II : 
In vitro dissolution study can be performedfor proniosome formulations using 
USP type II apparatus with suitable medium and rpm at 37
0
C.
29,70,77,91,92 
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Keshary-Chien (K-C) : 
In vitro drug release study for proniosome formulation can be carried out 
using egg membrane mounted Keshary-Chien (K-C) cell by portioning donor and 
receptor compartment. The receptor sector was filled with suitable medium and the 
temperature was maintained at 37 ± 0.5°C with the aid of a circulating water bath. 
The samples from receptor sector were withdrawn at fixed interval and restored with 
same volume of buffer solution to preserve the sink conditions.  Samples were 
estimated spectrophotometrically with appropriate dilution.
91 
(11) Stability studies:  
ICH guidelines recommend that the stability studies for the dried proniosome 
formulationshould be evaluated at 40°C/75%RH for accelerated stability study as per 
international climatic zones and conditions. (WHO, 1996).Long term stability study 
can be carried out at 25°C/60% RH for zone I & II countries and 30°C/65% RH for 
the countries come under Zone III & IV.Product should be analysed for 
colour,appearance, drug content, pH, pyrogenicity  and sterility.
31 
1.5.9. Targeting mechanisms of proniosomes: 
Proniosomes can be administered through various routes and their mechanism 
of drug targeting are as follows; 
1.5.9.1. Target to reticulo-endothelial system:  
One of the incredible aspects of niosomesgained from proniosome is their 
capability to target drugs. Niosomes can be utilized to target active pharmaceutical 
ingredients to the reticulo-endothelial system. The reticulo-endothelial system 
favourably takes up vesicles.
93
  
1.5.9.2. Cellular uptake via endocytosis:  
Cellular uptake of niosomes takes place by endocytosis process. The vesicles 
bind and fuse with plasma membrane of the cells via cellular receptors while the 
vesicle surface charge is adequately negative.
93 
 
Figure1.5.9: Endocytosis of vesicles through plasma membrane of cell 
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1.5.9.3.Drug release by desorption and diffusion of vesicles: 
Release of drug from proniosome derived niosomal system may pursue any 
one or more of the subsequent mechanisms; diffusion of API from bilayered 
membrane or desorption from exterior of vesicles or  united diffusion and desorption 
mechanism.
31 
1.5.9.4.Drug transfer across duodenum:  
Proniosomes must be hydrated to produce niosomal vesicles prior to the drug 
is liberated and permeates across the cells of duodenum. Numerous mechanisms 
possibly will elucidate the capability of niosomes to adapt drug transfer through 
duodenum.Some of the mechanisms are adsorption and fusion of niosomal vesicles 
onto the duodenal surface would assist drug permeation, the noisome vesicles may 
behave as penetration enhancers to diminish the barrier characteristics of the 
absorption site and the lipid bilayers of vesicles may perform as a rate-limiting 
membrane like barrier for drugs.
94 
1.5.9.5. Drug transfer across the skin:  
The ability ofdrug transport across the skin could be explained by the 
mechanismsincluding, 
 As soon as vesicles get in contact with stratum corneum of skin, they begin to 
aggregate, fuse and adhere with the surface of stratum corneal cell due to an 
elevated thermodynamic action gradient of the API at the boundary of vesicle 
and stratum corneum.
61
  
 The vesicles act as permeation enhancers and decrease the barrier character of 
stratum corneum.
65
 
 The bilayers of niosomes work as rate limiting membrane barrier in between 
drugs and stratum corneum during transdermal delivery.
 65
 
 
1.6 VIRAL INFECTIONS 
The viruses when exists in extracellular state are called virons and they are 
metabolically inert and do not carry out replication. When viruses are entering 
intracellular state replication occurs and the process is called infection and the cell in 
which the virus replicate is called host cell. The host cell may be animal cell, plant 
cell or bacterial cell.
95 
More than 400 different viruses can infect humans.
96 
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Viruses are the cause of many clinically important acute and chronic 
infections affecting virtually every organ system.
97 
A few common and important 
viral infections are decribed below, 
1.6.1. Viral infections affecting respiratory tract: 
Upper and lower respiratory tract infections; diarrhea, conjunctivitis 
(Adenovirus); upper respiratory tract infection (Rhinovirus); influenza (Influenza 
viruses A, B); bronchitis, pneumonia (respiratory syncytial virus).
96,97 
1.6.2. Viral infections affecting digestive tract: 
Mumps, pancreatitis, orchitis (mumps virus); childhood gastroenteritis 
(rotavirus); gastroenteritis (norovirus); acute viral hepatitis (hepatitis A virus); acute 
or chronic hepatitis (hepatitis B virus,hepatitis C virus); with HBV acute or chronic 
hepatitis (hepatitis D virus); enterically transmitted hepatitis (hepatitis E virus).
96,97
 
1.6.3. Systemic viral infection with skin eruptions: 
Measles (measles virus); German measles (rubella virus); chicken pox 
(varicella-zoster virus); oral herpes (herpes simplex virus 1); genital herpes (herpes 
simplex virus 2). 
1.6.4. Systemic viral infection with hematopoietic disorders: 
Cytomegalic inclusion disease (cytomegalovirus); infectious mononucleosis 
(epstein-bar virus); AIDS (HIV-1, HIV-2).
 96,97 
1.6.5. Arboviral and hemorrhagic fevers: 
Dengue hemorrhagic fever (dengue virus); yellow fever (yellow fever virus).
 
96,97 
1.6.6. Skin and genital warts: 
Candyloma, cervical carcinoma (papillomavirus).
 96,97
 
1.6.7. Central nervous system: 
Poliomyelitis (poliovirus); progressive multifocal leukoencephalopathy (JC 
virus).
 96,97 
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1.7 ACQUIRD IMMUNE DEFICIENCY SYNDROME 
Acquird immune deficiency syndrome (AIDS) is the most common problem 
throughout the world because of rapid increase in the number of victims. Infection 
occurs when a glycoprotein from HIV binds to surface receptors of T lymphocytes, 
monocytes, macrophages and dendritic cells leading to destruction of these cells.
98
 
Immuno suppression leads to opportunistic infections, secondary neoplasms and 
neurologic manifestations.
97
 
Acquird immune deficiency syndrome (AIDS) was first recognized in USA 
in1981. HIV is an RNA retrovirus. Two forms are known. HIV-1 is the organism 
responsible for human AIDS. The HIV-2 organism is similar to the HIV-1 virus in 
that it also causes immune suppression, but it is less virulent. HIV-1 is distributed 
around the world, whereas the HIV-2 virus is confined to parts of Africa.
99
 
1.7.1. Structure: 
 
 
Figure1.6.1: Structure of HIV virus 
HIV- 1 virion is spherical and contains an electron dense, cone shaped core 
surrounded by a lipid envelope derived from the host cell membrane. The virus core 
contains capsid protein (p24), nucleocapsid protein p7/p9, two copies of genomic 
RNA, three viral enzymes (protease, reverse transcriptase & integrase). The viral core 
is surrounded by a matrix protein called p17, which lies underneath the virion 
envelope. Studding the viral envelope are two viral glycoproteins, gp 120 and gp 41, 
which are critical for HIV infection of cells.
97 
1.7.2. Infection and life cycle: 
After entering the body of the host, the HIV activates the enzyme called 
reverse transcriptase. The RNA genome of the virus undergoes reverse transcription, 
leading to the synthesis of double-stranded complementary DNA. Now the viral DNA 
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gets incorporated into the host cell DNA. At the same time, the HIV increases in 
number inside the host’s body. The infected host cell ruptures and releases more 
number of HIV into the blood stream. After exposure to HIV, no symptoms develop 
for several weeks. This is the incubation period. The patient develops symptoms only 
when sufficient number of infected cells is ruptured.  
The common symptoms are fatigue, loss of weight, chronic diarrhea, low 
grade fever, night sweats, oral ulcers, viginal ulcers, etc. This phase prolongs for 
about three years before the disease is diagnosed.
97,98 
1.7.3. Epidemiology of AIDS: 
The global situation is improving but even so, 
 By early 1989 more than 140000 AIDS cases had been officially reported to 
WHO from around the world.
95
 
 By the end of 2006 more than a million cases of AIDS had been reported in 
United States.
97
 
 In 2007, the world health organization estimated that almost 33 million people 
were living with AIDS, and that women and children constituted appoimately 
half that total number.
99
 
 During the same year, some 2 million people died of the disease (including 
0.27) million children under 15 years), and there were a further 2.7 million 
new cases of AIDS infection reported.
99
 
 As per UNAIDS Global report 2013, an estimated 35million people are living 
with AIDS globally, out of which 50% are women and 3.3 million children 
under 15 years of age. 
1.7.4. Mode and patterns of transmission: 
The HIV infection spreads when the secretions from the body of infected 
individual come in contact with the blood of the recipient through the damaged skin 
or mucus membrane.
98
 The most common route of transmission are sexual contact 
(80%), parenteral inoculation including IV drug users (15%), transmission from 
mother to fetus during pregnancy, transmission from mother to child during delivery 
or breast feeding (3%)  and other accidental(2%).
95,96 
1.7.5. Opportunistic infection: 
  Infections caused due to weakness of immune system are called opportunistic 
infection
. 
Opportunistic infections underscore deficient cell mediated immunity of the 
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host, as they are only rarely seen in immunocompetent patients. 80% of AIDS patients 
die as a result of an infection other than HIV, with bacterial infections heading the 
list. The clinical spectrum of diseases caused by opportunistic infections is constantly 
changing as patients live longer and as new and better approaches to treatment and 
prophylaxis are developed. 
100
 
The following are some of the important opportunistic diseases. 
Fungal: Candidiasis, cryptococcosis, coccidiodomycosis, hitoplasmosis, 
nocardia. 
Viral: Cytomegalovirus, herpes simplex 1and 2, herpes zoster, EBV, HPV. 
Bacterial: Mycobacterioisis, M.tuberculosis, M.avium- intracellulare, 
nocardiosis, salmonellosis. 
Protozoal and helminthic: Pneumocystis carinii, toxoplasmosis, giardiasis, 
amoebiaisis, cryptosporidiosis, strongyloidosis. 
1.7.6. HIV Testing: 
The  investigations  of  a  suspected  case  for  of  AIDS  are  categorized  into  
3  groups, they are
101
 
1. Tests for  establishing  HIV  infection. 
2. Tests for  defects  in  immunity. 
3. Tests  for  detection  of  opportunistic  infections  and   secondary  tumours. 
1.7.6.1. Tests for  establishing  HIV  infection:
102
 
1.7.6.1.1. Indirect tests (Detection of anti-HIV antibodies): 
Screening tests: Agglutination assays, DOT BLOT assay/Comb test,ELISA. 
Supplemental tests for confirmation: 
Western Blot; Line immunoassay; Indirect fluorescent antibody (IFA); 
Radioimmunoprecipitation (RIPA) test; Recombinant immunoblot assay (RIBA) 
1.7.6.1.2. Direct tests: 
Detection of viral genomic material: Nuclear material, Polymerase chain 
reaction (DNA PCR; RT PCR), Nucleic acid sequence-based amplification (NASBA), 
Branched DNA technology (bDNA). 
Supplemental tests for confirmation: Viral Ag – p24 (p24 antigenemia), 
Viral Culture. 
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1.7.6.2.Tests  for  defects  in  immunity:  
CD4+  T  cell  counts, CD8+  T cells;  Reversal of  CD4+  to  CD8+  T  cell  
ratio; Lymphopenia; Polyclonal  hypergammaglobulinaemia, Increased  β-2  
microglobulin  levels and Platelet  count to  reveal  thrombocytopenia. 
1.7.6.3. Tests for  detection  of  opportunistic  infections  and  secondary  
tumours: 
101
 
Diagnosis  of  organs  involved   in  opportunistic  infection  and  specific  
tumours   secondary  to  HIV/AIDS  is  made  by  aspiration  or  biopsy  methods.   
1.8 RETICULOENDOTHELIAL SYSTEM 
1.8.1. Definition: 
           The combination of monocytes, mobile macrophages, fixed tissue 
macrophages, and a few specialized endothelial cells in the bone marrow, spleen, and 
lymph nodes is called thereticuloendothelial system.
103 
Reticuloendothelial system is a system of primitive cells, which play an important 
role in the defence mechanism of the body. These cells are found in the following 
structures.
98 
 The endothelial lining of vascular and lymph channels  
 Connective tissue and some organs like spleen, liver, lungs, lymph nodes, 
bone marrow, etc. the reticular cells in these tissues form the tissue 
macrophage system. The word macrophage refers to a large cell having the 
property of phagocytosis. So. The macrophage is defined as a large pagocytic 
cell. 
 Mononuclear – phagocytic system (MPS) also known as tissue-macrophage 
system is the new name given to the system previously called a 
reticuloendothelial system (RES).
104
 
1.8.2. Formation of mononuclear-phagocytic system:
104
 
The monocytes enter the blood from the bone marrow and circulate for about 
3 days. From the blood the monocytes migrate into the tissue where they attain 
maturity, i.e.they increase in size and a large number of lysosomes and mitochondria 
develop in their cytoplasm. In this way they acquire the ability to phagocytose and 
thus get converted to macrophages. The macrophages wander through tissues (mobile 
macrophages) and perform scavenger functions of eliminating micro-organisms and 
other foreign particles that invade the tissues. Some of these macrophages become 
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attached to certain tissues in the body (fixed macrophages) and remain there for 
several months. These tissue macrophages scattered in different parts of the body 
combinedly constitute the tissue macrophage system.  
The tissue macrophage system includes the macrophages present at following sites in 
the body: 
104 
 Macrophages lining the sinusoids of liver (Kupffer cells). 
 Spleen. 
 Bone marrow (littoral cells). 
 Lymph nodes. 
 Lungs (pulmonary alveolar macrophages or PAM also called dust cells), 
 Connective tissue (histiocytes), 
 Pleura and peritoneum, 
 Subcutaneous tissue, 
 Bones (osteoclasts) and  
 Central nervous system (microglial cells). 
1.8.3. Constituent cells of momononuclear – phagocytic system:104 
The term momononuclear – phagocyticsystemwas coined in 1960 to include the 
following constituents: 
 Precursor cells of the monocyte series from bone marrow, 
 Promonocytes from the bone marrow, 
 Monocytes from the bone marrow and blood, and  
 Tissue macrophages present in the above cited sites in the body. 
 The MPS does not include the following cells which were included in the 
reticuloendothelial system (RES): 
 Reticulum cells of the spleen and lymph nodes, 
 Endothelial cells and  
 Fibroblasts. 
 
1.8.4. Classification of reticuloendothelial cells:
1
 
The macrophages are distributed widely in different tissues like liver, spleen, lungs, 
central nervous system, bone marrow etc.
 
They are known by different names in 
different locations.
105 
The reticuloendothelial cells are classified into two types.
98
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a) Fixed reticuloendothelial cells or tissue macrophages 
b) Wandering reticuloendothelial cells. 
 
a. Fixed reticuloendothelial cells or tissue macrophages: 
Fixed reticuloendothelial cells are also called the tissue macrophage or 
fixed histiocytes because these cells are usually located in the tissues. The 
tissue macrophages are present in the following areas
98,103
 
1. Connective tissue 
2. Endothelium of Blood sinusoid 
3. Reticulum 
4. Central Nervous System 
5. Lungs 
6. Skin and Subcutaneous tissue. 
b. Wandering reticuloendothelial cells:98 
Thewandering reticuloendothelial cells are also called free histiocytes. 
There are two types of wandering reticuloendothelial cells. 
1. Free histiocytes of blood: 
a. Neutrophils. 
b. Monocytes, which become macrophages and migrate to the site 
of injury or infection. 
2. Free histiocytes of solid tissue: 
1.8.5. Functions of reticuloendothelial system
98
 
Most of the functions of the reticuloendothelial system are carried out by 
macrophages. Reticuloendothelial system play an important role in the defense 
mechanism of the body. The various functions of these cells are the following: 
1. Phagocytic function: 
Macrophages are the large phagocytic cells, which play an important role in 
defense of the body by phagocytosis. The invading organisms like bacteria and 
other foreign bodies are phagocytozed by the macrophages.
98
 
During infection, these cells rapidly increase in number resulting in enlargement 
of the organs which are rich in these cells, e.g. spleen, lymph nodes etc.
104 
CHAPTER 1                                                                                                                                    INTRODUCTION 
 
J.K.K.NATTRAJA COLLEGE OF PHARMACY Page 40 
 
When any foreign body invades, macrophages ingest them by phagocytosis and 
liberate the antigenic products of the organism. The antigens activate the B 
lymphocytes and helper T lymphocytes. 
2. Secretion of interleukins: 
 Macrophages secrete interleukin-1 (IL-1), interleukin-6 (IL-6) and interleukin 
12 (IL-12). IL-1 accelerates the maturation and proliferation of specific B 
lymphocytes and T lymphocytes. IL-6 causes growth of B lymphocytes and 
production of antibodies. IL-12 influences the T-helper cells. 
3. Secretion of tumor Necrosis Factor: 
 Tumor necrosis factor – alpha (TNF-∞) and Tumor necrosis factor beta alpha 
(TNF-β) are secreted by tissue macrophages. TNF- ∞ causes necrosis of tumor 
and activates the immune response in the body.  TNF-β stimulates immune 
system and vascular response in addition to causing necrosis of tumor. 
4. Secretion of platelet derived growth factor: 
 Tissue macrophages secrete the platelet derived growth factor (PDGF), which 
accelerates repair of damaged blood vessel and wound healing. 
5. Removal of Carbon Particle and Silicon: 
 The macrophages ingest the substances like Carbon dust Particles and Silicon 
which enter the body. 
6. Destruction of Senile red Blood Cell: 
 The reticuloendothelial cells particularly those in spleen destroy the senile red 
blood cells and release hemoglobin. 
7. Destruction of  hemoglobin: 
 The hemoglobin released from broken senile red blood cells are destroyed by 
the reticuloendothelial cells. 
8. Hemopoietic Function: 
 The reticuloendothelial cells also play an important role in the production of 
blood cells. 
9. Role in inflammation and healing:104 
 The cells of MPS ingest cell debris, broken down RBCs, fibrin and bacteria 
from the inflamed area and promote healing process. 
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10. Role in the immune response:104 
 The cells of MPS ingest and process the antigen entering the body. 
Processing of antigen is essential before an antigen can evoke cell-mediated 
immunity (CMI) or stimulate antibody formation in plasma cells. 
 The cells of MPS have receptors for immunoglobulins and complements, so 
these are very efficient in phagocytosing the antigen-antibody complement 
complexes. 
11. Role in removal of old WBCs and platelets:104 
  WBCs and platelets are removed by the cells of MPS system. 
12. Storage function:104 
  The cells of MPS store excess lipids and mucoprotein and become swollen. 
1.9. ANTIRETROVIRAL THERAPY: 
Antiretroviral therapy has undergone major changes over the past decades. To 
understand the current treatment strategies, the knowledge about the changes in 
therapy is important.
j
 
Antiretroviral drugs are drugs active against Human immuno-deficiency virus 
(HIV) which is a retrovirus. They are useful in prolonging and improving the quality 
of life and postponding complications of acquired immunodeficiency syndrome 
(AIDS) or AIDS related complex (ARC), but do not cure the infection.
107
 
Antiretrovirus Drugs:
108 
             There are several antiretroviral agents are available today and these drugs 
belongs to following classes, 
Nucleoside reverse transcriptase inhibitors (NRTIs):  
             Zidovudine, Didanosine, Stavudine, Lamivudine, Abacavir, Emtricitabine, 
Tenofovir. 
NonNucleoside reverse transcriptase inhibitors (NNRTIs):  
            Nevirapine, Efavirenz, Delavirdine. 
Protease inhibitors:  
            Ritonavir, Atazanavir, Indinavir, Nelfinavir, Saquinavir, Amprenavir, 
Lopinavir. 
Entry inhibitors:  Enfuvirtide. 
CCR-5 receptor inhiitots: Maraviroc. 
Integrase inhibitors: Raltegravir. 
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1.10. ANTIRETROVIRAL TREATMENT FAILURE: 
Although progresses in the management of people alive with HIV, and the 
significant developments in morbidity and mortality, failure in retroviral therapy still 
occurs. Along with treatment failure, the HIV virus becomes more and more resistant 
to antiretroviral drugs.
110 
1.10.1. Types of antiretroviralTreatment Failure: 
It can be divided into three types as follows,
110 
Virological failure:  
It is the incapability to attain maximal inhibition of HIV replication or the 
attainment of maximal inhibition followed by virological rebound.  
Immunological failure:  
It indicates the accomplishment of a very less or undetectable HIV viral load, 
but the continual reduction in CD4+ cell count.  
Clinical failure:  
It illustrates the condition in which the infected person shows disease 
progression of treatment and fall into opportunistic infection, weight loss, sweats and 
fatigue. 
1.10.2. Reason for antiretroviral treatment failure:
110 
Sub-optimal adherence:  
A number of general causes given for meager adherence encompass trouble in 
taking proper drug regimens due to excessive pill burden, more dosing frequency, 
adverse drug effects, restrictions in diet, forgetting to take given doses and suffering 
from drug toxicity.  
Poor local bioavailability:  
The soul reason for treatment failure is the insufficient local bioavailability of 
anti-HIV agents after systemic administration in cellular and anatomical sites where 
hidden virions remain and develop reservoir.
114 
Insufficient residence time: 
In order to the complete eradication of HIV infection, adequate residence time 
of the anti-HIV drugs are necessary. Example: Lymph nodes are a chief viral reservoir 
and it is take part an important task in organizing immune responses. Therefore, 
achieving sufficient amount of drug in the lymph node is necessary for best possible 
therapeutic activity.  
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1.10.3. Antiretroviral therapy and its current limitations: 
Anti HIV agents make a payment to the generation of drug resistance as their 
therapeutic efficiency is not extended as HIV mutates or alterations in genetic 
configuration, becoming resistant to antiretroviral agents. In addition, the continuous 
use of these drugs leads to noxious side effects anddecline the life quality of the 
infected patient. The efficiency of drug and side effects differ with HIV infectionlevel 
and type of individual body. Nausea, abdominal pain, fatigue, diarrhea, kidney stones, 
tingling, loss of sensation in feet and hand are the common undesirable effects caused 
by antiretroviral drugs. The high treatment cost also a major shortcoming in the 
antiretroviral treatment. Hence, there is an urgent call for better anti HIV drugs and 
highly efficient targeting systems that would deal with a range of above mentioned 
challenges.
111,112,115 
1.10.4. Progress in formulation-based approaches for antiretroviral therapy:
112 
The following drug delivery systems are the some of the approaches under research or 
moreover confirmed for the effective delivery of antiretroviral drugs. 
 Vaginal tablets and suppositories. 
 Vaginal creams and gels. 
 Sustained release dosage forms and ceramic implants 
 Bioadhesive intra-vaginal systems. 
 Micelles and microemulsions. 
 Transdermal systems. 
 Suspensions. 
 Buccal delivery. 
 Nanoparticle systems. 
 Vesicular and provesicular carrier systems. 
1.10.5. Role of vesicular system in improving efficacy of antiretroviral drugs:
 
1. Sustained Systemic Delivery: 
The frequency and multiplicity of drug use in HIV is more. The sustained 
delivery of anti retroviral drug by vesicular system improves therapeutic 
efficacy and patient compliance by reducing the frequency of drug 
administration.
115,118 
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2. Eradication of viral reservoirs and sanctuaries: 
Viral reservoirs are anatomic cellular sites that dock small levels of inert, 
however replication-competent virus.
 
The rate of viral decline kinetics in these 
areas is drastically low than that in the blood plasma compartment.
 
Therefore, 
prologed therapy is necessary to eliminate the virus and viral sanctuaries 
receive sub therapeutic drug concentrations.
118
 
Monocytes and macrophages are the another important viral reservoir.
 
Large 
number of viral particles present in the macrophagesdoes not have a cytopathic 
effect on these cells. But the virus distributed to all the systems of body 
through the HIV infected macrophages.
  
Due to these facts the macrophages 
are considered as vital targets for therapeutic intervention by vesicular system. 
B cells, NK cells and follicular dendritic cells are characterized as major 
anatomical HIV reservoirs.
 
As compared to peripheral circulation the 
concentration of immune cells is higher in lymphoid tissues. Also T 
lymphocytes and antigen-presenting cells are in close relation with lymph 
nodes.
115, 118
 
Vesicular drug delivery systems solve the drawbacks like low residence time 
and poor local bioavailability of anti-HIV agents after systemic administration 
in cellular and anatomical virions reservoirsites. 
Among the various vesicular systems the proniosome derived niosomes play 
an important role in promote the efficacy of anti HIV agents by improving the 
concentration of drugs in target.  
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2. AIM AND OBJECTIVE OF THE WORK 
2.1. Aim of the work: 
The aim of the present study was to investigate the feasibility of proniosomes 
as stable precursor for the oral drug delivery system for hydrophilic anti retroviral 
drug abacavir sulphate. 
2.1.1. Background of Aim/Need of study: 
Drugs regularly used for the management of the retroviral infection mostly 
exist as conventional dosage forms. The main shortcoming of these dosage forms are 
non specific or non targeting delivery of the drug in the site of action. By 
administration of the whole drug dose by conventional dosage forms, the entire 
amount is quickly released in to the stomach, gets absorbed into the systemic 
circulation and eliminated from body. Another problem of conventional dosage forms 
is the drug not delivered exactly into the site of action.Drug delivery systems by 
means of colloidalparticulate carriers such as liposomes, niosomes have distinct 
advantages over conventional dosage forms because the particles can act as drug 
containing reservoirs, and modification of the particle composition or surface can 
adjust the drug release rate and/or the affinity for the target site.
88
 However, there 
remain significant problems in the general application of liposomes for drug delivery. 
In a dispersed aqueous system, liposomes have problems associated with degradation 
by hydrolysis and sedimentation, aggregation, or fusion of liposomes. The problems 
associated with the clinical application of liposomes include difficulties in 
sterilization and large-scale production.
32 
These problems can be evaded by 
proniosomes. Proniosomes are dry, free-flowing formulations of surfactant-coated 
carrier, which can be rehydrated by brief agitation in hot water to form a multi-
lamellar noisome suspension suitable for administration by oral or other routes. In 
addition to that proniosomes are shown distinct advantages over conventional dosage 
forms in oral drug delivery.
116
 
Proniosomes have also demonstrated the capability to deliver various antiviral 
agents. Proniosomes prolonging the circulation of entrapped drug and altering its 
organ distribution and metabolic stability and enhance the efficacy and reduce the 
toxicity of encapsulated antiviral agents. Thus, an important contributing factor for 
the development of drug resistance appears to be the inability to achieve sufficiently 
high concentrations of the drugs at the sites of HIV-1 infection. Proniosomes enter in 
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the human body, they are recognized as the foreign bodies and easily taken up by the 
mononuclear phagocytic cells. HIV is present in mononuclear phagocytic cells of 
infected patient, so proniosomes represent suitable carriers for targeting anti-HIV drugs to 
the infected cells.117,118 Thus, proniosomes can improve the efficacy of anti-HIV drugs and 
reduce their toxic effects. By considering the above advantages of Proniosomes has been 
selected as a carrier to deliver the abacavir sulphate. 
Abacavir sulphate, the anti-HIV compound approved in 1998
119 
is still 
generally used alone or incombination with other anti retroviral agents for treatment 
ofAIDS and AIDS-related complex. It is the only approved antiretroviral that is active 
as a guanosine analog.
120 
Rapid diminution in plasma HIV –RNA count and quick rise 
in CD4 cell count has been well-known when abacavir was given to HIV infected 
patient.
120
 Abacavir has been reported to produce severe hypersensitivity reactions 
and adverse effects. The half life of hydrophilic abacavir sulphate is 1 to 1.5 hours.
121 
Marketed preparations of abacavir sulphate currently available are there in 
conventional dosage form. Thus current study was aimed to develop a prolonged 
release pronoisome formulation of abacavir sulphate for targeted delivery and to 
minimize the undesirable effects. 
2.2. Objectives: 
 Dicetyl phosphate is a charged lipid used to induce negative charge to vesicles. 
The first objective of these experiments was to assess the influence of negative 
charge inducer dicetyl phosphate in vesicle size, abacavir sulphate 
encapsulation and invitro release for equimolar (1:1) surfactant / cholesterol 
formulations.  
 To get the preferred characteristics of a proniosome formulation of hydrophilic 
drug abacavir sulphate in the presence of cholesterol, it is important to select the 
proper surfactant. Another objective of this study is to compare the effect of 250 
μM concentration of sorbitan fatty acid esters (spans) and polyoxyethylene 
sorbitan fatty acid esters (tweens) surfactants in the encapsulation of water 
soluble drug abacavir sulphate.  
 The niosomes are the vesicular systems have definite advantages by means of 
avoiding demerits coupled with conventional dosage forms by acting as drug 
reservoirs and which can be expected to extend the duration of the drugs in 
systemic circulation with diminish the drug toxicity. However, aqueous 
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dispersions of niosomes may exhibit physical instability problems such as 
aggregation, fusion of vesicles and hydrolysis or leaking of the encapsulated 
drug. Proniosomes are the dry free flowing granular niosomes and these can be 
hydrated instantly before use to obtain niosomal dispersion. The present work 
was objected to formulate and characterize the both noisomal and proniosomal 
formulation of abacavir sulphate to recognize the superiority of proniosomes 
over the conventional niosomes in all aspects in the vesicular formulation of 
antiretroviral drug abacavir sulphate.  
 To prolong the duration of action by increasing existence of drug in systemic 
circulation by using proniosomal formulation. 
 To improve efficacy and reduce the toxicity of abacavir sulphate by using 
proniosomal formulation. 
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3. REVIEW OF LITERATURES 
Sara et. al. (2016)
122
 optimized and evaluated the non-ionic surfactant based 
proniosomes by coacervation phase separation method using cremophor RH 40, 
cholesterol, soya lecithin and absolute ethanol. The formulations were optimized by 
using a 2
3
 full factorial design and characterized for morphology, surface charge, 
vesicle size, percentage entrapment efficiency, invitro release study, drug permeation 
study, stability study, bioavailability study, pharmacokinetic study and skin irritation 
study. The morphology of niosome vesicles were examined by using transmission 
electron microscope and optical microscope. Vesicle size and surface charge were 
determined using malvern zetasizer. Percentage entrapment efficiency was 
determined after separating unentrapped drug by filtration with whatman filter paper. 
Invitro release was performed using a slightly modified USP dissolution tester. Invivo 
bioavailability and pharmacokinetic studies were estimated by using the animal 
rabbit. Albino rats were used to determine the skin irritation test. Spherical shaped 
homogenous populations of vesicles were confirmed by optical photomicrograph and 
transmission electron microscopy image. The vesicles were found with negative 
charge and in nano size range with low PDI value. The percentage entrapment 
efficiency of lacidipine proniosome formulation was found to range from 44.06% to 
98.01%. Invitro drug release study had shown the rapid initial release and followed 
slower phase with minimum standard deviation. The optimized lacidipine proniosome 
formulation exhibited more skin permeation and higher bioavailability as compared 
with commercial tablet. Safety of the formulation was revealed from skin irritancy 
investigation of rat skin. Accelerated stability study results suggested that 
proniosomes offered a highly stable system that could reduce the problems of 
conventional niosomes. From the results it may be concluded that proniosome carrier 
is a promising system to deliver the anti hypertensive drug lacidipine. 
Jyotsana et.al.(2016)
123 
formulated and evaluated the proniosomes containing 
lornoxicam by coacervation phase separation method using lutrol F68, lipid-80 H and 
cabopol 974P NF. The resultant formulations were assessed for entrapment efficiency, 
percentage drug diffusion, vesicle size, polydispersity index, morphology, 
zetapotential, drug excipient compatibility and skin permeation study. Entrapment 
efficiency was determined by after separating the free lornoxicam by centrifugation 
technique. Franz diffusion cell was adopted for diffusion studies. Particle size and 
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polydispersity index were evaluated by photon correlation spectroscopy. The 
morphology of vesicle formed from proniosome was investigated by scanning 
electron microscopy. Vesicles surface change was determined by using zeta potential 
analyzer. Thermal characteristics of formulations were evaluated with differential 
scanning calorimetry and solid-state characteristics were evaluated by x-ray 
diffraction method. Exvivo skin permeation studies were carried out by using rat skin 
mounted franz diffusion cell. Percentage drug diffusion of lornoxicam proniosomal 
gel showed that the sustained release profile. Particle size, zeta potential, 
polydispersity index, entrapment efficiency of optimized formulation was found to be 
170.98, -17.95, 0.702 and 66.98 respectively. Nano sized spherical morphology was 
observed through scanning electron microscopy image. Differential scanning 
calorimetry and X - ray diffraction had shown the amorphization of drug lornoxicam 
in formulation. The skin permeability of finalized formulation of proniosomal gel was 
found to be 59.73%. From the study it could be concluded that coacervation phase 
separation method was a sound approach to get stable proniosomal gel formulation of 
lornoxicam.  
Kondru et.al.(2016)
124 
formulated and evaluated domperidone proniosomal gel by 
coacervation phase separation method using cholesterol as a membrane stabilizing 
agent, lecithin as a charge inducer and various ratios of nonionic surfactants like 
span20, span40, span60 and span80.Formulations were evaluated for optical 
microscopy, entrapment efficacy, drug content, exvivo drug permeation study, drug 
release mechanism and stability study. Hydrated proniosome gel had shown good 
spherical vesicles with 74.70entrapment efficacy for best formulation.The drug 
content was found to be in acceptable limit for all formulations. The formulations had 
shown highest exvivo permeation of97.55% and lowest permeation of 52.36%.Overall 
span20 formulations showed greater drug release than the other formulations. The 
stability studies revealed that the proniosome formulations were stable at 25°C.From 
the experimental results, it was concluded that proniosomes gel might be a promising 
carrier for the drug Domperidone. 
Yadavet. al. (2015)
125
 systematically optimized and characterized coenzyme q10-
loaded proniosomal formulation. There were 12 formulation were prepared by 
coacervation phase separation method using span 85, cholesterol and soya lecithin. 
Prepared formulations were characterized for entrapment efficiency, invitro release, 
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drug permeation and retention studies, vesicle size, morphology, rheological behavior 
and anti-aging evaluation. Entrapment efficiency was estimated after separating free 
untrapped drug by centrifugation process. Invitro release study was performed using 
egg shell membrane mounted franz diffusion cell. Exvivo drug permeation and 
retention studies were performed by swiss albino mice skin mounted franz diffusion 
cell. Vesicle size was measured by using malvern mastersizer and morphology was 
investigated by transmission electron microscope. Cup and bob rheometer was 
adapted to study the rheological behavior and texture analyzer was used to study 
spreadibility or texture of formulation. Anti-aging evaluation was done by using swiss 
albino mice and UV radiation. Entrapment efficiency study showed that the CoQ10 
enzyme was completely intercalated in niosome vesicles. The CoQ10 release was 
reduced with the increasing quantity of cholesterol. Exvivo permeation flux value and 
percentage skin retention were found to be higher in case of proniosome formulation 
while compared to carbogol gel. The average niosome vesicles size was found to be 
1.87µm and transmission electron microscopy image also proved the uniform and 
spherical nature of vesicles. Rheological behavior of gel was found to be good as 
higher plasticity and lesser fluidity. Good gel strength was observed from texture 
analysis. Anti-aging study of progel formulation revealed the better protection of skin 
compared to free CoQ10. From the study, it was considered that CoQ10 loadedprogel 
formulation would be safer than usual conventional formulation.     
Anahita et.al.(2015)
126
formulated and evaluated the proniosomes, niosomes, 
transferosomes, ethosomes, liposomes, and cerosomes, to investigate the most 
effective formulation for the skin delivery of diclofenac. Proniosomes formulations 
were prepared by coacervation and phase separation method. Encapsulation efficacy 
was determined by centrifugation method. Storage stability was assessed by storing 
proniosomes formulations at room temperature 25±2°C and fridge 4±2° C for a period 
of 60 days. Invitro skin permeation studies were carried out by using abdominal 
human skin. Stability study results showed that proniosome formulation had shown 
largest vesicle than other formulations and entrapment efficacy was unaffected during 
storage. Invitro drug permeation through human epidermis was found to be more for 
cerosomes compared to other formulation. Proniosomes and liposomes had the 
highest encapsulation rate than the other formulations. Transferosomes had given 
increase in diclofenac permeation relative to aqueous solution. Thus, it was concluded 
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that lipid vesicles could be developed into carriers of both hydrophobic and 
hydrophilic drugs for topical and transdermal delivery.  
Preethy et.al.(2015)
78 
formulated and characterized maltodextrin based proniosome 
formulation of cefuroxime axetil by slurry method. The total of 7 formulations 
wereformulated using span60, choestrol and maltodextrin. Formulations were 
evaluated for optical microscopy, flow properties, vesicle size and shape, entrapment 
efficiency, drug content, invitro release, drug release kinetic, scanning electron 
microscopy, fourier transform infrared spectroscopy, ex-vivo permeation studies, 
permeation data analysis, and  stability studies. Vesicle morphology, vesicle 
formation, vesicle shape and size were evaluated by optical microscopy. Angle of 
repose was determined by funnel method. Entrapment efficiency was analyzed by 
centrifugation method. Drug content was measured by spectroscopy analysis.In vitro 
release study was carried out by using dialysis membrane. Drug release kinetic was 
observed by using various kinetic equations. Surface characteristic was investigated 
by scanning electron microscopy.IR spectrum of optimized proniosome formulation 
(PN4) was obtained by using FT-IR spectrophotometer. Exvivo permeation studies 
was done by everted sac method using small intestine of chicken.Stabilitystudies was 
carried out by using storing the formulation at refrigerated temperature, room 
temperature and 40°C. The formation of noisome vesicle from proniosome powder 
was evidenced by optical microscope and photomicrograph. Small angle of repose 
assured good flow properties for proniosome formulation.The formulation containing 
cholesterol and span 60at a ratio of 1:1had exhibited good entrapment efficiency. The 
mean size of niosome vesicle was found in the range of 10-23µm. The optimized 
formulation had shown 85.3% drug content. The best formulation had given a 
cumulative release of 88.58% over a period of 24 hours. The SEM images revealed 
the absence of crystalline structure in the proniosome powder. No chemical 
interaction between drug, cholesterol, maltodextrin and span60 were found by FT-IR 
spectroscopy. Ex vivo permeation studies showed that the cumulative amount of 
cefuroxime axetil permeated was 22.98%. From the stability study data it was found 
that the percentage drug retained was more in the formulation stored at 2-8°C. The 
results of all the investigation concluded that the proniosome encapsulated cefuroxime 
axetil could be used for prolonged drug release and improved stability.  
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Mohammad et. al. (2014)
127
 manufactured the nonionic surfactant proniosomes for 
beclometasone  dipropionate entrapment using sucrose as a carrier. Proniosome 
powders were hydrated with high pressure homogenization technique. Proniosome 
were hydrated and characterized for size, zetapotential, entrapment efficacy, and 
sample contamination during size reduction. Niosomes derived by high pressure 
homogenization technique were compared with niosomes derived from conventional 
probe - sonication approach. Size analysis was conducted by using Malvern zetasizer. 
Sample contamination during size reduction wasinvestigated by optical microscopy 
with HPLC- grade water. The entrapment efficiency was calculated by UV 
spectrophotometry after separating unentrapped drug by membrane filteration.  High 
pressure homogenization technique was produced small size niosomes (209 nm)as 
compared with probe sonication (237 nm) method. No significant difference was 
found in the zeta potential of vesicles prepared by two techniques. Titanium particles 
contamination was confirmed in probe - sonication technique. The entrapment 
efficiency was found to be 36.4% and 29.65% for the probe-sonicated niosomes and 
the high pressure homogenized vesicles respectively. Overall the high pressure 
homogenization was found to be an applicable approach to producing niosome 
nanodispersion using proniosome technology. 
Sarfarazet.al. (2014)
128 
designed and evaluated selegiline proniosomal gel  by a 
coacervation phase separation method for antidepressant therapy. There were 8 
formulations prepared. The prepared formulations were evaluated for surface 
morphology, vesicle size analysis, rate of spontaneity, % entrapment efficiency, pH, 
invitro release, invitro permeation, invivo anti-depressent activity and skin irritation 
study. Surface morphology was studied by scanning electron microscopy and it had 
shown spherical and homogeneous vesicles. Vesicle size was analysed by observing 
under optical microscope and it was found in the range of 2.85±1.3 μm to 5.71±1.28 
μm.  Rate of spontaneity was determined by neubauers chamber and the results had 
shown proniosome formulations prepared with spans formed niosomes more 
spontaneously than tweens. % Entrapment efficiency was determined after separating 
unentrapped drug by centrifugation process and it was found to be higher in case of 
proniosomes prepared with span 40 and span 60 than proniosome prepared with 
tween. pH was determined by using pH meter and it was found in between 5.2  to 6.3  
which was well within the physiological skin surface pH, invitro release study was 
performed using franz-diffusion cell  with phosphate saline buffer pH 7.4 as 
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dissolution medium and it was evidented from the results that proniosome gels 
prepared with tweens gave a higher release than spans. Invitro permeation studies 
were carried out on optimized proniosome gel formulation using excised rat 
abdominal skin and it was found to be less in tween 80 forrmulation. Invivo  anti-
depressent activity was employed by tail suspension test in mice and had shown a 
significant anti-depressant activity with P<0.05. Skin irritation study was performed 
on  healthy albino rabbits it was concluded that the proniosome gel P8 remained non 
irritant to rabbit skin. The results of investigation demonstrated that proniosomes 
offers an alternative colloidal carrier approach in transdermal drug delivery of 
selegilne hydrochloride proniosomal gel. 
 
Bassem et.al.(2014)
37 
prepared permethrin proniosomes by solvent evaporation 
technique, using cyclohexane as solvent, cholesterol as a basic proniosomal 
component, brij 97 as a non ionic surfactant and aerosil 200 as carrier. Prepared 
proniosome was dispersed in topical powder and emulgel bases and evaluated through 
in-vivo trials as a treatment against S. scabiei and comparing its action with  
permethrin 5 % lotion. A study size of 10 rabbits and 2 local breed "baladi" sheep 
naturally infested with S. scabiei were enrolled in the study, none of them had been 
treated with any ecto-parasiticidal or steroidal anti-inflammatory drugs in the 30 days 
before the study. Treatment for 14 days regimen was selected for this study to identify 
an effect at a high dose regimen that could subsequently be optimized. Evaluation of 
clinical signs suggested that faster complete clinical cure of lesions of infested 
animals used topically applied (PP) emulgel was obvious than animals treated with 
5% permethrin lotion while (PP) topical powder was not effective as scabicide. In 
conclusion, the use of proniosome dispersed in emulgel base which act as penetration 
enhancer could be used together propelarly as good drug delivery system with 
permethrin as a new era for treatment of Sarcoptes scabiei in sheep and rabbits. 
 
Radha et.al.(2014)
129 
formulated and evaluated ornidazole proniosomal gel by 
coacervation-phase separation method using span, cholesterol, soya lecithin and 
alcohol. There were five formulations were prepared. Prepared formulations were 
characterized for vesicle formation, surface morphology, size distribution, FTIR 
studies, encapsulation efficacy, invitro release and invitro permeation studies. Vesicle 
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formation was confirmed by optical microscopy, surface morphology and size 
distribution were observed by scanning electron microscopy, encapsulation efficacy 
was carried out by centrifugation method, invitro release studies were performed by 
using franz diffusion cell, Invitro permeation study was performed by usingmale 
albino rat skin. From microscopical studyparticles were found to be spherical, size of 
the particles are in the range of 3.29μm to 30μm. FTIR studies were showed that there 
was no interaction between API and used excipients. The encapsulation efficiency of 
proniosomal formulations are in the range of 38% to 78%.  Invitro release  studies 
showed good control release for prolonged period of time. Span 20 non lecithin 
formulation showed  highest amount of drug release of 88% in 24 hours.  In vitro rat 
skin permeation studies proved that good amount of drug is permeated than the 
marketed formulation. The results suggest that ornidazole proniosome formulations 
can be used for topical drug delivery system for the treatment of skin infections. 
Sundarapandian et. al.(2014)
130 
prepared and optimized the atenolol proniosomal 
formulations by coacervation-phase separation technique using different grades of 
non-ionic surfactants in various combinations of sorbitan esters such as span 20, span 
40 and span 80 with addition of cholesterol. In order to optimize the formulations 
there were 10 formulations were prepared. All the formulations were evaluated for 
shape, surface characteristics, and size by using scanning electron 
microscope,morphology of the hydrated niosomal dispersions was determined by 
transmission electron microscopy, drug encapsulation efficiency wasdetermined by 
separating  the unentrapped drug by centrifugation, invitro release of prepared 
proniosomal gels were carried using modified franz-diffusion cell, The invitro 
permeation of drug was determined using different animal skins such as shed snake 
skin, albino porcine ear, male albino rat, male guinea pig in order to observe the 
absorption of drug and stability studies were carried outat different temperature 
conditions over a period of 90 days. From the results it was found that Formulation 
A8 prepared with span 40 & 60 was smaller in size, shows higher entrapment 
efficiency and uniform surface area. The SEM and TEM images show that 
formulation (A8) was well-identifiedspherical nano vesicular and homogenous. In 
invitro release of all the formulation exhibited zero order release. The drug release 
was maximum (99.68%) from A8 formulation among all tested formulations. Also the 
drug diffusion across snake sheded skin, guinea pig abdomen skin, albino rat, porcine 
ear correlates better with invitro drug release studies. The formulation was found to be 
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stable when stored at room temperature and at refrigeration temperature for 90 days. 
In conclusion, the proniosomes proved to be efficient carriers for the delivery of 
atenolol across skin. 
Sandeep et.al.(2014)
131
 Formulated and evaluated the fluconazole pro-niosomal gel 
for topical administration by coacervation method using different nonionic surfactants 
(spans and tweens). The formulations were evaluated for vesicle size, shape, stability, 
entrapmentefficiency, in-vitro release, ex-vivo skin permeation and retention study. 
Morphological characterization was done by using inverted microscope and scanning 
electron microscope. Entrapmentefficiency was determined by centrifugation method. 
Physical stability of vesicles was studied at refrigerated conditions (4 ±1 °C) for two 
months. Invitro release studies through artificial membrane wasperformed using 
fabricated vertical franz diffusion cell. Ex-vivo skin permeation and retention study 
was carried out by animal skin inserted franz diffusion cell. Results showed that 
proniosomes composed of span 20, span 60, span 80  were more stable compared with 
tween 20  and tween 80  with smaller size, “i.e.” 4.08±0.18 μm, 2.61±0.15 μm, 
2.01±0.12 μm, 8.56±0.20 μm, and 7.10±0.31 μm, respectively, along with higher 
entrapment efficiency (approx. >46%). Ex-vivo skin penetration and retention studies 
revealed that cutaneous deposition was affected by the nature of surfactant and vesicle 
size. Therefore the proniosomes containing span 60 having high amount of drug 
retained in skin, “i.e.” 25.97%±1.28 which can help in localized delivery of drug 
especially in fungal mediated skin diseases. Thereby fluconazole pro-niosomal gel 
can be formulated for topical administration using nonionic surfactant. 
Seetha et.al.(2014)
132 
formulated and evaluated candesartan cilexetil proniosomal gel 
by coaservation phase separation method by using different surfactants, cholesterol 
and soya lecithin. Drug – excipients compatability studies were carried out by FT-IR 
spectroscopy. The solubility of candesartan cilexetil was determined in water and 
different pH buffers. The prepared proniosomal gel formulations were evaluated for 
physical appearance, vesicle size, surface morphology, pH, encapsulation efficiency, 
In vitro drug release, release kinetics, ex vivo skin permeation studies and vesicular 
stability at different storage conditions. Physical appearance of the formulations were 
viewed through naked eye, vesicle size was observed under optical microscope, 
surface morphology  was studied using scanning electron microscope, pH was 
determined using pH meter, encapsulation efficiency was evaluated by separating 
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unentrapped drug by centrifugation, In vitro drug release was performed using franz-
diffusion cell, various kinetic models were used to study the release kinetics, and  
wistar albino rat abdominal skin was used for ex vivo skin permeation studies. 
Vesicles formed with Spans were smaller in size than vesicles formed with tweens. 
pH of all the formulations were in the range of 5.64 to 7.20, which suits the skin pH, 
indicating skin compatibility. An optimised preparation with 9:2:9 ratio of span 60, 
cholesterol and lecithin gave maximum encapsulation efficiency (92.29%) and 
showed drug release (95.89±0.26%) in a controlled manner with a flux value of 1.89 
μg/cm2 /hr and permeability co efficient value of 0.094 cm2/hr as compared to other 
compositions. No significant changes in relation to vesicle size and encapsulation 
efficiency were recorded after stability studies. It is evident from the study that 
proniosomes are a promising prolonged delivery system for candesartan cilexetil and 
have reasonably good stability characteristics 
 
Gamalet. al. (2014)
133
 investigated the effect of incorporation of skin penetration 
enhancers in nisoldipine proniosomes on the transdermal drug delivery systems. The 
proniosome systems were formulated by coacervation-phase separation method. Plain 
proniosomes comprising sorbitan monostearate, cholesterol, ethanol and a small 
quantity of water were initially prepared. Consequently, proniosomes containing 
lecithin or skin penetration enhancers were prepared. The formulations were 
evaluated for entrapment efficacy, drug content, viscosity, drug release and skin 
permeation. Entrapment efficacy was determined by dialysis method, drug content 
was analysed by HPLC method, viscosity was determined by using brookfield 
viscometer, drug release studies was employed by franz diffusion cells and skin 
permeation study was employed by excised rabbit ear skin. The entrapment efficiency 
was ranged from 80.3+ 0.3% to 88.2 +0.2%.  Flow behaviour of the formulations 
followed a non- newtonian system with a shear thinning behaviour. Incorporation of 
penetration enhancers resulted in a significant increase in the rate of drug release 
compared with the plain formulation. Incorporation of penetration enhancers into 
proniosomes resulted in significant increase in the transdermal flux of nisoldipine 
compared with the plain proniosomes. From the study it was found that enhanced 
proniosomes as a promising transdermal delivery carrier and also the study 
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highlighted the role of penetration enhancing mechanisms in enhanced proniosomal 
skin delivery.  
Shuangshuang et.al.(2013)
134 
formulated and evaluated the proniosome system to 
improve the oral bioavailability of vinpocetine using span 60, sorbitol, cholesterol by 
a slurry method. The formulations were evaluated for entrapment efficiency, particle 
size, size distribution, morphology, physical nature of drug in formulation, invitro 
release, stability study and pharmacokinetic studies. Encapsulation efficiency was 
calculated by determining free vinpocetine by centrifugation method. Average particle 
diameter and their size distribution were found by laser particle size analyzer. 
Morphology was observed by means of light microscope, transmission electron 
microscopy and scanning electron microscopy. Nature of vinpocetine in formulation 
was confirmed by powder x-ray diffraction analysis and fourier transform infrared. 
Dissolution study was carried out by using dissolution test apparatus and release study 
was investigated by dialysis bag method. Stability study of Vinpocetine loaded 
proniosomes was performed for about six months at 37⁰C. Intestinal perfusion study 
was carried out by using sprague-dawley rats. Pharmacokinetic study was performed 
using healthy New Zealand white rabbits. Optical micrograph revealed that the 
vesicles were homogeneous and spherical in shape. Perfect sphere with a internal 
aqueous space was confirmed by transmission microscopy image. SEM images 
illustrated that the distinct difference between the surface morphology of proniosome 
powder and sorbitol powder. Molecular or amorphous state of vinpocetine was proved 
from XRD spectrum. The dissolution and invitro release of vinpocetine in pH 1.2 
HCL was much more than that in pH 7.2 phosphate buffer solution. The formulation 
with 7:3 molar ratio of span 60 and cholesterol showed that the excellent 
gastrointestinal integrity at different pH ranges and stability at storage temperature. 
Intestinal perfusion study indicating that the formulations were absorbed from the 
whole intestine. Improvement in bioavailability was observed from pharmacokinetic 
study. From this study it was concluded that proniosome powder of vinpocetine 
would be a good carrier in industrial production.  
Mishra  et.al.(2013)
135 
formulated and  optimized proniosomal gel for transdermal 
delivery of Naproxenby coacervation phaseseparation method using span 40, span 60 
as  nonionic surfactants cholesterol as membrane stabilizer. There were 9 
formulations were prepared and characterized for various parameters. Noisome 
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vesicle formations were observed by optical microscopy. Entrapment efficiency was 
analyzed by centrifugationmethod. The morphology of the vesicles was evaluated by 
TEM. Invitro release studies were performed by using franz-diffusion cell. Rate of 
spontaneity was determined with the aid of neubauers chamber. Zetasizer was used to 
evaluate the size of the finalized vesicular formulation.2% Naproxen containing plain 
carbopol Gel was prepared and compared the invitro release with proniosome using 
franz diffusion cell. Stabilitystudywas carried out for three months at 3 different 
temperature conditions. Two formulations were optimized from the images of optical 
microscopy evaluation.The entrapment efficiency of the formulations varied from 
41.7 to 71.62% and span 60 formulaion had shown more entrapment than that of span 
40. Vesicularsizeof optimized batch was found to be 195.2 and poly dispersity index 
was 0.185. TEM studies confirmed that the vesicle formation from proniosomes after 
hydration. The span 60 gave better invitro drug release than other formulations and 
carbopol gel.  Thus it was concluded that the proniosomal gel is an appropriate carrier 
for the delivery of naproxen. 
Monika et.al.(2013).
136
 formulated and evaluated standardized withania somnifera 
leaf extact loaded transdermal gel by coacervation phase separation method using 
lecithin, cholesterol, ethanol and span 60. The air dried and coarsely podered leaves of 
the plant were exhaustively extracted with methanol in a soxhlet apparatus. The 
qualitative and quantitative analysis of plant extracts were carried out by HPLC 
method. The formulations were evaluated for particle size, morphology, entrapment 
efficacy, invitro release, and anti-inflammatory activity. The average particle size of 
the prepared proniosomes was determined by laser diffraction particle size analyser, 
Surace morphology was evaluated by scanning electron microscopy, entrapment 
efficacy was determined by filtration method, invitro release study was performed by 
franz diffusion cell and anti-inflammatory activity was evaluated by  carrageenan-
induced rat hind paw edema method. The average particle size was found to be 2-
11µg with a good entrapment of 87.2%. Invitro release study showed that the slow 
release of the drug at almost constant rate and gave sustained release. Anti 
inflammatory activity was exhibited up to 5 hours and peak activity was observed 
between 3-5 hours. From the study, it was concluded that proniosomes were very 
stable and promising delivery system for withania somnifera leaf extract. 
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Swati et.al.(2013)
137
 developed and evaluated proniosomes as a drug carrier for 
transdermal delivery of candesartan cilexetil by  coacervation phase separation 
method using lecithin, cholesterol as encapsulating agents, span  20, 40, 60 and 80 as 
surfactant. The pH of each formulation was determined using pH meter. Viscosities 
were determined using brookfield viscometer. Vesicle formation and morphology was 
determined by optical, scanning and transmission microscopy. In vitro release studies 
on proniosomal gel were performed using locally manufactured franz-diffusion cell. 
Ex- vivo skin permeation studies werecarriedoutthrough excised rat skin, skin 
irritation study was performed  using albino wistar rats.  Stability studies were carried 
out by storing the optimized formulation at various temperature conditions as per ICH 
guidelines.It was observed that the gel formulations showed good spreadability and 
viscosity. The particle size was found to be in the range of 175.0- 277.7 nm. The 
proniosomes showed spherical and homogenous structure in optical microscopy. 
Candesartan cilexetil was best encapsulatedby proniosomal prepared using span 
20:span 60 (AH2). All formulations showed zero order drug release by diffusion 
mechanism. The stability studies showed that proniosomal gels were stable at 4 to 
8°C and 25±2°C. The above results indicated that the proniosomal gel could be 
formulated for controlled release of candesartan cilexetil.  
Dinesh et.al.(2013)
138 
Formulated and characterized the Proniosomal gel of 
Flurbiprofen  by coacervation phase separation method.A total of 17 batches were 
designed using box behnken design and batches were evaluated on the basis of 
particle size, and entrapment efficiency. A three-factor, three-level box-behnken 
experimental design was used to optimize theformulation development.  In this study, 
3 independent variables drug-polymer ratio, cholesterol, brij 93 were taken which 
significantly influence the observed response forparticle size, entrapment efficiency. 
Particle size of different batches was found to be between 215 to365 nm. Drug 
entrapment efficiency of various batches were found to be in the range of 59.32 to 
74.46% respectively. The optimized formulation was prepared with drug: polymer 
ratio 1:1,100mg cholesterol and using brij 93(75mg). Optimized formulation showed 
drug entrapment efficiency of 74.46% and particle size 215nm. In-vitro drug release 
of  optimised formulation was found to be 84.15%after  24 hrs and it was best 
explained by zero order kinetics, as the plot showed highest linearity (R
2
 = 0.990) and 
release was governed by quasi fickian diffusion. Fom the study it was revealed that 
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the increase in cholesterol concentration maximizes the drug loading but to a 
maximum value above which this will disrupt the vesicular membrane structure. 
Hayderet. at. (2013)
139 
Prepared the metoprolol tartrate proniosomal gel as 
transdermal drug delivery system by coacervation-phase separation method. The 
prepared formulations were estimated for their physical manifestation include color, 
consistency and fluidity, pH in order to investigate the possibility of any irritant 
effects on skin, entrapment efficiency by separating unentrapped drug using 
centrifuge, vesicle size using optical microscopy, surface morphology by  scanning 
electron microscopy,  the compatibility of the drug and additives  by fourier transform 
infra red (FT-IR) spectroscopy, in-vitro release rate by dialysis tubing method.  The 
physical manifestation estimation of four formulas gave a white and yellow semisolid 
state, two showed a brown liquid state. The pH range was found within the 
physiologically skin surface pH. Higher entrapment efficiencies was obtained with 
span 40 formulation  (86.6%±8.07) and the release rate at 11 hr from span 40 
niosomes is found to be 31.18%.fourier transform infra red (FT-IR) studies, confirm 
that there was no interaction between drug and other formulation components of 
niosome. span 40 niosomes is found to be 31.18%.  SEM image had shown spherical 
structures for proniosome derived niosomes. According to the achieved results from 
study, the preparation of niosomes from proniosome by coacervation-phase separation 
method was found to be simple and straight forward method. 
Agaiahet. al. (2012)
140 
improved the oral absorption of carbamazepine from sorbitan 
monolaurate based proniosome systems containing charged surface ligands. 
Proniosome systems with cholesterol were formulated by slurry method using neusilin 
as carrier, polysorbate-80 as non ionic surface ligand in nonionic vesicles, cetyl 
pyridinium chloride as cationic charged surface ligand in cationic vesicles and 
docussate potassium as anionic charged surface ligand in anionic vesicles. All the 
three reconstituted provesicular systems were characterized for size, zeta potential, 
drug content and entrapment. In vitro release was carried out for provesicular solids 
using USP dissolution apparatus. In Situ absorption study was accomplished by static 
diffusion model using rat intestinal absorption technique.The pharmacokinetic 
parameters were assessed with a standard software package. Differences in the 
pharmacokinetic parameters due to various treatments were validated by ANOVA and 
paired t test. The results revealed that the vesicle size of cationic vesicles had the 
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minimal size (287 ± 23nm), The zeta potentials were 76.2 ± 9.3 mv, -26.73 ± 3.8 mv 
and 38.7 ± 6.8 respectively for cationic, anionic and nonionic systems. The 
entrapment efficiencies were more than 95% in all the systems.Among the charged 
ligands, positively charged system showed maximum absorption enhancement effect. 
This could be due to nano size of vesicles and positive charge on their surface. 
Therefore the study concluded that a dry free flowing proniosomal formulation of 
carbamazepine could be produced with ease. 
Parthibarajan et.al.(2012)
76 
formulated and evaluated methotrexate proniosomal 
powder by slurry method using cholesterol, the non-ionic surfactant span 80 and the 
carrier maltodextrin. The angle of repose of the dry proniosome powder was 
evaluated by funnel method. Surface morphology was analysed by scanning electron 
microscopy and photography. Vesicle formation was confirmed by spontaneity study. 
Prepared proniosome was optimized for highest percentage drug entrapment by 
dialysis method. Stability of finalized formulation was analyzed by kept the 
formulations at 4°C and room temperature for 30 days. From the results it was found 
that the angle of repose of dry proniosome powder was smaller than that of pure 
maltodextrin. The proniosomes were observed as spherical vesicles with smooth 
surface by microscopic evaluation. The spontaneity study, confirmed the formations 
of niosomes from proniosomes. From the drug leakage study it was observed that the 
drug leakage from the vesicles was least at 4°C followed by 37°C. From the results of 
encapsulation efficiency it was found that encapsulation efficiency increased when 
Span- 80 concentration was increased. The in-vitro release studies of drug from 
proniosomes exhibited a prolonged release as studied over a period of 24 hrs. Thus, it 
was concluded that proniosomes could be used as a drug carrier for methotrexate, for 
producing prolonged activity. 
Gomes et.al.(2012)
84
 developed and evaluated norfloxacin loaded maltodextrin based 
proniosomes by slurry method using span 60 as surfactant and cholesterol as 
membrane stabilizer. The total numbers of 7 formulations were prepared. The 
prepared formulations were evaluated for angle of repose, surface morphology, 
vesicle formation, entrapment efficacy, invitro release study, stability study and 
colloidal property. Angle of repose of the dry proniosome powder was measured by 
funnel method. Surface morphology was evaluated by scanning electron microscopy. 
The vesicle formation was confirmed by optical microscopy.Entrapment efficacy and 
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invitro release were estimated by dialysis bag method.Stability study was carried out 
at refrigerator condition (2-8°C) for a period of three months. Colloidal property was 
measured by  zeta potential probe. Angle of repose of the proniosome formulations 
indicated that the fluidity of proniosome formulation is better than the maltodextrin 
powder. Surface morphology evaluation illustrated that the smooth surface of the 
formulation. The shape and size of the noisome vesicles formed from proniosome 
were found to be uniform. On using of different ratios, 170:80 µmol ratios of the 
surfactants to cholesterol preparation had shown the highest entrapment efficacy and 
good release characteristics. Drug release kinetics were followed Higuchi’s and 
peppa’s model. Stability study report revealed the truth that the proniosomes are 
stable to store under refrigeration temperature with least leakage. By these facts of 
study it was concluded that norfloxacin will be successfully entrapped within the 
bilayer of the vesicles and the slurry method was found to be simple and suitable for 
laboratory scale. 
Akhilesh et.al.(2012)
88 
developed and optimized the proniosomes for oral delivery of 
glipizide by the slurry method using cholesterol, span 60, sorbitol, mannitol and 
maltodextrin.Drug excipient compatability was confirmed by of FT-IR spectra of   
physical mixture.  The formulations were evaluated for FT-IR study, angle of repose, 
scanning electron microscopy, entrapment efficiency,  in-vitro release study, kinetic 
data analysis and  stability study. The angle of repose of proniosomes powder and 
maltodextrin powder was evaluated by a funnel method. The vesicle formation was 
confirmed by optical microscopy.Drug entrapped vesicles were estimated by dialysis 
method. In-vitro release pattern of the niosomal suspension was carried out by 
dialysis bag method. The release data obtained from various formulations were 
studied further for their fitness of data in different kinetic models like Zero order, 
Higuchi’s and Peppa’s. Physical stability study was carried out to investigate the 
degradation of drug from proniosome during storage. The IR spectra of physical 
mixture confirmed that the stability of drug during formulation. Angle of repose of 
dry proniosome powder is nearly equal to that of pure maltodextrin, but slightly 
differentiates with other carriers. The result from SEM analyses had confirmed the 
coating of surfactant on the surface of carrier. The optical microscopy confirmed that 
the vesicle formation and it was found to be uniform in size and shape.  Maltodextrin 
based formulation had shown higher entrapment efficiency of 82.64% ± 1.25 and in-
vitro release of 98% at the end of 24hours was found to be best among the various 
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formulations.Drug release pattern was best explained by the zero order kinetics and it 
was followed super case II transport diffusion. Maltodextrin based proniosome 
formulation had shown appropriate stability for 90 days when compared with other 
carriers reconstituted niosomes by storing the formulation at refrigerator condition. 
Thus the slurry method was found to be simple and suitable for laboratory scale 
preparation of maltodextrin based glipizide proniosomes. 
Asthaet. al. (2012)
141 
formulated and evaluated proniosomal drug  carrier for 
transdermal drug delivery of clotrimazole  using different non-ionic surfactants such 
as span 60, span 40, brij 72 and tween 80. The formulations were characterized by 
light microscopy, scanning electron micrscopy, rate of spontaneity, drug entrapment, 
and stability. The release was studied by using cellulose membrane and hairless mice 
skin.From the results it was observed that the vesicles of the niosomes formed by 
hydration of proniosomal gels were almost spherical in shapeand the vesicles 
produced from formulation span 60 have larger size than span 40. Brij 72 did not form 
uniform vesicles. The vesicles of tween 80 were ruptured due to its high H.L.B 
value.The rate of spontaneity was highest with formulation containiing Span 60 as 
compared to span 40, brij 72 and tween 80.The % Encapsulation of different 
surfactants followed the order Span 60>Span 40>Brij 72>Tween 80.The invitro 
release studies as carried out showed that the % release of span 60 was highest in 
comparison to other surfactants used in the study. By comparing the results obtained 
from permeation of clotrimazole through hairless rat skin, it was found that the release 
of clotrimazole proniosomal gel through rat skin was significantly higher than its 
permeation across skin. The results of the study showed that the proniosomal gel 
formulation was quite stable at refrigeration and room temperature as not much 
leakage of drug was found at these temperatures. Percent drug retained at 45°C might 
have decreased due to melting of the surfactant and cholesterol at this 
temperature.The proniosomes prepared from span 60: cholesterol (9:1) proved to be 
stable with high entrapment and release efficiencies as compared to span 40, brij 72 
and tween 80. From the study it was concluded that proniosomal gel might be a 
promising carrier for the transdermal delivery of the antifungal drug Clotrimazole. 
Alpana et.al.(2012)
87 
developed  a proniosomal carrier system composed of various 
ratios of sorbitan fatty acid esters, cholesterol, lecithin  for hydralazine by 
coacervation-phase separation method. The formulated systems were characterized 
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invitro for  drug excipient compatibility, physical appearance, vesicle shape and 
surface characteristics, vesicle size and size distribution, rate of spontaneity, drug 
entrapment efficacy, invitro drug release, invitro skin permeation  and vesicular 
stability at different storage conditions. Drug excipient compatibility study was 
performed by differential scanning colorimetry. Physical appearance was viewed by 
optical microscopy. Vesicle shape and surface characteristics was evaluated by 
transmission electron microscopy. Rate of spontaneity was evaluated using neubauers 
chamber. Drug entrapment efficiency was determined by centrifugation method. Drug 
diffusion studies were carried out through cellophane membrane. In vitro skin 
permeation studies were carried out using excised human abdomen skin and excised 
cadaver skin mounted franz cell. Stability studies for proniosomal gel were carried out 
for 6 weeks at three different temperature conditions, i.e., refrigeration temperature 
(4-8°C), room temperature (25±2°C) and oven (45±2°C).  The DSC thermograms of 
proniosome suggested that no interaction had taken place between drug and other 
formulation ingredients. TEM imaging of hydralazine loaded niosome produced from 
proniosome revealed that vesicles were spherical in shape. Proniosome containing 
span:lecithin:cholesterol ratio of 9:9:2 produces niosome of smallest size range. The 
formulation prepared with span 40, span 60 and tween 60 were formed niosome more 
spontaneously. Niosome composed of span 40, 60 have shown highest entrapment 
efficacy. The result indicate that the proniosome with increased ratio of cholesterol 
have high release rate. The drug release kinetics followed the higuchi kinetics. Drug 
release through human skin had shown excellent slow sustained release. From 
stability study it was found that the optimized formulation was stable at refrigeration 
and room temperature as well. Thus proniosomal gel will be the suitable drug delivery 
system for hydralazine HCl due to ease of preparation and incorporation of less 
number of excipients. 
Walve et.al.(2012)
142 
developed and evaluated the proniosomal transdermal drug 
delivery system for diclofenac by phase separation-coacervation method. There were 
10 formulations were formulated by using carbopol, cholesterol, lecithin and various 
surfactants like span 20, span 60, span 80, tween 20 and tween 80. The formulations 
were evaluated for encapsulation efficiency, vesicle size and shape, scanning electron 
microscopy analysis, ex-vivo drug permeation study and stability study.Encapsulation 
efficiency was determined by centrifugation method, vesicle size and shape 
determined by using optical microscope, Scanning electron microscopy was adopted 
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to study the vesicle surface morphology, Ex- Vivo drug permeation was determined  
using franz diffusion cell and stability study was carried out by storing the finalized 
formulation at various temperatures for a period of 1 month. The encapsulation 
efficacy of proniosomes with span 60 surfactant had shown a very high value. The 
vesicles formed from the proniosomes prepared with tween were significantly larger 
than those prepared with span. The vesicles were found to be spherical and discrete 
with sharp boundaries from the optical microscopy images. Proniosomes prepared 
with the surfactant span 60 provided a higher penetration across the skin than did 
those formulated with other spans and tweens. The optimized formulation was found 
to be stable for period of one month at all temperature range. From the experimental 
results and supportive theoretical analysis it was concluded that proniosomes may be 
a promising carrier for diclofenac due to their simple production and too easy scale 
up. 
Prajapati et.al.(2012)
143
 designed and evaluated the proniosomaldrug delivery system 
for flurbiprofen by coacervation-phase separation method using span 20, span 40, 
span 60, span 80, brij 35 as surfactants and cholesterol as membrane stabilizer.The 
formulated proniosomal systems were characterized invitro for vesicle size, drug 
entrapment, invitro drug release profiles and vesicular stability.The vesicle size was 
measured by optical microscopic examination, loading capacity was evaluated by 
centrifugation method, in-vitro release study was carried out using  franz-diffusion 
cell and stability study was carried outat refrigeration temperature (4-8°C), room 
temperature (25±2°C) and oven (45±2°C). Vesicle size analysis report suggested that 
vesicle size was decreased with decreasing HLB value of surfactant. Overall, the data 
clearly indicated that the proniosomal formulation with 50% w/w cholesterol and 50% 
w/w brij-35 had shown the optimum size (315.6 nm), highest entrapment efficiency 
(82.56 %) and highest amount of percentage drug release (80.42%).  Stability study 
results showed that proniosome formulation was stable at refrigeration and room 
temperature. It was evidenced from the study that the proniosomes are the promising 
extended delivery system for the drugflurbiprofen. 
Viviane et.al.(2012)
94 
formulated and evaluated the proniosomal systems foracyclovir 
by adopting three different methods such as Slow spray-coating method,slurry method 
and coacervation phase separation method. Prepared systems were evaluated through 
angle of repose, IR spectroscopy, differential scanning calorimetry, microscopical 
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examination, particle size analysis, invitro release studies, intestinal permeation 
studies and stability studies. Angle of repose was investigated by funnel method. IR 
spectroscopy and differential scanning calorimetry were used to evaluate interactions. 
Vesicle formation and vesicle morphology was evaluated by microscopical 
examination. Particle size and size distribution were investigated by using a laser 
diffraction particle size analyzer.  In vitro release study was carried out by USP type 
II dissolution apparatus. Intestinal permeation study was employed by using guinea 
pigs small intestine. Stability study was carried out by storing the formulation at 4°C 
± 1 and at 25°C ± 2. Optical microscopical images showed that the uniform vesicles 
in all formulations. Spherical, discrete vesicles were observed by transmission 
electron microscopy. The data indicated that higher lipid concentration increased the 
vesicle size as well as entrapment efficacy. Dry proniosome powder had shown 
smaller angle of repose value than that of the carrier. IR and DSC spectras proved that 
there were no chemical interactions between carrier and drug. Invitro release profiles 
pointed to an initial higher release of drug from formulations followed by less release 
up to 8 hours. Exvivo intestinal permeability studies revealed that drug diffused at a 
higher rate from the formulations than from pure drug solution.  From the stability 
study data it was found that 4°C±1°C was optimal temperature for storing proniosome 
derived noisome and 25°C±2°C for dry proniosomes. Thus, it was concluded that 
proniosomes might be a promising carrier for the entrapment of acyclovir.
 
Rita  et.al.(2012)
144 
prepared and evaluated the modified proniosomal gel by modified 
coacervation phase separation technique with different combination of non-ionic 
surfactants (tweens and spans) with phospholipids such as phospholipon 80H and 
90H. Taguchi design of experiments was used to optimize the various formulation 
variables.The formulations wereevaluated for entrapment efficiency, vesicle 
formation, surface morphology, invitro release study, exvivo permeation study, skin 
deposition study, skin irritation study and stability studies. Entrapment efficiency was 
carried out by centrifugation method, Vesicle formation was examined under 
triangular research microscope with fujifilm digital camera. Vesicle size was analysed 
by malvern particle size analyser.The surface morphology was studied by scanning 
electron microscope. Invitro release studies were performed using locally fabricated 
franz-diffusion cell. Exvivo permeation and skin deposition study was determined by 
using the male wistar rat  skin mounted franz diffusion cell. Skin irritation study was 
performed using control, standard skin irritant, placebo and test on rabbit skin. 
CHAPTER 3                                                                                               REVIEW OF LITERATURES 
 
J.K.K. NATTRAJA COLLEGE OF PHARMACY Page 67  
 
Physical stability testing was carried out to  investigate the leaching of drug from the 
vesicles  by stored at refrigeration temperature (4˚C - 8˚C) and at 30˚C for three 
months. From the results it was found that noisome vesicles were smaller with HMPG 
formulation containing tween 60: span 40 with phospholipon 90 H and tween 20: 
tween 60 with phospholipon 80 H. Tween 60: span 40 with phospholipon 90 H 
formulation (H90-5) showed the highest entrapment efficiency of 94.8%. The vesicles 
were found to be round, smooth surface without the  formation of aggregates. For the 
optimized H90-5 and H80-4 formulations the drug releasemechanism from the 
vesicles followed korsmeyer-peppas kinetics with anomalous transport and fickian 
diffusion mechanism. Exvivo drug permeation into the skin showed only 1.18 % and 
drug deposition in the SC was found to be 88.24% at the end of 24 hours. The H90-5 
formulation was found to be stable for three months at refrigeration temperature. The 
results revealed that modified proniosomal formulations of hydroxyzine 
hydrochloride were suitable for topical drug delivery system for the treatment of 
localized urticaria. 
Ashish et.al.(2012)
40
 developed and characterized the perindopril erbumine loaded 
proniosomal gel by coaservation phase separation method  using different surfactants 
in different ratios. The prepared proniosomal formulation were evaluated for vesicle 
size analysis, rate of spontaneity, surface morphological studies,  encapsulation 
efficiency, invitro release study,  stability studies, invitro permeation study and drug 
release kinetic data analysis. Vesicle size was observed under optical microscope, rate 
of spontaneity was evaluated using neubauers chamber, surface morphology was 
studied using scanning electron microscopy, encapsulation efficiency was determined 
by centrifugation method, invitro release study was performed by using franz-
diffusion cell, stability studies. was assessed by keeping the proniosomal gel at three 
different temperature conditions, i.e., refrigeration temperature (4-8°C), room 
temperature (25±2°C) and oven (45±2°C), invitro permeation study was determined 
by using abdominal rat skin  mounted franz diffusion cell, Fitness of the drug release 
data in different kinetic models like zero order, Higuchi’s and Peppa’s were studied. 
The results of vesicle size analysis indicated that vesicle formed with span is smaller 
in size than vesicle formed with tweens. rate of spontaneity was found between 
9.10±0.65mm3×1000 and 15.26±5.35mm3×1000,  entrapment efficiency was found 
to be higher in case of proniosome prepared with span40 and span60 thanproniosome 
prepared with tween. It was found that the optimized formulation showed controlled 
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releaseproperty from 10 to 24 hrs and the he release rate was constant from 10
th
to 24
th
 
hrs. Thus the formulation exhibited zero order release over this period. From stability 
study the optimum storage condition forniosomes was found to be 4°C. From 
permeation study it was found that the formulation prepared with tween was slower as 
compared to proniosomal gel formulation prepared with span. The results of 
investigation demonstrated that proniosomes offers an alternative colloidal carrier 
approach intransdermal drug delivery of perindopril erbumine. 
Kapil et.al.(2011)
30
 developed and evaluated the proniosome- encapsulated curcumin 
for transdermal delivary by ether injection process using cholesterol, span 80 and 
diethyl ether. The formulated systems were characterized for vesicle size, drug 
content, surface morphology, drug entrapment, angle ofrepose, rate of hydration, 
vesicular stability and invitro skin permeation study.Vesicle size was measured by 
optical microscope. Drug content was measured spectrophotometrically.  Surface 
morphology was examined using scanning electron microscope. Drug entrapment was 
determined by exhaustive dialysis method.  Angle ofrepose was measured by funnel 
method.  Rate of hydration was evaluated by using neubaur’s chamber. Vesicular 
stability was assessed by storing the formulations at various temperature conditions. 
Invitro skin permeation study was carried out by using albino rat’s abdominal skin 
mounted franz diffusion cell.The proniosome formulations had shown the size range 
of 3.84 - 4.66 μm.Drug content was maximum in formulation containing 200mg 
cholesterol. The noisome formulations were unilamellar and sphere-shaped with a 
smooth surface.Angle of repose of the formulation was found between 33.2°and 
36.2°. Rate of spontaneity was found between 11.19 and 16.58.The results showed 
that the formulation was quite stable at refrigeration temperature and room 
temperature. The formulations containing maximum amount of cholesterol showed 
prolonged invitro drug release of 61.8% over a period of 24 hours. It was revealed 
from the study that proniosomes are very stable and hopeful prolonged delivery 
system for the entrapment of curcumin. 
Hemant et.al. (2011)
145 
developed and evaluated the proniosomal gel of carvedilol by 
coacervation-phase separation method using  various ratios of sorbitan fatty acid 
esters, polysorbates, cholesterol and lecithin. The drug – excipients compatibility 
studies were performed in order to confirm absence of any interaction between drug 
and excipients. Proniosomal gel formulations of carvedilol were characterized for 
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entrapment efficiency, pH, vesicular shape and size, viscosity, drug content, invitro 
drug permeation study, stability study and skin irritation study. The drug – excipients 
compatibility studies were performed by differential scanning calorimetry and   FT-
IR. Encapsulation efficiency was determined by centrifugation method. The pH of 
each formulation was determined using pH meter. Vesicle size and shape of each 
formulation was determined by electron microscope. Viscosities of the formulated 
proniosomal gels were determined by brookfield viscometer. The drug content was 
determined by U.V. spectrophotometer. Invitro drug permeation was determined by 
dorsal abdominal skin of the wistar rat mounted franz  diffusion cell. The invitro flux 
was determined by fick’s law of diffusion. Stability studies were carried out by 
storing the optimized formulation at various temperature conditions as per ICH 
guidelines. Skin irritation study was performed using dorsal abdominal skin of rats. 
The results of DSC and FT-IR indicated that there were no interaction between the 
drug and excipients used in the formulation. The results of encapsulation efficiency 
determination indicated that formulation containing tween-80 had high encapsulation 
efficiency than formulations containing other surfactants. The pH of all the 
formulations were in the range of 5.24 to 7.60 that suits the skin pH, the formulations 
containing tween as surfactants had shown larger vesicles than span containing 
formulations. Viscosity measurement of all the formulations revealed optimum 
consistency. Uniformity in content of proniosomal gel was confirmed to assure 
uniformity in dosages. The drug permeation was maximum from formulation 
containing span 60 among all tested formulations. The results of stability study 
revealed that the formulation was stable at and room temperature as well. Skin 
irritation study had shown the suitability of formulation for transdermal application. 
Thus proniosomal gel will be suitable drug delivery system for carvedilol because of 
ease in preparation and stability for prolonged period. 
Hanan et.al.(2011)
146 
developed the proniosomes for transdermal delivery of 
vinpocetine by coacervation-phase separation method usingfood-grade sugar esters as 
non-ionic surfactant. The formulations were evaluated for the invitro aspects like 
encapsulation efficiency, vesicle size, morphology, interactions, invitro release, 
Exvivo permeation, stability, irritation studies and invivo absorption study. 
Encapsulation efficiency was evaluated after separating the unentraped drug by 
centrifugation method. The vesicle size was measured by mastersizer S – laser 
diffractometer. The morphology was examined by scanning electron microscope. 
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Interactions between vinpocetine and vesicle ingredients were studied by differential 
scanning calorimetry. The invitro drug release was determined by using USP 
dissolution tester. All formulations exhibited high entrapment efficiencies, apart from 
of the surfactant HLB and the entrapment efficacy was varied with varying 
concentration of surfactant, cholesterol, lecithin and drug load. Vesicle size analysis 
showed that all vesicles were in the size ranging from 0.63 µm to 2.52 µm. SEM 
images had revealed that the formation of spherical vesicles with sharp boundaries. 
DSC results proved that the entrapment of drug into the bilayers of niosomal vesicles. 
Invitro drug release profile had shown slower release of drug from vesicle.Stability 
study results revealed that after storage for 3 months, theentrapment efficiency as well 
as mean vesicle size were not significantly differ from the same formulation when 
freshly prepared. Invivo absorption study revealed that the absorption of drug from 
proniosomal formulation wasextended and much slower over a longer period of time 
than that of the oral tablet. Thus it was concluded that sugar esters proniosomes could 
be a promising carrier for the drug vinpocetine. 
Shamsheer et.al (2011)
147 
formulated and evaluated the lisinopril dihydrate 
transdermal proniosomal gels by coacervation phase separation method using span 20, 
span 40, span 60, span 80, cholesterol and lecithin.The compatibility between 
lisinopril dihydrate and excipients was determined by using FTIR spectrophotometer, 
viscosity of the gel was determined by brook field viscometer. Vesicle size analysis 
was done by using optical microscope. Rate of spontaneity was determined with 
neubauers chamber. Entrapment efficiency was evaluated by centrifugation method. 
Invitro permeation studies were performed in franz diffusion cell. Stability studies 
were carried out at 3 different temperature conditionsover a period of one month. 
Drug release kinetics was evaluated by subjecting drug release data with  different 
kinetic models such  zero order, first order, higuchi model, and korsemeyer peppa’s 
equation model. FTIR spectral studies revealed that there was no interaction between 
drug and excipients. All the formulations showed that good viscosity and 
spreadability. The vesicle size was found in between 20.10 and 26.23μm. Optical 
microscopy revealed that the niosomes were homogenous and spherical. All 
formulations had shown zero order drug release via diffusion mechanism. The 
stabilitydata showed that proniosomal gel formulations were stable at 25±2°C and 4 
to 8°C. Thus it was concluded that, proniosomal gel of lisinopril dihydrate could be 
an effective for transdermal delivery. 
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Ammar et.al.(2011)
148
 formulated and evaluated the proniosomes as a carrier system 
for transdermal delivery of tenoxicam by modifieodd coacervation and phase 
separation methodusingdifferent types of non-ionic surfactants such as span 20, span 
60, span 80, tween 20,tween 60 and tween 80 in addition to cholesterol. Vesicle 
formation of the formulations were evaluated by light microscopy, Morphology of the 
prepared proniosome formulations were determined by transmission electron 
microscopy, Entrapment studies were carried out after separating the unentrapped 
drug by centrifugation method, The average size of the prepared proniosomes was 
performed by laser diffraction particle size analysis, stability studies were performed 
for three months to find out the aggregation or fusion of the vesicles. Invitro release 
studies were assessed for the selected proniosomal gel formulations by placing the 
proniosome gel containing cellulose bag at the bottom of the USP dissolution tester 
paddle type. Exvivo permeation studies were carried out by using male wistar rat’s 
skin. Skin irritancy test was carried out by using male albino rabbits, anti-
inflammatory effect was evaluated in arthritis induced male wistar rats, assessment of 
antinociceptive activity was done by using mice. The results of the microscopic 
examination revealed that the proniosomal vesicular structure.  The examined 
formulations appeared as spherical nano vesicles under the transmission electron 
microscope. The lecithin-free formulation showed the highest entrapment efficacy 
than the lecithin containing formulations and also it was found that entrapment 
efficacy was higher in tween 60 containing formulations than other formulations.  The 
particle size of the prepared proniosomes was found that size range lied between 50 
and 980 nm. The stability study revealed that the formulation prepared with distilled 
water were more stable. The release of drug from the stable formulations followed 
zero order kinetics. The irritation potential results proved that the formulations 
werenon-irritant to human skin. The optimized formulation had shown the higher anti-
inflammatory and analgesic effects compared to that of the oral marketed tenoxicam 
tablets.From the study, it was cleared that the lecithin-free proniosomal gel 
formulation provided both the highest entrapment efficiency and stability among other 
proniosome formulations. 
Gamal et.al.(2010)
73 
formulated and evaluated proniosomes as a drug carrier for 
transdermal delivery of meloxicamby modified coacervation-phase separation method 
using span 20, span 60, span 80, tween 20, tween 60, tween 80,  lecithin and 
cholesterol. Entrapment efficiency was performed by centrifugation method. Scanning 
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electron microscopy was used to characterize the surface morphology. In-vitro release 
was determined by franz diffusion cell. Invitro permeation of meloxicam from 
proniosomal gel formulations was investigated by albino rat skin mounted franz 
diffusion cell. The anti-inflammatory efficacy of span 60 containing formulation was 
evaluated by  male rats. The results of encapsulation efficacy revealed that the higher 
entrapment efficiency (95.20%) of span 60 formulations than the other formulations. 
Scanning electron microscopy results had shown the spherical and discrete vesicles 
with sharp boundaries. Niosomes prepared with tween 80 were significantly larger 
than those prepared with span 60. Lower invitro drug  release rate was observed from 
span 60 formulation compared to tween 80formulation. Proniosomes prepared with 
span 60 showed a higher permeation rate than those prepared with tween 80. 
Pronisomal maltodextrin gel exhibited  higher anti-inflammatory activity compared to 
standard gel. The results suggestedthat proniosomes could act as promising carriers 
offer an alternative approach for transdermal delivery of meloxicam. 
Intakhab et.al.(2010)
149 
developed and evaluated the proniosomaltransdermal  gel 
containing celecoxib by coacervation and phase separation method using span 40, 
span60, cholesterol and soya lecithin. All the prepared systems were subjected to 
physicochemical evaluations and anti-inflammatory studies. Vesicle size and size 
distribution were determined by photon correlation spectroscopy. The morphology 
and structure of formed vesicles were observed using transmission electron 
microscope. Entrapment efficiency was determined after separating the unentrapped 
drug by centrifugation method. Invitro skin permeation study was determined by 
albino rats skin mounted keshary- chien type diffusion cell. Stability of the 
formulations was determined by storing at room temperature and in a refrigerator. The 
anti-inflammatory activities of the formulation were evaluated by the carrageenan-
induced hind-paw oedema method. The results of vesicle size and size distribution 
indicated that the vesicles of niosomes formed from ethanol as a solvent were 
observed to be moderately larger than those formed from isopropanol as a solvent. 
The transmission electron microscope images of the niosomes obtained from 
proniosomal formulation had shown that the vesicles of spherical and separate with 
sharp boundaries. Vesicles formed from the proniosomal formulations containing 
span 40 and span 60 exhibited high entrapment. The formulation prepared by using 
span 40 exhibited high cumulative percentage of drug permeation across the skin.The 
consistency of the gel increased after one-month stability studies. The selected 
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proniosomal gel produced 100% inhibition of paw oedema in rats up to 8 hours after 
carrageenan injection.  It produced 95% and 92% inhibition after 12 hours and 24 
hours, respectively.  Thus celecoxib can be formulated into a low dose proniosomal 
gel that can save the recipient from the adverse effects of large doses. 
Lintu et.al.(2010)
150
 prepared and characterized the rifampicin proniosomes to 
improve the stability of conventional niosomes using rotary flash under vaccum 
condition. Sixformulations were prepared with three different surfactants by thin 
filmhydration method using myristyl alcoholand cholesterol as membrane 
stabilizers.The niosomal formulations were evaluated for size, percentage drug 
entrapment and invitro drug release. Size evaluation was done by optical microscope. 
Percentage drug entrapment was evaluated by using centrifuge. Lyophilization was 
also carried out for niosomal formulation.Invitro release studies were carried by 
himedia dialysis membrane. Unsonicated vesicles were found to be spherical and span 
20 preparation with cholesterol had large vesicle size when compared to the 
preparation Span 40 with myristyl alcohol. The formulations of span 20 with 
cholesterol andspan 40 with myristyl alcohol showed higher entrapment efficiency. 
Invitro drug release from span 20 preparation with cholesterol was found to be slower 
than with the preparation containing span 40 with myristyl alcohol. The study 
confirmed that the membrane stabilizing property of cholesterol had shown feasibility 
of preserving niosomal suspension in the form of proniosomes for a longer duration. 
Mohamed (2010)
29 
prepared and evaluated celecoxib proniosomesformulation by 
sequential spraying method using span 60, cholesterol and dicetyl phosphate. The 
formulations were evaluated for surface morphology, particle size and size 
distribution, entrapment efficiency, dissolution study and invivo evaluation study. 
Surface morphology was determined by transmission electronmicroscopy, particle 
size and size distribution was determined by a laser diffraction technique, entrapment 
efficiency was determined by centrifugation method, dissolution study was carried out 
by USP type II apparatus and invivo evaluation was done using human subjects. 
Perfect sphere shaped vesicles were observed from transmission electron microscopy 
images.  Size distribution study had shown that the limited variation in particle size. 
The mean encapsulation efficiency of proniosome-derived niosomes was found to be 
95.14±1.31%. The proniosomes exhibited slow drug release upto 1 lour and it was 
increased after 1 hour. invivo evaluation study proved that the improved 
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bioavailability of optimized proniosome formulation. Thus it was concluded that the 
proniosome formulation of celecoxib could be successfully formulated to enhance 
thebioavailability. 
Alaaet.al.(2010)
62 
prepared and evaluated proniosomal gel for terbutaline sulfate as 
transdermal drug delivery system by  coacervation-phase Separation method. There 
were 18 formulations were formulated  from mixing of one or two types of surfactants 
(span 20, span 40 ,span 60 span 80 ,tween 20 , tween 40 , tween 60 and tween 80 ), 
cholesterol and soya bean lecithin . The formulations were evaluated for appearance, 
pH, spontaneity (rate of hydration), surface morphology, three dimensional nature of 
vesicles, vesicle size and sizedistribution, encapsulation efficiency and invitro 
permeation study.Color, consistency and fluidity of the formulations were checked as 
appearance, pH was determined in order to avoid acidic and alkaline pH producing 
skin irritation. Spontaneity was observed by microscopic observations, surface 
morphology and three dimensional nature of vesicles were revealed by scanning 
electron microscopy, vesicle size and size distribution studies were done by  
calibrated ocular and stage micrometer fitted optical microscope, Centrifugation 
method was adopted for evaluating encapsulation efficiency. Invitro permeation was 
studied by franz glass diffusion cells. Microscopic observations showed that 
proniosomal gel formulations immediately converted to niosomal dispersions upon 
hydration. Optical microscope and scanning electron microscope pictures showed 
spherical shaped for all niosomes formulations and the size range in micrometer were 
2.35 to 8.82, the encapsulation efficiencies were 39.46% to 88.06%. In additionbetter 
permeation was obtained from proniosomal gel through rabbit skin. Thus the study 
concluded that proniosomal gel can be encapsulated hydrophilic drug such as 
terbutaline sulfate by coacervation-phase separation method. 
Tanket.al.(2009)
151 
formulated and evaluated aceclofenac loaded proniosome  by 
slurry method using span 60 as  surfactant, cholesterol as membrane stabilizer and  
maltodextrin as carrier. The formulations were evaluated for FT-IR studies, angle of 
repose, scanning electron microscopy, optical microscopy, entrapment efficiency, in-
vitro  drug release study, drug release kinetic data analysis, stability study, in-vivo 
anti-inflammatory study. Angle of repose was evaluated by a funnel method, 
entrapment efficiency was studied by dialysis method, in-vitro drug release was 
studied by dialysis bag method, kinetic data analysis was carried out by various 
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kinetic models, stability study was carried out for 3 months, in-vivo anti-inflammatory 
study for the best formulation was carried out using male wistar albino rats. FT-IR 
spectra confirmed that the firmness of aceclofenac during formulation. Results of the 
angle of repose measurements indicated that the smaller value than that of pure carrier 
maltodextrin. The images of SEM analyses had shown smooth surface of proniosome 
formulation. Optical microscopy results had shown the uniform size and shape of the 
vesicles. The optimized formulation had shown the higher encapsulation efficiency of 
83.24 ± 1.34 and in-vitro drugrelease of 97.122% at the end of 24hours. Drug release 
kinetics was best fitted to zero order kinetics and the drug release was followed super 
case II transport diffusion. The formulations had shown the stability for 90 days by 
storing at refrigerator condition. The optimized formulation had shown better 
therapeutic efficacy as compare to the pure drug solution. From the study it was 
concluded that aceclofenac loaded proniosome could be formulated to sustain the 
drug release and to reduce the side effects. 
Sankar et.al.(2009)
152 
formulated and evaluated the  proniosome drug delivery system 
for hydrocortisone by  coacervation-phase separation method. Vesicle size was 
observed under an optical microscope, encapsulation efficiency was evaluated by 
centrifugation method, drug content uniformity was assayed by spectroscopy, invitro 
release studies were carried out by himedia dialysis membranes and invivo anti-
inflammatory study was carried out in mice. The formulations were compared with 
each other and with a commercial cream. Vesicles formed from proniosome 
formulations with the combination of span were found to be in the range of 3 – 6 µM 
and in span, tween combinations the size range was 4 – 7 µm. Among the all 
proniosome formulations, encapsulation efficiency was maximum in span 20:40 and 
minimum in span20:tween 80 formulations. The drug content analysis showed that 
1% hydrocortisone proniosome gel formulation had a higher drug content uniformity 
than 2.5% hydrocortisone proniosome gel formulation. The proniosomal 
hydrocortisone gel formulations had shown more drug release than that of the 
marketed formulation. Proniosome hydrocortisone gel had shown diffusion type 
drugrelease which was confirmed by peppas and higuchi plot. In vivo studies 
confirmed that1% hydrocortisone proniosomeformulation was more active than a 
marketed 1 % hydrocortisonecream. The conclusion of this study showed that 
hydrocortisoneproniosome gel leads to prolonged action than commercial cream. 
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Ajay et.al.(2008)
153 
prepared, characterised and optimized aceclofenac proniosomes 
using central composite design and carry out stability studies. Three independent 
variables selected were molar ratio of drug to lipid, surfactant loading and volume of 
hydration. The dependent variables evaluated were percentage drug entrapment and 
mean volume diameter of proniosome-derived niosomes. Based on central composite 
design, 16 batches of proniosomes were prepared by slurry method. Contour plots 
were constructed to further elucidate the relationship between the independent and  
dependent variables. The second order polynomial equation generated from this 
experimental design using microsoft excel. The conformity of the polynomial 
equations was checked by preparing three checkpoint batches. From the computer 
optimization process and contour plots, predicted levels of independent variables for 
an optimum response of PDE with constraints on MVD were determined. The 
optimized batch was subjected to stability studies. The polynomial equations and 
contour plots developed using central composite design allowed us to prepare 
proniosomes with optimum responses. Proniosomes stored refrigerated and at room 
temperature, were both found to be stable. The study reveals that theslurry method 
was simple and suitable for laboratory scale preparation of aceclofenac proniosomes. 
The statistical approach for optimization of formulation is a useful tool, when several 
variables are to be studied simultaneously. 
Mahmoud  et.al.(2008)
154
 formulated and evaluated the proniosomal drug delivery 
system for flurbiprofen by coacervation-phase separationusing different non-ionic 
surfactants, namely span 20, span 40, span 60 and span 80 with and without 
cholesterol. Aqueous and alcoholic gels of HPMC-400 cP were simply prepared for 
the comparative study. The formulations were evaluated for microscopic examination, 
invitro drug release and invitro skin permeation study. Presence of insoluble drug 
crystals and proniosomal gel structure were examined by ordinary light microscopy. 
Invitro drug release was carried out by using semipermeable cellophane membranes. 
Invitro skin permeation study was carried out using albino male rabbits abdominal 
skin mounted dissolution – dialysis apparatus. Microscopical study of all span 
containing formulations showed that randomly scattered, spherical assemblies 
comprising multivesicular and multilamellar vesicles when hydrated. span 20 and 
span 80 comprising liquid proniosomal formulations showed a larger amount of drug 
penetration than the span 40 and span 60 containing proniosome formulations. Results 
showed that the controlled drug delivery for flurbiprofen, when all formulation 
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compared to the control. The quantity of drug released from cellophane membrane 
was significantly higher compared to the quantity permeated through the skin. From 
the investigation it was concluded that proniosomal drug delivery system of 
flurbiprofen is possible for topical drug delivery. 
Mahmoud et.al.(2008)
85
 developed proniosomal gels or solutions of flurbiprofen 
using nonionic surfactants span 20, span 40, span 60, and span 80 without and with 
cholesterol by the method reported by coacervation-phase separation with some 
modifications. Formulations were evaluated for vesicles structure by microscopic 
examination, entrapment efficiency by exhaustive dialysis of freshly prepared 
niosomes or centrifugation of freeze-thawed vesicles and the release of the prepared 
niosomes in phosphate buffer (pH 7.4) . The influence of different processing and 
formulation variables such as surfactant chain length, cholesterol content, drug 
concentration, total lipid concentration, negatively or positively charging lipids, and 
the pH of the dispersion medium on flurbiprofen EE% was demonstrated. Statistical 
analysis of the data was carried out using one way ANOVA followed by LSD test at a 
level of significant of P < 0.05. Results indicated that the EE% followed the trend 
span 60 (C18)> span 40 (C16)> span 20 (C12)> span 80 (C18). Results clearly 
revealed that the drug entrapment efficiency determined by the exhaustive dialysis 
method was lower than that determined bythe freeze thawing/centrifugation technique 
for both span 40 and span 60 systems. The effect of cholesterol on flurbiprofen 
entrapment was varied according to the nonionic surfactant used. Incorporation of 
cholesterol into span 40 and span 60 showed an initial increase in entrapment 
efficiency of flurbiprofen as cholesterol content was increased from 0 to 10 mol% 
followed by a decrease upon further increase in cholesterol content. Also flurbiprofen 
entrapment efficiency had shown highest level at acidic pH conditions and at higher 
drug concentration. Incorporation of either dicetyl phosphate which induces negative 
charge or stearyl amine which induces positive charge decreased the EE% of 
flurbiprofen into niosomal vesicles. Invitro release data for niosomes of span 40 and 
span 60 showed that the release profiles of flurbiprofen from niosomes of different 
cholesterol contents is an apparently biphasic release process.  It was cleared that 
niosomal formulations containing 10% cholesterol were the most stable among other 
tested formulations. As a result, this study suggested the potential of proniosomes as 
stable precursors for the immediate preparation of niosomal carrier systems for the 
drug flurbiprofen. 
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Chandra et. al. (2008)
57
 prepared and evaluated the maltodextrin and sorbitol based 
proniosome for the transdermal drug delivery system of piroxicam by modified 
reported methods using surfactant, cholesterol, lecithin. The formulations were 
characterized for encapsulation efficiency, surface morphology, in vitro skin 
permeation studies, in vivo anti-inflammatory studies. Encapsulation efficiency was 
studied by himedia dialysis membrane inserted glass tube. Surface morphology was 
evaluated by scanning electron microscopy. Invitro skin permeation studies were done 
by using abino wistar rat skin mounted keshary chien diffusion cel. In vivo anti 
inflammatory studies were performed by using carrageenan  injected male wistar rats. 
Among the all noisome formulation niosomes prepared with span 40 and span60 
showed maximum percentage encpsulation that was, 90.4 and 94.8% respectively. 
Maltodextrin bases proniosomes had shown 97.2% and sorbitol bases proniosomes 
had shown 98.6% entrapment.  The particle size analysis exposed that niosomes from 
span 40 were larger as compared to those of span 60. Niosomes of Span60 
formulation was smaller in size and better permeated through the skin. The amount of 
drug permeated across rat abdominal skin from piroxicam carbopol gel, lecithin 
containing span 60 niosomes, maltodextrin based proniosomes and sorbitol based 
proniosomes flux attained at the end of 24 hour was 4.82, 35.61, 20.14 and 19.05 
μg/cm2/h respectively and their enhancement ratios were 1.00, 7.39, 4.18 and 3.95 
respectively. The inclusion of maltodextrin and sorbitol retarded drug release. The 
outcome of the anti-inflammatory studies revealed that span 60 based lecithin vesicles 
showed significant reduction in paw swelling. Thus Proniosomes could be capable of 
delivering piroxicam via transdermal delivery system. 
Ajay B Solanki et. al. (2007)
155
 formulated and optimized proniosomes for piroxicam 
by slurry method using 3-factor, 3-level box-behnken design. Fifteen batches of the 
formulations were prepared by adopting molar ratio of span-60: cholesterol, surfactant 
loading and amount of drug as independent variables and percentage drug entrapment 
as dependent variable.The formulations were evaluated for surface characteristics, 
vesicle size and percentage drug entrapment. The surface characteristics of all batches 
were observed by scanning electron microscopy. The vesicle sizes were evaluated by 
using a particle size analyzer. The percentage drug entrapment was calculated after 
finding the concentration of unentrapped piroxicam by dialysis method. Scanning 
electon microscopy images of proniosomes showed the images of surfactant mixture 
coated on the carrier particle. The percentage drug entrapment values measured for 
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the various batches showed wide difference from 68.58% to 85.72%.The optimum 
formulae had shown 82.16% drug entrapment and 4.86µm vesicle size. The present 
work conclusively explained the application of a Box-Behnken design in optimization 
of Piroxicam proniosome formulations. 
Ankur et.al (2007)
156 
designed and developed the proniosomal transdermal drug 
delivery system for captopril by coacervation-phase separation method. There were 
18 formulations were prepared using various ratios of sorbitan fatty acid esters, 
cholesterol and lecithin. The formulations were characterized invitro for vesicle size, 
rate of spontaneity, drug entrapment efficacy, drug release and vesicular stability 
stidies. Vesicle size was observed under optical microscope.  Rate of spontaneity was 
evaluated by neubauers chamber.  Drug entrapment efficacy was determined by 
centrifuge. Drug release studies were performed using locally manufactured franz-
diffusion cell. Vesicular stability studies were carried out for 4 weeks at different 
storage conditions.From the results it was observed that captopril was best entrapped 
by proniosomesprepared with Spans 40 and 60.Vesicle size was found to be smallest 
in span 85 containing formulation. Niosomes containing butanol and isopropanol 
were formed more spontaneously than niosomes containing ethanol and propanol. 
Spherical and homogenous vesicles were observed by TEM. Invitro studies showed 
controlled release of entrapped captopril from the formulations. From the stability 
study results, high drug retention was observed at refrigerated conditions. It was 
evidencedfrom the study that proniosomes are a promising prolonged delivery system 
for captopril and have reasonably excellent stability characteristics. 
Jaleh et. al. (2005)
157
 developed and characterized sorbitan monopalmitate based 
chioropheniramine maleate proniosomes for transdermal deliveryusing span 
40,cholesterol,lecithin,dicetyl phosphate and different alcohols by coacervation phase 
separation method.The formulations were evaluated for vesicle formation, size, size 
distribution,entrapment efficiency,invitro release and stability studies. Vesicle 
formation was confirmed by optical microscopy. Size and size distribution was 
measured by laser light scattering method. Entrapment efficiency was measured by 
spectrophotometrically from unentrapped free drug and also from drug in vesicles. 
Invitro release studies were evaluated by a franz-cell using cellulose nitrate 
membrane.Stability studies were performed at room temperature and in refrigerator 
for 90 days. Microscopic studies showed that formulation produced more 
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spherical,larger and multilamellar structures as compared with others. The dissolution 
profile showed that the presence of DCP and lecithin slow down the drug 
release.Lecithin containing formulation had shown more stability. Finally it was 
concluded that proniosome derived niosome appear to be as better or good than 
conventional niosomes. 
Ibrahim et.al.(2005)
82
 developed and characterized the proniosomes as a drug carrier 
for transdermal delivery of ketorolac by modified coacervation-phase separation  
method using surfactants and membrane stabilizers. Encapsulation efficiency was 
evaluated after separating unentrapped drug by centrifugation method. The shape, 
surface characteristics, and size of the niosomes were observed by scanning electron 
microscopy. Invitro release study was carried out by  cellophane dialyzing membrane 
mounted glass tube. Invitro permeation study was determined using dorsal skin of 
albino rabbit, mounted  Franz diffusion cell. As per the results, niosomes formed from 
span 60 and tween 20  exhibited a very high encapsulation efficiency. Niosomes 
prepared with tween 20 were significantly larger than those prepared with span. The 
scanning electron microscopy images had shown spherical and discrete vesicles with 
sharp boundaries. Drug release from proniosomes prepared with tween showed no 
significant difference from the control. A higher drug release had seen from niosomes 
prepared with span 60 than from the control. Increasing the cholesterol content in the 
vesicles did not affect the transdermal delivery of the drug. On the other hand, 
reducing lecithin content resulted in a lower flux. The experimental results and 
supportive theoretical analysis suggest that either fusion of the vesicles with the 
intercellular lipid of the stratum corneum and direct transfer of drug from vesicles to 
the skin and/or the penetration enhancement effect of the nonionic surfactants may 
contribute to the mechanism of drug permeation enhancement by proniosomal 
formulations containg ketorolac 
Almira et.al. (2001)
39 
evaluated the SEM imaging to predict the quality of niosomes 
from maltodextrin-based proniosomes. The proniosome formulations were prepared 
by slurry method using span 60, cholesterol, dicetylphosphate and maltodextrin 500 
and 700. The morphology of proniosome powder was evaluated by scanning electron 
microscopy. Proniosomes were converted into niosomes using vortex mixer. 
Niosomes were characterizeed by particle size measurement using an accusizer, 
vesicle formation was confirmed by using inverted-stage microscope. The 
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morphological study revealed that the uncoated solid particles were highly convoluted 
and irregular, but the hollow particles have balloon-like forms with a smooth surface. 
The surface characteristics of proniosomes showed that much of the fine structure on 
the surface of particles had been filled by surfactant in the proniosome, even at the 
low loading. The surface texture was found to be smooth up to 16× surfactant loading, 
but at (32×) it was rough and cracked. The surfaces of high load proniosomes were 
quite thick and coarse in texture. Based on light scattering measurements the yield of 
niosomes in the 0.5 to 100 mm size range was lesser for proniosomes with high 
surfactant load and it was similar in all formulation. The optical micrographs showed 
that the number of small diameter vesicles was higher  in samples made from low 
load proniosomes, and that the number of large vesicles was more in the samples from 
high load proniosomes. It was found that M700 can carry 3–4 times as much 
surfactant as M500 particles because of the more surface area of M700. Thus it was 
concluded that M700 proniosomes were more efficient system for niosome formation 
than that of M500 proniosomes. 
Jia et al.(2001)
158 
prepared and characterized the proniosome formulations of 
estradiol by coacervation phase separation method using span 40, 60 & 85, tween 20, 
40 & 80, lecithin and cholesterol. The physiochemical properties were characterized 
for encapsulation percentage, vesicle size, invitro permeation study and drug content. 
The percentage encapsulation was determined after separating the untrapped drug by 
centrifugation method. Vesicle size was analyzed with coulter submicron particle-size 
analyzer. Invitro permeation study was determined by wistar rat skin mounted franz 
diffusion cell. HPLC analytical method was adopted to study the drug content. From 
the results it was found that the percentage entrapment efficiency was high in 
proniosomes prepared from span series and vesicle sizes were lower in tween 
containing formulations. Invitro permeation study showed that the differences 
between the various formulations of different cholesterol content and surfactant ratio 
in the behavior of transdermal delivery of drug across skin. The experimental results 
and supportive theoretical analysis suggested that proniosome systems may become a 
very useful dosage form for the delivery of estradiol across skin.   
Almira et.al.(2001)
66
 discovered the novel maltodextrin based proniosomes by slurry 
method as an alternative to sorbitol based proniosomes. Two morphological forms of 
maltodextrin such as maltrin QD M500 and maltrin M700 were used as carrier to  
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encapsulate alprenolol hydrochloride. Span 60 was used as surfactant, cholesterol was 
used as membrane stabilizer and dicetylphosphate was used as negative charge 
inducer. The formulations were characterized for morphology, entrapment efficacy 
and particle size. The morphology of the proniosome powder was evaluated by 
scanning electron microscopy. Entrapment efficacy was measured by using 
centrifugation assay. Particle size of niosome suspensions was measured by light-
blockage particle sizer. SEM images of M700 proniosomes appeared very similar to 
the original material, but,the process of coating the maltodextrin 500 with surfactant 
leads to clumping and larger particles.Entrapment efficacy results had shown the 
higher entrapment at 1mmol/L drug concentration and lower entrapment at 10mmol/L 
drug concentration. The vesicle diameter distribution of niosomes from maltodextrin 
based proniosomes was  centered at 4-5 µm with a width at half maximum of 7-8 µm. 
This method solved the problems associated with traditional methods for producing 
niosomes. The results of the study indicated that hydrophobic or amphiphilic drugs  
can be successfully encapsulated in the maltodextrin-based proniosomes by slurry 
method. 
Chengjiu et.al.(1999)
68
 prepared and evaluated the novel drug carrier proniosomes for 
ibuprofen and 5(6)-carboxyfluorescein by modified slurry method using span 60, 
cholesterol, dicetyl phosphate, chloroform and ethanol. Conventional niosomes were 
prepared by thin film hydration method. The prepared systems were evaluated for 
microscopical analysis, angles of repose, particle size and size distribution, 
entrapment efficiency and  invitro drug release. The morphology was observed under 
microscopically by scanning electron microscopy and transmission electron 
microscopy. Angles of reposewasmeasured by funnel method.   Particle size and size 
distribution was measured with laser diffraction particle size analyzer. Entrapment 
efficiency was measured by centrifugation method. Invitro drug release was carried 
out by dialysis tubes. Scanning electron microscopy images of uncoated sorbitol and 
dry proniosome powder revealed that the slight difference in the appearance of the 
surfaces. Results of the angle of repose measurements of proniosome powder and 
sorbitol  indicated that the angle of repose of dry proniosome powder is lesser than 
that of pure sorbitol.Transmission electron microscopy images had shown that 
niosomes formedby the conventional methods are very heterogeneous, but niosomes 
derived from proniosomes were more uniform. Particle size of noisomes prepared 
from proniosomes were smaller than that of the conventional niosomes. The 
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entrapment efficiencies were about 85–97% under all conditions due the lipophilic 
character of drug ibuprofen. The entrapment efficiency of 5(6)-carboxyfluorescein in 
conventional niosomes is much higher than that of proniosome-derived niosomes. 
Overall, gastric fluid release profiles and simulated intestinal fluid release profiles of 
ibuprofen from niosomes prepared from proniosomes or by conventional methods had 
shown little difference. (6)-carboxyfluorescein released very rapidly from niosomes in 
simulated gastric fluid and in intestinal fluid it was significantly lower thanthat of the 
control solution. In all comparisons, proniosome-derived niosomes were as better than 
conventional niosomes. 
Bhavana et.al.(1998)
67
 developed and characterized the proniosome system for the 
transdermal delivery of levonorgestrel by coacervation phase separation method using 
span 20, 40, 60 and 80, lecithin, cholesterol, DCP, PEG-200 and various alcohols. The 
system was evaluated for morphology, size, size distribution, entrapment efficiency, 
invitro permeation study, invivo study and biological assay.Morphology, size and size 
distribution were evaluated using optical microscope. Entrapment efficiency was 
evaluated after separating the free drug by cellophane dialysis tubing. Drug diffusion 
studies were performed using rat skin mounted keshary-chien type diffusion 
cell.Stability studies were performed at 4⁰C and 30⁰C. Invivo evaluation was 
performed with female albino rats.Biological assay for progestational activity was 
estimated by endometrial assay method. Vesicle size was found to be reduced during 
agitation and ultrasonication and it was varied based on the alcohol content. The 
entrapment efficiency was varied from 92.3% to 97.9%. Drug release was found to be 
maximum for DCP containing formulations than that of other 
formulations.Formulations made with isopropanol gave maximum drug permeation 
with flux score of 3.19µg cmˉ2hˉ1. The selected formulations were found to be more 
stable at 4⁰C temperature. From the results of invitro study and biological assay it was 
concluded that the utility of levonorgestrel proniosomal transdermal patch effective 
for contraception.    
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4. SCOPE AND PLAN OF WORK 
4.1. Scope of the work : 
 Provide an ideal drug delivery system of anti HIV drug abacavir sulphate in 
order to maintaining the therapeutic plasma concentration for a required period 
of time to achieve optimal drug therapy.  
  Help patients by developing clinically safe and effective formulation. 
  Improve patient compliance and effectiveness of antiretroviral therapy.  
 Reduction of toxicity.  
 Efficient drug delivery with minimum dose  
4.2. Plan of work: 
Phase I  
Review of literature. 
Phase II 
Procurement of drugs, surfactants, cholesterol and other excipients for 
formulation development.  
Phase III 
Preformulation study: 
 Screening of drugs. 
 Evaluate organoleptic property, particle size, solubility and partition co-
efficient of selected drug.  
 Drug – excipients compatibility studies to confirm absence of any interaction 
between drug and excipients. 
 Determination of abacavir sulphate amount to be used in a proniosome 
formulation. 
 Preparation of calibration curve of drug. 
Phase IV 
 Primary development of trial batches of niosomes to establish the required 
profiles. 
 Physico chemical evaluation of prepared niosome formulations and selection 
of best formulation in each category based on the evaluation. 
 In vitro drug release study of noisome formulations.  
 Stability study of best noisome formulation.  
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Phase V 
 Formulation development of proniosome formulation based on the 
concentration of surfactant and cholesterol used in the noisome formulations.  
 Physico chemical characterization of prepared proniosome formulations and 
selection of best formulation in each category based on the evaluation. 
 In vitro drug release study of pronoisome formulations. 
 Stability study of best proniosome formulation.  
Phase VI 
Pharmacokinetic study of best noisome and proniosome formulations.  
  Phase VII  
Comparition of noisome with proniosome formulations and prove the 
advantages of proniosome formulations.  
Phase VII  
Anti HIV testing of best abacavir sulphate loaded proniosome formulation. 
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5.1. MATERIALS AND EQUIPMENTS 
5.1.1. MATERIALS 
Table 5.1.1: Materials used 
 
 
 
 
 
S.No. Materials name Manufacturer name 
1 Abacavir sulphate Cipla Limited, Mumbai. 
2 Cholesterol SDFCL sd fine – chem. Limited, Mumbai. 
3 Maltodextrin Loba Chemie pvt. Ltd, Mumbai. 
4 Span 20 Tokyo Chemical Industry Co., Ltd, Japan. 
5 Span 40 SDFCL sd fine – chem. Limited, Mumbai. 
6 Span 60 Loba Chemie pvt. Ltd, Mumbai. 
7 Span 80 SDFCL sd fine – chem. Limited, Mumbai. 
8 Tween 20 HiMedia LaboratoriesPvt. Ltd, Mumbai. 
9 Tween 40 Tokyo Chemical Industry Co., Ltd, Japan. 
10 Tween 60 HiMedia LaboratoriesPvt. Ltd, Mumbai. 
11 Tween 80 Tokyo Chemical Industry Co., Ltd, Japan. 
12 Ethyl alcohol 
Jiangsu Huaxi International Trade Co. Ltd, 
China 
13 Sodium hydroide pellet Merck Specialties  Private Limited, Mumbai. 
14 
Potassium   dihydrogen       
orthophosphate 
HiMedia LaboratoriesPvt. Ltd, Mumbai. 
15 Chloroform SDFCL sd fine – chem. Limited, Mumbai. 
16 Carbinol for HPLC Ultra International, Bangalore. 
17 Methanol SDFCL sd fine – chem. Limited, Mumbai. 
18 n-Butyl Alcohol S d fine – Chem Limited, Mumbai. 
19 Hydrochloric Acid Merck Specialties  Private Limited, Mumbai. 
20 Ethanol Changshu yangyuan chemical, China. 
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5.1.2. EQUIPMENTS 
Table 5.1.2: Equipments used 
S.No. Equipments name Equipment manufacturer Model 
1 Rotary flash evaporator 
Heidolph Instruments 
GmgH &CO, Germany 
RW-1025G 
2 
UV-Visible  
spectrophoto meter 
Shimadzu corporation, Japan UV-260 
3 Refrigerated centrifuge Eppendorf AG, Germany. 5430R 
4 ZetaSizer (Nano – ZS) 
Malvern Instruments Ltd., 
England 
Nano-ZS 
5 
Differential scanning 
calorimeter 
Perkin Elmer, India DSC 6000 
6 
FT-IR  spectrophoto 
meter 
Jasco, Japan FTIR-6300 
7 
Scanning electron 
microscopy 
Jeol Ltd., Tokyo, Japan JSM 6390LA 
8 
Transmission electron 
microscopy 
Jeol Ltd., Tokyo, Japan JM 2100 
9 Probe sonicator Sonics & Materials.Inc, U.S.A. VCX750 
10 
Electronic digital 
balance 
Sartorius AG, Germany. CP225D 
11 Magnetic stirrer 
Remi Lab World, Mumbai, 
India 
2ML DX 
12 
Ultra performance 
liquid chromatography 
Shimadzu corporation, Japan NexeraX2 
13 Electronic microscope Labomed T250L250 CE 
14 Bath sonicator Branson 3800 
15 
Lyophilizer freeze 
dryer 
Penquin classic plus - 
16 Ice flaking machine Castle Mac, Italy. F – 80C 
17 
Dissolution test 
apparatus 
Labindia Instruments pvt.ltd. 
Mumbai. 
DS8000 
18 Hydraulic pellet press 
Kimaya Engineers, 
Maharashtra. 
- 
19 
Ultra – low 
temperature freezer 
Panasonic, Japan. 
MDF-U55V-
PE 
20 Desiccator TarsonsRockwac - 
21 Refrigerator Whirl Pool FF 2D27543 
22 Stability Chamber BIO. NIIK innovation - 
23 Vortex mixer Spinix, Delhi, India - 
24 Fuming Hood 
Modern Lab furnishers, 
Chennai. 
- 
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5.2. DRUG PROFILE 
NAME        : ABACAVIR SULPHATE 
CHEMICAL STRUCTURE          : It is a synthetic carbocyclic purine 
(guanosine) analog.
120,159
 
 
Figure 5.2.1: Structure of abacavir sulphate 
IUPAC NAME   :  [[(1S, 4R)-4-[2-amino-6- (cyclopropylamino)-
9H-purin-9-yl] cyclopent -2-enyl-1]- 
methanol] sulfate.
160,161
 
MOLECULAR FORMULA         :     (C14H18N6O) 2•H2SO4
160,161
 
MOLECULAR WEIGHT          :    670.74
160
 
MELTING POINT                        :     165°C 
DESCRIPTION                             :    White or almost white crystalline   
       powder.
161,162
 
PLASMA HALF LIFE                  :     1-1.5 hours
121
 
DRUG APPROVAL                      :     It was approvedin 1998 as a nucleoside 
reverse transcriptase inhibitor.
119
 
USUAL DOSE                               :     Adult:300 mg twice daily or 600 mg once   
                                                              daily.
120,121,161,163,164
 
Child: 3 months to 12 years – 8 mg/kg body 
weight every 12 hours (maximum 600 mg 
daily)
164
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DOSAGE ADJUSTMENTS 
163
    :   CrCl 50-80ml/min  -  No change 
 CrCl 10-50 ml/min  -  No change. 
 CrCl < 10 ml/min  -  No change.                                                         
   Mild hepatic insufficiency  - 200 mg BD. 
                            Moderate or severe hepatic insuiency  - Avoid 
ORAL BIOAVAILABILITY   : 80-85%
165 
SOLUBILITY                            : Soluble in water
166
, methanol and buffers 
PHARMACOKINETICS: 
Absorption: Wellabsorbed(>75%) after  oral administration.
119,159,167 
Distribution: It penetrates the cerebrospinal fluid.
119
 
                      It is50% bound to plasma protein.
120
 
Metabolism: 
               Extensively metabolized via step wise phosphorylation to 5’-mono-,di-,and 
triphosphate.
119 
Metabolized to inactive metabolities via alcohol dehydrogenase and 
glucuronyl transferase and metabolities appear in the urine.
159
 
Excretion: 
              Abacavir is eliminated by metabolism tothe5’carboxylic  acidderivative 
catalyzed by alcohol dehydrogenase, and by glucuonidation to the 5’-glucuronide. 
These metabolites account for 30% - 36% of elimination, especially.
120
 
Primary mode of elimination is through liver.1.2% is excreted unchanged in urine.
163 
SPECIAL PROPERTY :Abacavir is the only approved antiretroviral that is active  
as a guanosine analog.
120
 
 
MECHANISM OF ACTION: 
This guanosine analogue is a clinically potent ARV drug.
121 
It is initially 
monophosphorylated by adenosine phosphotransferase. The monophosphate is then 
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converted to (-)-carbovir 3’-monophosphate, which is then phosphorylated to the di- 
and triphosphates by cellular kinases. Carbovir 5’- triphosphate terminates the 
elongation of proviral DNA because it is incorporated by reverse transcriptase into 
nascent DNA but lacks a 3-hydroyl group.
120
 
Rapid reduction in plasma HIV –RNA count and rapid rise in CD4 cell count 
has been noted when abacavir was given to AIDS patient.
121
 
ADVERSE DRUG REACTION: 
  Headache, nausea, vomiting, malaise, skin rash, diarrhea, renal failure, 
dyspnoea, cough, sore throat, paraesthesia, arthralgia, dizziness, conjunctivitis, 
oedema, lymphocytopenia, lymphadenopathy,  hypotension, and possible increase in 
episodes of myocardial infarction.
119,159,164,165 
Abacavir has been reported to produce 
life-threatening hypersensitivity reactions in 5% of patients.
120,159,163,164,167,168 
CONTRAINDICATION 
              Pregnancy, lactation and moderate or severe hepatic insufficiency and renal 
disease.
163,164
 Abacavir can never be restarted once discontinued for hypersensitivity 
because reintroduction of the drug leads to rapid recurrence of severe symptoms, 
accompanied by hypotension, a shock like state and possibly death.
120 
DRUG FOOD INTERACTION:It can be taken without regard to meals.
119 
DRUG DRUG INTERACTION: 
   The drug does not show any clinically significant   drug-drug interactions.
119 
Increase methadone clearance with abacavir 600 mg bid.
163
                                                               
Abacavir is partly metabolized by alcohol dehydrogenase, hence concomitant intake 
of large dose of ethanol (0.7 g/Kg) increase the serum level of abacavir and may 
increase the toicity.
120,163.165
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PATIENT COUNCELLING DURING ABACAVIR SULPHATE 
ADMINISTRATION: 
 All patients should be screened for the HLA-B*5701 allele prior to initiating 
therapy with abacavir.
169
 
 Patient should be told the importance of regular dosing and how to recognize 
signs of hypersensitivity. 
164
 
 Suggest the patient to discontinue the therapy immediately if any symptoms of 
hypersensitivity develop and do not rechallenge because of rapidly appearing 
severe reactions that may lead to death. 
159,164
 
THERAPEUTIC USE:  

 It is a guanosine nucleoside analogue devoid of a 3’ – OH group and is 
indicated for the therapy of HIV-1 infection in adults and children as well as 
for post exposure prophylaxis.
165 

 It is approved for the treatment of HIV-1 infection , in combination with other 
antiretroviral agents.
120 

 In initial monotherapy studies, abacavir reduced HIV plasma RNA 
concentration upto 300 times more than that seen with other antiretroviral 
nucleosides, and it is increased CD4+ lymphocyte count by 80-200 
cells/mm
3
.
120 

 Adding abacavir to zidovudine and lamivudine resulted in a substantially 
greater decrease in plasma HIV-1 RNA than seen with the two - drug regimen 
of zidovudine plus lamivudine in adults or children.
 120 

 Abacavir is available in a co-formulation with lamivudine for once-daily 
dosing, which is how it is most commonly used.
 120 

 Abacavir is approved for use in adult and pediatric patients ≥ 3months of age, 
with dosing in the latter based on body weight.
 120 
STORAGE   : Store at a temperature not exceeding 30°C.
161,164
 
MARKETED PRODUCTS : Ziagen (abacavir sulphate), Kivexa(abacavir 
sulfate and lamivudine),Epzicom (abacavir and lamivudine).
170, 171,172,173,174. 
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5.3. EXCIPIENT PROFILE 
5.3.1. CHOLESTEROL
175 
Structure                                      :  
 
        Figure 5.3.1: Structure of cholesterol 
Synonyms   :           Cholesterolum; Cholesterin.  
Empirical Formula  :           C27H46O 
Molecular Weight  :           386.67 
Chemical Name :           Cholest-5-en-3b-ol 
Melting point   : 146 - 148°C 
Density   : 1.05gm/ml at 25°C 
Solubility   : Insoluble in water, soluble in organic solvents. 
Description                             : White or slightly yellow, approximately 
odorless, needles, powder, or granules.  
Incompatibilities             :  Cholesterol is precipitated by digitonin. 
Applications in Pharmaceutical Formulation: 
 Used in cosmetics and topical pharmaceutical formulations at concentrations of 
0.3–5.0% w/w as an emulsifying agent.  
 It imparts water-absorbing power to an ointment and has emollient activity. 
 To impart rigidity and orientational order to the niosomal bilayer.32 
 Used to increase the stability, permeability and encapsulation efficiency of 
vesicular membrane.
25
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Handling Precautions: 
 Use rubber or plastic gloves, eye protection, and a respirator during handling. 
 Avoid prolonged inhalation and ingestion of cholesterol to prevent 
atherosclerosis and gallstones. 
 When heated to decomposition, it emits acrid smoke with irritating fumes. 
Storage Conditions  : Stored in a well-closed container, protected from 
light. 
5.3.2. SPAN 20 
Structure   : 
 
Figure 5.3.2: Structure of span 20
 
Synonyms   : Sorbitan monolaurate
61
, Arlasel 20, Sorbitan 
laurate. 
IUPAC name                         : [2-[(2R,3R,4S)-3,4-dihydroxyoxolan-2-yl]-2-
hydroxyethyl] dodecanoate 
Molecular formula  : C18H34O6  
63
 
Molecular weight  : 346.5gm/mol
63
 
HLB Value   : 8.6
61,63,131,159
 
Phase transition tem. : - 16°C 
61,63,154 
Density   : 1.032 g/ml
61
 
Flash point   :  > 230°F
61 
Description   :  Clear viscous liquid 
63 
Use                                          : Emulsifying agents in the preparation of creams, 
emulsions and ointments. 
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5.3.3. SPAN 40 
Structure   : 
 
Figure 5.3.3: Structure of span 40 
Synonyms   : Sorbitan monopalmitate,
61
 
Molecular formula  : C22H44O6  
63
 
Molecular weight  : 402.6gm/mole
63
 
HLB Value   : 6.7
63
 
Phase transition tem.  : 42°C 
61,63,154 
Melting point   : 46-47°C
61
 
Flash point   : 113°C
61
 
Description   : Non toxic, odorless, yellowish powder 
63 
Preparation   : By sorbitol and palmitic acid anhydride  
                                                             reaction.
176 
Uses:
175,176 
 Used in pharmaceuticals industry, cosmetics, textiles as emulsifiers, thickening 
agent, stabilizing agent, lubricants, softening agent, antistatic agent, finishing 
agent and spinning additives. 
  Also used as a oil emulsifier, dispersant ink and the emulsion polymerization 
stability agent.  
5.3.4. SPAN 60 
Structure  : 
 
 
Figure 5.3.4: Structure of span 60 
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Synonyms   :  Sorbitan monooctadecanoate, Sorbitan   
                                                              Monostearate
61 
IUPAC name                         : Octadecanoic acid [2-[(2R,3S,4R)-3,4-
dihydroxy-2- tetra hydro furanyl]-2-
hydroxyethyl] ester.
177
 
Molecular formula  : C24H46O6  
63 
Molecular weight  : 430.6gm/mole
63
 
HLB Value   : 4.7
61,63,131
 
Phase transition tem.  : 53°C 
61,63,154 
Flash point   : > 110°C 
Melting point   : 54-57ºC 
61
 
Description   : White waxy powder 
63 
Application
175,177
  : 
 Used to encapsulate of various drugs in niosomes for targeted delivery.  
 It is on the investigation of use of surfactants as contrast agents  in diagnostic 
ultrasounds. 
 Showing higher entrapment efficiency in comparison with those of other 
surfactants.
32
 
5.3.5. SPAN 80 
Structure  :
 
 
 
Figure 5.3.5: Structure of span 80 
Synonyms : Sorbitan monooleate, Sorbitan (Z)-mono-9- 
octadecenoate
40 
IUPAC Name             : [(2R)-2- [(2R,3R,4S) -3,4- dihydroxyoxolan-2-yl]-2-
hydroxyethyl] (Z)-octadec-9-enolate. 
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Molecular formula : C24H44O6  
63 
Molecular weight : 428.6gm/mole
63
 
HLB Value  : 4.3 
61,63,131,154
 
Phase transition tem.: -12°C 
61,63,154
 
Density  : 0.994 g/ml at 20 °C
178 
Flash point  : >110ºC 
61 
Density  : 0.986 
61 
Description  : Amber viscous liquid 
63 
Viscosity  : 1000 centipoises
180 
Solubility                    : Soluble in mineral oils and vegetable oils, slightly 
soluble in ether, insoluble in acetone and dispersible in 
water.
180 
Stability                      :  Stable, combustible and incompatible with some strong 
oxidizing agents.
178 
Uses                             :  Used in medicine, textiles, cosmetics, paints etc. 
Used as solvent, lubricant, emulsifier, stabilizer and   
 softener.
179
  
Storage                        :  Store in dry and cool place.
179 
5.3.6. TWEEN 20
 
Structure   : 
 
Figure 5.3.6: Structure of tween 20 
Synonyms  : Polyoxyethylene (20) sorbitan monolaurate. 
Molecular formula : C58H114O26  
63 
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Molecular weight : 1227.54gm/mole
63 
HLB Value  : 16.7
60,61,131
 
Density  : 1.106 
61
 
Aq.solubility  : 100 g/L 
61 
Boiling point  : 100 ºC 
61
 
Description  : clear yellow to yellowish green viscous liquid
63 
Application  : It forms noisome vesicle in the presence of   
                   cholesterol.
175 
5.3.7. TWEEN40 
Structure  : 
 
Figure 5.3.7: Structure of tween 40 
Synonyms  : Polyoxyethylene sorbitan monopalmitate 
61 
Molecular Formula : C62H123O26   
Molecular weight : 1283.65 
HLB value  : 15.6 
61
 
Density  : 1.083gm/ml 
61 
Flash point  : > 230°F
182 
Solubility                          : Soluble in water, most organic solvents, diluted acids 
and alkalies; insoluble in vegetable oil.
182 
Water solubility : 100 g/L 
61 
Description  : Yellow to amber colored oily liquid. 
Use                              : Used as diffusant, solubilizer, emulsifier, stabilizer, and 
lubricant etc.
180 
Storage                       : Store in cool and dry draughty place.
181 
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5.3.8. TWEEN 60 
Structure  : 
 
Figure 5.3.8: Structure of tween 60 
Synonyms                         : Polyoxyethylene (20) Sorbitan Monostearate; 
Polyoxyethylene sorbitan monostearate
183 
Molecular formula : C64H126O26
63
 
Molecular weight : 1311.90gm/mole
63 
HLB Value  : 14.9
61,63 
Density  : 1.044 g/ml at 25 °
C183 
Water solubility : 100 g/l
61 
Description  : Amber colour viscous liquid 
63 
Storage temperature : Store at room temperature.
183 
Applications  : Usedas emulsifier in food and pharmaceutical  
                                                 preparations. 
 Used to solubilizes the essential oil in aqueous 
pharmaceutical products. 
    Used in colloidal targeted drug delivery system.
175 
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5.3.9. TWEEN 80 
Structure   :
 
 
Figure 5.3.9: Structure of tween 80 
 
Synonyms   : Polyoxyethylene (20) sorbitan monooleate.   
IUPAC name                         :  2-[2-[3,4-bis(2-hydroxyethoxy)oxolan-2-yl]-2-
(2-  hydroxyethoxy)ethoxy]ethyl octadec-9-
enoate.
184 
Molecular formula   :  C64H124O26
184
   
Molecular weight  : 1310 gm/mole
185 
HLB value   : 15.0
61 
Density   : 1.064 
61 
Flash point   : >110 ºC 
61 
Boiling point   : >100°C 
184
  
Viscosity   :  300-500 centistokes at 25°C
184
   
  
Description              :  Yellowish amber colored viscous liquid.  
Solubility                               :  Very soluble in water, soluble in vegetable oils, 
ethyl acetate, ethanol, methanol, toluene and insoluble 
in mineral oil. 
Water solubility                    :   5-10 g/100 ml
61 
Uses 
175
                                   : 
 Uses as emulsifier in foods in the concentration of 0.5% (v/v). 
 Used in soaps and mouthwash. 
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 Used to stabilize the aqueous pharmaceutical products for parenteral 
administration.  
 Used in the laboratory to identify the mycobacteria along with phenol red. 
Storage                               : Stored in cool, dry and draughty place.
175 
5.3.10. MALTODEXTRIN
175 
Structure                           : 
 
Figure 5.3.10: Structure of maltodextrin 
Synonyms                           : Maltodextrinum, Maltosweet, C*Dry MD. 
Empirical Formula            : (C6H10O5)nH2O. 
Molecular Weight              : 900–9000 
Category                             : Mixture of D-glucose, disaccharides 
88
and    
Polysaccharide.
57
 
Functional Category          : Diluent, binder in tablets and capsules, coating agent 
and  viscosity increasing agent. 
Solubility                             : Minimal solubility in organic solvents.
57
 freely soluble 
in water.
88
 
Speciality                             : Nonsweet nutritive saccharide 
Description                          : A white or almost white, odorless, slightly hygroscopic 
powder or granules.
 88
 
Preparation                         : It is prepared by the partial hydrolysis of starch with 
appropriate acids and/or enzymes. 
Application in pharmaceutics: 
 Used in tablet preparations as a binding agent and diluents in both direct-
compression and wet-granulation processes. 
 It does not adversely affect the dissolution rate of tablet and capsule. 
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 Used to increase the bioavailability of poorly soluble API in oil-in-water 
emulsion. 
 Useful in chewable tablet formulations and to augment the viscosity of 
solutions. 
 Used as a carbohydrate source in oral nutritional supplements. 
 The higher surface area results in a thinner surfactant coating, which makes the 
rehydration process more efficient.
 57
 
 The use of maltodextrin as the carrier in the proniosome preparation permitted 
flexibility in the ratio of surfactant and other components which can be 
incorporated.
57
 
 It can also be given to diabetic patient  because maltodextrin is non sweet 
polysaccharide i.e. beneficial for the patient of heart and sugar.
26
 
Limits: 
Aqueous film-coating      2–10% 
Carrier       10–99% 
Crystallization inhibitor for lozenges and syrups  5–20% 
Osmolarity regulator for solutions    10–50% 
Tablet binder (direct compression)    2–40% 
Tablet binder (wet granulation)    3–10% 
Storage:  
Maltodextrin should be stored in a well-closed container in a cool, dry place. 
Incompatibilities: 
Incompatible with strong oxidizing agents and undergo maillard  reaction with 
aminoacids. 
Handling Precautions: 
Observe normal protection appropriate to the situations and quantity of material 
handled. 
  Eye protection is suggested. 
 It should be handled in a well-ventilated surroundings and excessive dust 
production should be avoided. 
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5.3.11. DIACETYL HYDROGEN PHOSPHATE
186,187 
Structure  : 
 
Figure 5.3.11: Structure of diacetyl hydrogen phosphate 
Synonyms  : Bis(hexadecyl)phosphate, Dihexadecyl phosphate 
IUPAC name  : Dihexadecyl hydrogen phosphate 
Molecular formula :  C32H67O4P 
Molecular weight : 546.85 
Melting point  : 74-75°C 
Description  : Anionic surfactants - phosphate, white solid, 
Solubility  : Slightly soluble in water, soluble in ethanol. 
Storage temperature :  −20°C 
Safety and hazards : Take precautions to avoidskin irritation and eye 
damage. 
Stability  :  Stable at strong acid, easily hydrolyzed. 
Applications  : 
 Excellent dispersing, lubricating, antirust, anticorrosive, cleansing, wetting, 
emulsifying and fat-liquoring abilities. 
  Intolerance to hard water. 
  Low foaming and resistance to high concentrations of alkali and acidic 
conditions. 
  Does not affect surface activity and can be used as soap substitutes.  
 Compatible with skin as like natural phospholipids. 
 Used in children cleaning products. 
 To impart negative charge to the niosome vesicles.25 
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5.4. METHODOLOGY 
5.4.1. Preformulation studies: 
5.4.1.1. Screening of drugs: 
Various antiviral drugs like abacair sulphate, zidoudine, tenofoir, efairenz, 
lamividine, and staudine were selected. The comparitive table of selected drugs was 
prepared to find out the suitability of drugs for proniosome formulation.Based on the 
solubility, dosage frequency, half life, suitability to controlled release and adverse 
drug reaction abacavir sulphate was screened. 
5.4.1.2. Preparation of reagents:  
5.4.1.2.1. Preparation of phosphate buffer pH 7.4: 
Dissolve 6.8 gm of potassium dihydrogen orthophosphate and 1.56 gm of 
sodium hydroxide in 900 ml of water, adjust the pH 7.4 with sodium hydroxide 
solution and dilute the water to produce 1000 ml.
166
 
5.4.1.2.2. Preparation of phosphate buffer pH 6.8: 
Dissolve 28.8 gm of disodium hydrogen phosphate and 11.45 gm of potassium 
dihydrogen phosphate in sufficient water to produce 1000 ml.
166
 
5.4.1.2.3. Preparation of 0.1N HCl: 
Measure 8.5 ml of hydrochloric acid in 1 litre standard volumetric flask and 
make up the volume using demineralized water. 
5.4.1.3. Calibration of standard curve: 
Preparation of stock solution: 
Accurately weighed abacavir sulphate which is equivalent to 100 mg of 
abacavir was taken in three 100 ml standard volumetric flask with proper label. The 
content of first, second and third flask were dissolved in pH 7.4 phosphate buffer, pH 
6.8 phosphate buffer and 0.1N hydrochloric acid respectively. The volume of each 
flask was made upto 100 ml using respective buffer solutions to obtain a stock 
solution-1 containing 1000µg/ml abacavir. 
Identification of analytical wave length: 
The three stock solutions were appropriately diluted with their respective 
buffer solutions and scanned using the UV visible spectrophotometer (UV-260, 
Shimadzu, Japan) in wavelength range in between 400 nm to 200 nm. 
CHAPTER 5                                                                                             MATERIALS AND METHODS 
 
J.K.K. NATTRAJA COLLEGE OF PHARMACY Page 104 
 
Standard graph: 
From the stock solution-1, of three standard flask 10 ml of the contents were 
pipetted out into three 100ml standard volumetric flask and made upto the marks 
using respective buffer solutions (stock solution-2).  From thesethree stock solutions -
2, aliquots of 2ml, 4ml, 6ml, 8ml and 10ml were pipetted out into a series of 100 ml 
standard volumetric flasks and the volume was made upto the mark with respective 
buffer to get drug concentration in the range of 2 to 10 µg/ml. The absorbance of the 
resulting solutions were then measured at 285 nmincase of pH 7.4 and pH6.8 
phophate solution and 295 in case of 0.1N hydrochloric acid using UV double beam 
spectrophotometer against proper buffer solutions as blank. Three standard curves 
were obtained by plotting concentration (µg/ml) values in X-axis and absorbance 
values in Y-axis. 
5.4.1.4. Organoleptic properties of abacavir sulphate:
 
Organoleptic properties like color, odor and taste of abacavir sulphate were 
recorded.
188 
5.4.1.5. Particle size analysis: 
Particle size distribution of the abacair sulphate was estimated by analytical 
sieving method. The sieves were stacked on top of one another in ascending degrees 
of coarseness. The abacair sulphate powder was placed on the top sieve. The nest of 
sieves was subjected to a standard period of agitation. The weight of material retained 
on each sieve was exactly determined.
189 
5.4.1.6. Solubility Studies of pure drug: 
An excess amount of abacavir sulphate was added to each of distilled water, 
chloroform, ethanol, nbutanol,methanol, 0.1 N hydrochloric acid and phosphate buffer 
(pH 6.8 and 7.4). The mixtures were then kept in a well closed air tight containers at 
ambient temperature for 24 hours in vortex mixer to get equilibrium. The equilibrated 
samples were centrifuged at 3000rpm for 5 minutes. Aliquot portions of the 
supernatants were taken and properly diluted with phosphate buffer (pH 7.4) for 
quantification of abacavir sulphate spectrophotometrically at 285 nm.
56,85,132 
Approximate solubility of drug was indicated from the following limits.
166
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Very soluble: 1 part of the substance is soluble in less than 1 part of the solvent. 
Freely soluble: 1 part of substance is soluble in 1 to 10 parts of solvent. 
Soluble: 1 part of substance is soluble in 10 to 30 parts of solvent. 
Sparingly soluble: 1 part of substance is soluble in 30-100 parts of solvent. 
Slightly soluble: 1 part of substance is soluble in 100 to 1,000 parts of solvent. 
Very slightly soluble: 1 part of substance is soluble in 1,000 to 10,000 parts of 
solvent. 
Practically insoluble or insoluble: More than 10,000 parts of solvent is required to 
dissolve 1 part of substance. 
5.4.1.7. Partition co-efficient of pure drug: 
Accurately weighed quantity of abacavir sulphate equivalent to 100mg 
abacavir was dissolved in pH 7.4 phosphate buffer and  is shaken with theother 
partitioning organic solvent (n-butanol) for 30minutes, allowed tostand for 5 minutes, 
and then removed the lower and upper parts separately. Then the partitioning 
coefficient was obtained using the formula as follows. 
Kw
o
= Concentration of drug in organic phase/Concentration of drug in 
aqueous phase
56 
5.4.1.8. IR spectrum of pure Abacavir sulphate: 
The drug abacavir sulphate was confirmed by comparing the IR spectrum of 
the drug with published IR spectrum of abacavir sulphate in Indian Pharmacopoeia.
161
 
5.4.1.9. Drug – excipients compatability studies by FT-IR spectroscopy: 
The Drug – excipients compatibility studies were performed in order to 
confirm absence of any interaction between drug and excipients.
145 
Disappearance of 
an absorption peak or reduction of the peak intensity combined with the appearance of 
new peaks give a clear evidence for interactions between drug and excipient.
129
 
Compatibility studies were performed by preparing blend of different 
excipient with drug. These blend were placed in air tight screw cap amber colored 
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vials at accelerated condition like 40°C/75% RH for one week and carry out FT-IR 
analysis with saturated potassium bromide using pellet making method. Abacavir 
sulphate was also stored alone as a reference and each drug - excipient blend is further 
evaluated for changes like caking, liquefaction, discoloration and odor (or) gas 
formation. 
56,190
 
Table 5.4.1:  Drug :excipient compatibility protocol 
Sl.No Composition Quantity 
Ratio 
(Drug:Excipient) 
1 Abacavir Sulphate 100mg - 
2 Abacavir Sulphate + Cholesterol 150 mg 1:0.5 
3 Abacavir Sulphate+ Maltodextrin 300 mg 1:2 
4 Abacavir Sulphate+ Span 20 150 mg 1:0.5 
5 Abacavir Sulphate + Span40 150 mg 1:0.5 
6 Abacavir Sulphate + Span60 150 mg 1:0.5 
7 Abacavir Sulphate + Span 80 150 mg 1:0.5 
8 Abacavir Sulphate + Tween 20 150 mg 1:0.5 
9 Abacavir Sulphate + Tween 40 150 mg 1:0.5 
10 Abacavir Sulphate + Tween 60 150 mg 1:0.5 
11 Abacavir Sulphate + Tween 80 150 mg 1:0.5 
12 
Abacavir Sulphate + Dicetyl 
Phosphate 
125 mg 1:0.25 
 
5.4.1.10. Determination of abacavir sulphate amount to be used in a proniosome 
formulation: 
Molecular weight of abacavir is 286.33232 and molecular weight of abacavir 
Sulphate is 335.37132. The total amount of abacavir sulphate to be used in 
formulation to fulfill the required abacavir was calculated. 
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5.4.2. Formulation: 
5.4.2.1. Concentration and process optimization: 
The concentrations of nonionic surfactant and cholesterol were optimized to 
develop the stable dosage form with different nonionicsurfactants (spans and tweens) 
at 100, 150, 200 and 250 μM concentrations with an equalratio of cholesterol. 
Although vesicles were formed in all concentrations, the encapsulation efficiency was 
found to be very less except at 250 μM ratio. Thus 250:250μM ratio of 
surfactant:cholesterol was preferred for present formulation. The process-related 
variables like speed of rotation of flask, hydration medium and hydration time were 
optimized by trial and error method. 
 5.4.2.2. Abacavir sulphate niosome preparation: 
Niosome containing abacavir sulphate formulations were prepared by thin film 
hydrationmethod. The surfactants, cholesterol and dicetyl phosphate in 250: 250: 
5µM ratios were accurately weighed and transferred into a long necked 100 ml round-
bottom flask and dissolved in 10 ml chloroform. The flask was attached to a rotary 
evaporator and the organic solvent wasslowly evaporated at 60°C under reduced 
pressure at 100-150 rpm such that a thin dry film of the constituents was formed on 
the inner wall of the flask. Any excess chloroform was removed by leaving the flask 
in a desiccator under vacuum overnight. The dried thin film was then hydrated with 
10 ml pH 7.4 phosphate buffered saline containing 25 mg abacavir sulphate, (or 10 ml 
pH 7.4 phosphate buffered saline) by rotating the flask in the same rotary evaporator 
under normal pressure at 60°C in order to ensure complete hydration of the film. The 
prepared niosomal preparations (drug loaded/ blank) were stored in a refrigerater for 
the further evaluations.
 191,192
 
Table 5.4.2: Composition of abacavir sulphate  niosomal  formulations without 
charge inducer 
S.No Formulation 
code 
Surfactant used 250µM 
Surfactant 
250µM 
Cholesterol 
1 BNF1 Span 20 84.302 µl 96.66 mg 
2 BNF2 Span 40 100.64 mg 96.66 mg 
3 BNF3 Span 60 107.66 mg 96.66 mg 
4 BNF4 Span 80 108 µl 96.66 mg 
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5 BNF5 Tween 20 278.9 µl 96.66 mg 
6 BNF6 Tween 40 396.32 µl 96.66 mg 
7 BNF7 Tween 60 312.5 µl 96.66 mg 
8 BNF8 Tween 80 303.24 µl 96.66 mg 
9 DNF1 Span 20 84.302 µl 96.66 mg 
10 DNF2 Span 40 100.64 mg 96.66 mg 
11 DNF3 Span 60 107.66 mg 96.66 mg 
12 DNF4 Span 80 108 µl 96.66 mg 
13 DNF5 Tween 20 278.9 µl 96.66 mg 
14 DNF6 Tween 40 396.32 µl 96.66 mg 
15 DNF7 Tween 60 312.5 µl 96.66 mg 
16 DNF8 Tween 80 303.24 µl 96.66 mg 
# Drug content used 25 mg per batch, BNF-Blank noisome formulations, DNF- Drug 
loaded noisome formulation 
Table 5.4.3: Composition of abacavir sulphate niosomal formulation  with 
charge inducer 
S.No Formulation 
code 
Surfactant 
used 
250µM 
Surfactant 
250µM 
Cholesterol 
5µM Dicetyl 
Phosphate 
1 CBNF1 Span 20 84.302 µl 96.66 mg 2.73 mg 
2 CBNF2 Span 40 100.64 mg 96.66 mg 2.73 mg 
3 CBNF3 Span 60 107.66 mg 96.66 mg 2.73 mg 
4 CBNF4 Span 80 108 µl 96.66 mg 2.73 mg 
5 CBNF5 Tween 20 278.9 µl 96.66 mg 2.73 mg 
6 CBNF6 Tween 40 396.32 µl 96.66 mg 2.73 mg 
7 CBNF7 Tween 60 312.5 µl 96.66 mg 2.73 mg 
8 CBNF8 Tween 80 303.24 µl 96.66 mg 2.73 mg 
9 CDNF1 Span 20 84.302 µl 96.66 mg 2.73 mg 
10 CDNF2 Span 40 100.64 mg 96.66 mg 2.73 mg 
11 CDNF3 Span 60 107.66 mg 96.66 mg 2.73 mg 
12 CDNF4 Span 80 108 µl 96.66 mg 2.73 mg 
13 CDNF5 Tween 20 278.9 µl 96.66 mg 2.73 mg 
14 CDNF6 Tween 40 396.32 µl 96.66 mg 2.73 mg 
15 CDNF7 Tween 60 312.5 µl 96.66 mg 2.73 mg 
16 CDNF8 Tween 80 303.24 µl 96.66 mg 2.73 mg 
# Drug content used 25 mg per batch, CBNF- Charge inducer added blank niosome 
formulations, CDNF- Charge inducer added drug loaded noisome formulation 
5.4.2.3. Abacavir sulphate proniosome preparation: 
Proniosome formulations were prepared by the slurry method.  The slurry 
method is comparatively simple and is mostly useful for the carriers which are not 
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dissolving in organic solvents. In brief, accurately weighed amounts of lipid mixture 
(500 μM) comprising of surfactant and cholesterol, with 5 μM DCP were dissolved in 
4ml chloroform. The drug was dissolved in 6 ml methanol and the resultant 
solutionswere transferred to a 250 ml round bottom flask having maltodextrin 
carrier.Additional chloroform: methanol solution was added to form slurry in the case 
of inferior surfactant loading. The flask was attached to a rotary flash evaporator to 
evaporate solvent at 100-150rpm, a temperature of 60°C, and a reduced pressure of 
600mmHg until the mass in the flask had become a dry, free flowing product. After 
ensuring the complete removal of solvent, the resultant materials were further dried 
overnight in a desiccator under vacuum at room temperature. This dry preparation is 
referred to as ‘proniosomes’ and was used for preparations and for further study on 
powder properties. These proniosome granules were stored in a tightly closed 
container at refrigerator temperature until further evaluated.Blank proniosomes were 
made in the same way without incorporating drug.
66,94 
The composition of different 
batches of abacavir sulphate proniosomal formulations are represented in Table 5.4.4 
&5.4.5. 
Table 5.4.4: Composition of abacavir sulphate proniosomal  formulations 
without charge inducer 
S.No Formulation 
code 
Surfactant 
used 
250µM 
surfactant 
250µM 
Cholesterol 
Maltodextrin 
1 BPF1 Span 20 84.302 µl 96.66 mg 500 mg 
2 BPF2 Span 40 100.64 mg 96.66 mg 500 mg 
3 BPF3 Span 60 107.66 mg 96.66 mg 500 mg 
4 BPF4 Span 80 108 µl 96.66 mg 500 mg 
5 BPF5 Tween 20 278.9 µl 96.66 mg 500 mg 
6 BPF6 Tween 40 396.32 µl 96.66 mg 500 mg 
7 BPF7 Tween 60 312.5 µl 96.66 mg 500 mg 
8 BPF8 Tween 80 303.24 µl 96.66 mg 500 mg 
9 DPF1 Span 20 84.302 µl 96.66 mg 500 mg 
10 DPF2 Span 40 100.64 mg 96.66 mg 500 mg 
11 DPF3 Span 60 107.66 mg 96.66 mg 500 mg 
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12 DPF4 Span 80 108 µl 96.66 mg 500 mg 
13 DPF5 Tween 20 278.9 µl 96.66 mg 500 mg 
14 DPF6 Tween 40 396.32 µl 96.66 mg 500 mg 
15 DPF7 Tween 60 312.5 µl 96.66 mg 500 mg 
16 DPF8 Tween 80 303.24 µl 96.66 mg 500 mg 
    # Drug content used 25 mg per batch, BPF- Blank proniosome formulations, DPF- 
drug loaded proniosome formulations. 
Table 5.4.5: Composition of abacavir sulphate proniosomal formulation  with 
charge inducer 
S.No Formulation 
code 
Surfactant 
used 
250µM 
Surfactant 
250µM 
Cholesterol 
DCP Maltodextrin 
1 CBPF1 Span 20 84.302 µl 96.66 mg 2.73 
mg 
500 mg 
2 CBPF2 Span 40 100.64 mg 96.66 mg 2.73 
mg 
500 mg 
3 CBPF3 Span 60 107.66 mg 96.66 mg 2.73 
mg 
500 mg 
4 CBPF4 Span 80 108 µl 96.66 mg 2.73 
mg 
500 mg 
5 CBPF5 Tween 20 278.9 µl 96.66 mg 2.73 
mg 
500 mg 
6 CBPF6 Tween 40 396.32 µl 96.66 mg 2.73 
mg 
500 mg 
7 CBPF7 Tween 60 312.5 µl 96.66 mg 2.73 
mg 
500 mg 
8 CBPF8 Tween 80 303.24 µl 96.66 mg 2.73 
mg 
500 mg 
9 CDPF1 Span 20 84.302 µl 96.66 mg 2.73 
mg 
500 mg 
10 CDPF2 Span 40 100.64 mg 96.66 mg 2.73 
mg 
500 mg 
11 CDPF3 Span 60 107.66 mg 96.66 mg 2.73 
mg 
500 mg 
12 CDPF4 Span 80 108 µl 96.66 mg 2.73 
mg 
500 mg 
13 CDPF5 Tween 20 278.9 µl 96.66 mg 2.73 
mg 
500 mg 
14 CDPF6 Tween 40 396.32 µl 96.66 mg 2.73 
mg 
500 mg 
15 CDPF7 Tween 60 312.5 µl 96.66 mg 2.73 
mg 
500 mg 
16 CDPF8 Tween 80 303.24 µl 96.66 mg 2.73 
mg 
500 mg 
# Drug content used 25 mg per batch, CBPF- Charge inducer added blank proniosome 
formulations, CDPF- Charge inducer added drug loaded proniosome formulations. 
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5.4.3. Characterization of abacavir sulphate noisome formulation: 
5.4.3.1. Optical microscopy: 
The niosomal formulations were confirmed for vesicle formation by optical 
microscopy at suitable magnification. The niosome dispersion was mounted over a 
microscopic slide and fixed over by drying at room temperature. The dried thin film 
of noisome suspension was observed for the formation of vesicles. Photo microscopic 
images of the formulations have been taken by using a digital camera.
94,88,151
 
5.4.3.2. Vesicle size, size distribution zeta potential determination: 
Size and charge of noisome vesicles have a significant outcome on their 
stability and drug encapsulation. 
35 
Zeta potential was evaluated to measure the 
stability of niosome by studying its colloidal property.
65,88 
The polydispersity index  
was determined as a measure of homogenecity. Small values of PI (<0.1) indicate a 
homogeneouspopulation, while PI values >0.3 indicate high heterogeneity.
146
 
Vesicle size, size distribution and zeta potential of niosome samples were 
determined by photon correlation spectroscopy using the Malvern ZetaSizer. A 
zetacell was washed several times with deionized water beforebeing loaded with 
niosome suspensions to measure the zeta potential.
127
 Each sample was diluted to a 
appropriate concentration with demineralized water and the vesicle size was analyzed 
with an angle of detection of 90° at 25°C. Size of the vesicles, polydispersity index of 
niosomes, and their mean ZP values were obtained from the instrument.
 
Three 
replicates were taken for each formulations.
32 
5.4.3.3. Entrapment Efficiency 
83,141,150,152,156 
Free abacavir sulphate was separated from noisome entrapped abacavir 
sulphateby     centrifugation at 15,000 rpm and 4°C for 1 hourusing a cooling 
centrifuge.The supernatant was taken and diluted with phosphate buffer pH 7.4, for 
spectrophotometric estimation of free drug at 285 nm. The concentration of 
encapsulated abacavir sulphate was calculated by subtracting the concentration of free 
drug in the supernatant from the total drug incorporated as follows:  
      % Encapsulation efficiency = [(total drug - free drug)/ total drug] X 100 
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5.4.3.4. Drug content: 
Abacavir sulphate content in niosomes was obtained by an UV 
spectrophotometric method. Niosomal formulation containing 10 mg abacavir was 
taken into a standard volumetric flask.  The vesicles were destructed with 50ml 
propane-1-ol by shaking and 1ml of the mixture subsequently diluted with phosphate 
buffer pH 7.4. The absorbance was measured spectrophotometrically against blank at 
285 nm and drug content calculated from the calibration curve of Abacavir sulphate in 
phosphatebuffer pH 7.4. The average abacavir content of three determinations was 
reported in table 6.14. 
30,78,92
 
5.4.3.5. Transmission electron microscopy (TEM) 
The morphology of abacavir sulphate optimized niosomal formulation was 
investigated by transmission electron microscopy. A drop of niosomal dispersion was 
diluted 10 folds with deionized water and a drop was spread to a carbon-coated 200 
mesh copper grid and left for a minute to stick on the carbon substrate. The excess 
diluted formulation has been then drawn off by using piece of filter paper and 
observed under the transmission electron microscope. By using imaging viewer 
software the images were examined and captured.
94,135,193
 
5.4.3.6. In viro drug release from niosomal vesicles:  
In-vitro release model of niosomal dispersion was carried out by dialysis bag 
method. 3ml of abacavir sulphate noisome dispersion was taken in dialysis bag (Hi 
media).Dialysis bag was mounted in a beaker containing 100ml of 0.1N HCl and 
pH6.8-phosphate buffer. Magnetic stirrer was used and the temperature was 
maintained at37±1ºC. Samples were collected periodically up to 24 hours. The sink 
condition was continued throughout the experiment. The withdrawn samples were 
suitably diluted and analyzed for drug content using U.V. spectrophotometer at 
285nm keeping phosphate buffer pH 7.4 as blank. All the observations were made in 
triplicate.
76,195 
5.4.3.7. Release kinetics 
Release kinetics is an essential part for the dosage form development. 
Mathematical approach is an important scientific methods to evaluate and optimize 
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the error in terms of deviation in the drug release profiles of formulated dosage form 
during the formulation development phase. In formulation and development 
mathematical model approach used to diminish the number of trials in ultimate 
optimization. In order to realize the kinetic of drug release, the observation of in-vitro 
drug release study of niosomes were subjected with various kinetic equation models 
like zero order (cumulative percentage release vs. time), first order (log percentage 
drug remaining vs time), Higuchi’s model (cumulative percentage drug release vs. 
square root of time) and Erosion (cubic root of the unreleased fraction of the drug vs 
time).
40,78, 151
 
To confirm the mechanism of abacavir release from formulation, the drug 
release data was integrated into Korsmeyer and Peppas equation (log cumulative 
percentage of drug released vs. log time).  The exponent n was computed from slope 
of the straight line. The value of n denotes the release mechanism of drug. If exponent 
value is 0.5, then diffusion mechanism is fickian; if 0.5<n <0.89, drug release 
mechanism is non- fickian, n = 1 to Case II (relaxational) transport and n > 1 to super 
case II transport. 
The basis for selecting the most suitable model is lowest sum of square of 
residuals (SSR) and utmost R
2
 value. Lowest SSR indicates the lowest variance 
between the predicted and observed drug release data. Highest R
2
 value indicates 
linearity of drug release data. 
Zero order kinetics 
147 
C = K0t 
Where,   
K0 - Zero order rate constant (hr
-1
) expressed in units of concentration/time. 
t- Time in hours. 
If the plot is linear then the data obeys zero- order equal to K0. 
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First order Kinetics 
147
 
Log C=log Co- Kt /2.303. 
Where, 
 C - Amount of drug remained at time‘t’.  
Co - Initial amount of drug. 
 K- First order rate constant (hr
-1). The constant ‘k’ can be procured by multiplying 
2.303 with the slope values. 
If the plot yields a straight line, it indicated that the release pursue first order kinetics.  
Higuchi model 
88,147
 
Drug release from the matrix device by diffusion has been described by 
diffusion equation; 
Q = [D€ /τ( 2A-€Cs)Cs t ]1/2 
Where,  
Q -  Amount of drug released at time ‘t’. 
 D - Diffusion coefficient of the drug in the matrix. 
A - Total amount in unit volume of matrix. 
Cs - The solubility of drug in the matrix. 
 € -  Porosity of the matrix. 
 τ – Tortuosity. 
 t - Time (hrs) at which ‘q’ amount of drug is released. 
  Above equation may be simplified if one assume that ‘D’, ‘Cs’ and ‘A’ are 
constant. Then equation become, 
Q=KHt
1/2
 
k
H
 -  Higuchi’s square root of time kinetic drug release constant 
If the plot yields a straight line, indicating that the drug was released by 
diffusion mechanism. 
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Korsemeyer peppa’s equation model 88,147 
It is often used to explain the drug release manners from polymeric system. 
Mt/Mα=Ktn 
Where,  
M 
t 
- Amount of drug release at time t. 
M
∞ 
- Overall amount of the drug. 
Mt/Mα - The fraction of drug released at a time t’. 
K – Constant. 
n - Release exponent related to the mechanism of the release.  
Above equation can be simplified by applying log on both side; 
Log Mt/Mα = Log K + n Log t. 
If the exponent n = 0.5 or near, then the drug release mechanism is fickian 
diffusion, and if n have value near 1.0 then it is non-fickian diffusion. 
26,88
 
5.4.3.8. Lyophilization 
150 
Ten milliliter of the noisome formulation was prefrozen at -20
o
c for 1hour and 
then frozen at -70
o
c for 2 hours. Vaccum manifolds were closed in the freeze dryer, 
and the temperature was brought down to -40
o
c. Vacuum was applied to 0.01M Pascal 
and the frozen samples were now attached to vaccum manifold and the process was 
continued for 8 hours. At the end of operation, vaccum was reduced and the freeze 
dried samples were taken out. The sample was found to be sticky even after overnight 
storage in desiccator.
 
5.4.3.9. Fourier transform infrared (FTIR) spectroscopy: 
FT-IR spectrum of optimized niosome formulation CDNF7 and blank 
formulation CBNF7 were obtained using FT-IR spectrophotometer by the KBr pellet 
method to examine interactions between drug and excipients in the formulation. The 
lyophilized noisome formulation was grounded properly with anhydrous KBr and 
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compressed to make pellet. The scanning limit was 400 and 4000 cm
-1
 and the 
obtained results were compared with the IR spectrum of pure abacavir sulphate.
32,78
 
5.4.3.10. Differential scanning calorimetry: 
The molecular state of abacavir sulphate in optimized noisome formulation 
was investigated by performing differential scanning calorimetry analysis.The DSC 
thermograms of the drug loaded (CDNF7) and blank (CBNF7) formulations were 
obtained by a differential scanning calorimeter. Each noisome formulation was 
positioned in flat bottomed aluminum pans and then crimped with an aluminum wrap. 
The samples were heated from 30 to 400°Cusing a platinum crucible and heat flow 
rate was kept at 10°C/min with a nitrogen stream at 20ml/min.
32,70 
5.4.3.11. X-ray diffractometry 
XRD analysis was carried out using an Ultima 3 theta- theta goniometer for 
pure drug, lyophilized blank and optimized abacavir sulphate noisome formulations. 
The samples were measured with a K-beta filter, fixed monochromator using 40kV 
voltage and 32mA current. The continuous scanning was carried out at the scanning 
mode of 2 theta/theta.
70,77 
5.4.3.12. Osmotic shock studies 
The consequence of osmotic shock on optimized noisome formulations was 
evaluated by incubating of niosomal suspensions in media of diverse tonicities. The 
niosomal formulations were incubated with hypotonic (0.5%NaCl), isotonic 
(0.9%NaCl), and hypertonic solutions (1mol/L sodium iodide solution) for 3 hours. 
Then the changes in the vesicle size in the formulations were observed.
 26,132 
5.4.3.13. Stability study 
Physical stability study was carried out to investigate the degradation of drug 
from niosome during storage. The optimized noisome formulation with the 
composition of tween 60 and cholesterol in 250:250 µM ratio with 5 µM DCP was 
divided into two sets of samples. The samples were sealed in glass vials and stored at 
(2-8°C) in refrigerator and room temperature 25±2°C for a period of 3 months. 
Samples were withdrawn at definite periods of time and analyzed for vesicle size, % 
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drug remaining and percent drug entrapment. The results obtained were compared to 
the freshly prepared niosomes.
 132,146,151,194,196
 
5.4.4. Characterization of abacavir sulphate proniosome formulations 
5.4.4.1. Preparation of niosomes from proniosomes 
The proniosomal powder was transformed to noisome vesicles by hydrating 
with phosphate buffer (pH 7.4) at 80°C by means of vortexing using vortex mixer for 
2 min. The niosomal dispersion was placed over a glass slide and the vesicle 
formation was observed under optical microscope. There resultant niosomal 
dispersion was subsequently subjected to evaluation of zetapotential, vesicle size, Size 
distribution, Encapsulation Efficacy and morphology as per the procedure of noisome 
specified in 4.4.3.1, 4.4.3.2 and 4.4.3.3.
 32,78,85 
5.4.4.2. Drug content 
Abacavir Sulphate content in proniosomes was obtained by an UV 
spectrophotometric method. Niosomes obtained from proniosomal formulation 
containing 10 mg abacavir was taken into a standard volumetric flask.  The vesicles 
were destructed with 50ml propane-1-ol by shaking and 1ml of the mixture 
subsequently diluted with phosphate buffer pH 7.4. The absorbance was measured 
spectrophotometrically against blank at 285 nm. The average abacavir content of three 
determinations was reported in table 6.15.
78 
5.4.4.3. Dissolution study 
Dissolution is the procedure of extracting the active pharmaceutical ingredient 
out of the solidpharmaceutical dosage form matrix into solution within the 
GIT. Dissolution study is an in vitro method that describess how an active 
pharmaceutical ingredient is take out of a solid dosage form.
197 
It is an acceptable 
toolthat predicts and offers rough assessment of the invivo routineof the 
formulation.
198
 
The dissolution studies were carried out according to the US Pharmacopeia 
(USP) type I apparatus (basket method). The abacavir sulphate proniosome 
formulations corresponding to 10 mg abacavir were filled into hard gelatin capsule. 
The dissolution medium was 900ml 0.1N HCl/ phosphate buffer solution (pH 6.8) in 
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six dissolution jars to maintain sink conditions. The capsules were placed in basket 
and immersed in dissolution medium. The stirring speed was 50 rpm, and the 
temperature was maintained at 37°C±0.5°C. The samples (3 ml) were withdrawn at 
fixed time intervals using a syringe and passed through 0.2 μm membrane filter. 
Withdrawn samples from dissolution jarswere replaced by fresh medium. The 
abacavir content was evaluated by UV spectrophotometer at 285 nm in case of pH 6.8 
phosphate buffer as dissolution medium and 295nm in case of 0.1N HCl as 
medium.The cumulative percentage of abacavir release from formulation was plotted 
as a function of time.
29,75 
5.4.4.4. Release Kinetics: 
Release kinetics is an essential part for the dosage form development. 
Mathematical approach is important scientific method to evaluate and optimize the 
error in terms of deviation in the drug release profiles of formulated dosage form 
during the formulation development phase. In formulation and development, 
mathematical model approach used to diminish the number of trials in ultimate 
optimization. In order to realize the kinetic of drug release, the release data got from 
different formulations weresubjected with various kinetic equation models like zero 
order, first order, Higuchi’s model and Hixson model. Abacavir release from 
proniosome formulations were integrated into Korsmeyer & Peppa’s equation and the 
exponent n was computed from slope of the straight line (table 6.25).
78,151 
5.4.4.5. Osmotic shock studies 
The consequence of osmotic shock on optimized pronoisome formulations 
was evaluated by incubating of niosomal suspensions obtained from proniosomes in 
media of diverse tonicities. The formulation was divided into three parts incubated 
with hypotonic (0.5%NaCl), isotonic (0.9%NaCl), and hypertonic solutions (1mol/L 
sodium iodide solution) for 3 hours. Then the changes in the vesicle size in the 
formulations were observed and specified in table 6.52.
32 
 
 
 
 
CHAPTER 5                                                                                             MATERIALS AND METHODS 
 
J.K.K. NATTRAJA COLLEGE OF PHARMACY Page 119 
 
5.4.4.6. Solid state characterization proniosome powder 
5.4.4.6.1. Micromeritic properties 
The flow properties of powder are essential in handling and processing 
procedures. The flow properties of abacavir sulphate proniosome powder was studied 
through assessing the angle of repose, Carr’s compressibility index and Hausner’s 
ratio.
78
 
a. Angle of repose77,78,188 
The angle of repose was determined by using usual fixed funnel 
method.Briefly, proniosome powder and the puredrug were poured into afunnel which 
was placed at a height of 2.5 cmfromblackhorizontalsurface. The powders were 
flowed down from the funnel to form a cone shape on the horizontal surface. The 
angle of repose was determined by measuring the elevationof the cone (h) and the 
diameter of its base (d).Each trial was done in triplicate and outcomes were only 
considered suitable, whena symmetrical cone of dry powder was formed. 
The angle of repose (ѳ) was calculated from the subsequent equation: 
Tan ѳ = 2h/d 
B. Carr’s compressibility index and Hausner’s ratio 
The Carr’s compressibility index and Hausner’s ratio were calculated from the 
bulk and tapped density of the proniosome powders.
78 
5.4.4.6.2. Scanning electron microscopy (SEM) 
The exterior characteristics of the proniosome powder and maltodextrin was 
examined by scanning electron microscope (JSM 6390LA, Jeol,Tokyo, Japan). Each 
sample was smeared  on a small piece of adhesive carbon tape which was fixed  on a 
brass stub and subjected to gold coating using sputtering unit for 10 sec at 10mA of 
current. The gold coated sampleswere placed in chamber of SEM and images were 
recorded.
70,78 
5.4.4.6.3. Fourier transform infrared (FT-IR) spectroscopy 
FTIR spectra of pure abacavir sulphate, surfactants, cholesterol, maltodextrin, 
blank proniosome formulation (CBPF7) and optimized proniosome formulation 
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(CDPF7) were obtained using FT-IR spectrophotometer (FTIR-6300, Jasco, Japan) by 
the usual KBr pellet method to scrutinize the interactions between drug and excipients 
in formulation. The scanning range was 4000-400 cm
−1
 at ambient temperature. The 
smoothing of the IR spectra and the baseline correlation procedures were 
applied.
32,70,77 
 
5.4.4.6.4. Differential scanning calorimetry 
The physical nature of abacavir sulphate in optimized proniosome formulation 
was evaluated by performingdifferential scanning calorimetry analysis of pure 
abacavir sulphate, maltodextrin, tween 60, cholesterol and formulation (CDPF7). 
TheDSC thermograms of the samples were gained by a differential scanning 
calorimeter (DSC  6000, Perkin Elmer). Each sample was held in an aluminum pan 
and then crimped with an aluminum cover. All the five samples were scanned at 
10°C/min from 30 to 400°C under a nitrogen purge at 20 mL/min.
70
 
5.4.4.6.5. X-ray diffractometry 
Crystallinity of abacavir sulphate after encapsulation into provesicular system 
was evaluated by X-ray diffraction recorded for pure abacavir sulphate, opimixed 
formulation and other formulation excipients.  
XRD analysis was carried out using an Ultima 3 theta- theta goniometerfor 
pure abacavir sulphate, maltodextrin, tween 60, cholesterol and optimized proniosome 
formulations. The samples were measured with a K-beta filter, fixed monochromator 
using 40kV voltage and 32mA current. The continuous scanning was carried out at 
the scanning mode of 2 theta/theta. 
32,70,77 
5.4.4.6.6. Stability study
 
Physical stability study was carried out to investigate the degradation of drug 
from proniosome during storage. The optimized pronoisome formulation with the 
composition of tween 60 and cholesterol in 250:250 µM ratio with 5µM DCP was 
divided into 3sets of samples. The samples were sealed in glass vials and stored at (2-
8°C) in refrigerator, room temperature 25±2°C and 45±2°C for a period of 3 months. 
Samples were withdrawn at definite periods of time and analyzed for vesicle size, % 
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drug remaining and percent drug entrapment. The results obtained were compared to 
the freshly prepared niosomes.
199 
5.4.5. Pharmacokinetic parameters of optimized noisome and proniosome 
formulation
 
Pharmacokinetics studies in rats 
Study design 
The pharmacokinetic study was carried out with the previous approval of 
Institutional Animal Ethical Committee, J.K.K. Nattaraja College of Pharmacy, 
Namakkal District, Tamil Nadu, India. The study was aimed to compare the 
pharmacokinetic profile of abacavir sulpahate -optimized proniosomal formulation 
and abacavir sulpahate -optimized niosomal formulations. Male albino wistar rats 
(200–250 g) were preferred for the study and had free access to water and food. 
Before dosing, the rats were kept for overnight fasting. The rats were divided into four 
groups containing three in each. The treated animals were set aside in separate cages 
and upheld under laboratory environment. The study was planned as a single oral 
dose. All groups of animals received an equivalent of 8.57 mg abacavir/kgbody 
weight of rats. Group - I received pure drug in solution, Group - II received blank 
proniosomal formulation, Group - III received abacavir sulphate optimized niosomal 
formulation and Group –IV received abacavir sulphate optimized proniosomal 
formulations. 500 μL blood samples were collected from tail vein  into heparinized 
tubes at 0.5, 1, 2, 4, 8, 12 and 24hours after administration. The Plasma samples were 
separated by centrifugation at 10,000 rpm for 10 min in a micro-centrifuge 
(Eppendorf AG, Germany. 5430R,) and stocked at −20°C until drug analysis was 
done by HPLC method.
29,92,146,200 
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Table5.4.6: Pharmacokinetics studies design 
 
Group 
 
Animals 
Number 
of 
Animals 
 
Treatment 
Group – I Male albino Wistar 
Rats 
3 animals Pure drug in solution 
Group – II Male albino Wistar 
Rats 
3 animals Blank formulation 
Group – III Male albino Wistar 
Rats 
3 animals Optimized niosome formulation 
Group – IV Male albino Wistar 
Rats 
3 animals Optimized Proniosome 
formulation 
 
Abacavir sulphate HPLC method of analysis conditions 
Table 5.4.7: HPLC analytical conditions of abacavir sulphate for 
pharmacokinetics studies 
System Agilent 1200 HPLC series 
Detector(wavelength) Diode Array detector, DAD (298 nm) 
Column Phenomenex C18 (150 mm length x 2 mm I.D x 3 µm particle 
size) 
Column Temperature Ambient (30°C) 
Injection Volume 10 uL 
Auto sampler 
Temperature 
4°C 
Mobile phase Isocratic A:B, 70:30 %v/v 
A 0.1% Formic acid in milli-Q-water 
B 0.1% Formic acid in methanol 
Flow 0.80 ml/min 
Analyte Retention Time (minutes) 
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Calibration of standard 
Stock solution preparation 
Abacavir sulphate equivalent to 10 mg abacavir was weighed into 10mL 
standard volumetric flask and dissolved with methanol and shake well and made up to 
the mark with methanol. 
Preparation of Calibration solution 
From the 100µg/ml diluted stock solution, 1, 2, 5, 10, 25 & 50 µg/ml 
calibration solution were prepared using methanol. 
Sample analysis 
Sample preparation and extraction 
0.1ml of plasma was transferred in to the eppendorf vial and added 0.4 ml of 
methanol. Shaken well and centrifuged with cooling centrifuge at 3000rpm for 10min 
until the precipitate was settled completely. Decanted the supernatant and tranfered in 
HPLC injector vial for HPLC-DAD analysis. 
Plasma analysis:  10µl of the methanol aliquot of sample was injected into HPLC. 
Screening parameters 
The pharmacokinetic parameters like C max, Tmax, Area under the curve 
(AUC),Volume of distribution (Vd),Clearance (cl), Half-life (t1/2),Mean residence 
time (MRT) and Elimination rate constant (Kel)  
5.4.6. Anti HIV testing 
Anti HIV activity was carried out against cell associated HIV-1 primary 
isolates to check the replication inhibition. The results were compared with purest 
form of abacavir sulphate as a drug control.The blank proniosomal preparation 
without abacavir sulphatewas used to compare the inhibitory potential of test product. 
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Assay: Cell associated assay against two primary isolates of HIV-1. 
Compounds: Abacavir proniosomal formulation  
In vitro testing includes cytotoxicity testing and anti-HIV testing of newly 
synthesized molecules. The primary testing is carried out using TZM-bl cell line (a 
genetically modified human cell line having two reporter genes namely, firefly 
Luciferase and E.coli Beta galactosidase. The cells express CD4 and CCR5 receptors 
being permissive to HIV-1 infection) 
The testing proceeds through following steps :  
A. Maintenance of cell lines: The TZM-bl cells were maintained in DMEM 
supplemented with   10%FCS and antibiotics; penicillin (50U/ml) and 50ug/ml 
Streptomycin at 37
0
C with 5% CO2.  
B. Preparation of virus stocks: Freshly collected blood from healthy, HIV 
seronegative individual is obtained. The peripheral blood mononuclear cells 
(PBMCs) were separated on ficoll-hypaque and stored at -196
o
C in liquid 
nitrogen. The cells then stimulated with PHA (Phytohaemagglutinin-A) as and 
when needed. Two HIV-1 strains namely UG070(X4 tropic) and VB59 (R5 
tropic) strains were obtained from NARI virus repository. These strains then 
allowed to infect the two separate sets of PHA stimulated PBMCs. Each virus 
culture is maintained in RPMI 1640 medium supplemented with 10% FCS, 5U 
IL2 and antibiotics; penicillin+streptomycin (50U/ml + 50ug/ml) at 37
0
C with 
5% CO2. Culture supernatant is collected and tested for P24 antigen ELISA. 
Culture supernatant (virus stock) is stored at -70
0
C. Subsequently, the 50% 
tissue culture infectivity dose (TCID50) of each isolate is determined in the 
TZM-bl cell line.  
C. Seeding of 96 well plates:  The TZM-bl cells were trypsinized, enumerated 
and then added to the 96 well flat bottom plates. The plates then incubated at 
37
0
C with 5% CO2 for 10 to 12 hrs. The cytotoxicity and anti-HIV assays are 
performed in such preseeded TZM-bl plates. 
D. Preparation of Test compound: The test compound is dissolved in suggested 
solvent, filter sterilized and used for the assays.  
E. Cytotoxicity Assay: The cytotoxicity assay is carried out by preparing double 
dilutions of ‘Test compound’ in a preseeded TZM-bl plate. The cell viability is 
determined using MTT assay and percent viability and CC50 value (the 
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concentration of a compound at which 50% cells are viable) is calculated by 
comparing with the cell control (only cells without ‘Test compound’).  Sub 
toxic concentrations are selected for anti HIV assays. 
 
Note: All the three compounds were taken for cytotoxicity testing and found 
non toxic to the cells.  Amongst them, blank proniosomes (CBPF7) were first 
tested against R5 tropic virus but it did not show any inhibition against HIV. 
Hence, sub toxic concentrations of optimized proniosome (CDPF7) were 
tested, and compared with the pure abacavir sulphate. Also, we standardized 
the IC50 value for pure abacavir sulphate in the cell line used. 
 
F. Anti-HIV testing: Anti-HIV activity is measured as a function of reduction 
in Luciferase reporter gene expression after virus infection in TZM-bl cells. This 
testing is carried out using cell associated assay (to test the replication 
inhibition of HIV-1) against two Primary isolates of  
a. HIV-1 (X4 tropic and R5 tropic). 
b. Following are the details of anti-HIV assay are carried out to evaluate 
the test Compound: 
Cell associated assay:  
 The TZM-bl cells are infected with the pre-titrated HIV-1 UG070 & 
VB59 viruses. Subsequently, the sub toxic concentrations of the ‘Test compound’ are 
overlaid on to the infected cells and incubated at 37
0
C with 5% CO2 for 48 hrs. After 
48 hrs, the supernatant is tested for luciferase activity using ‘britelite assay’. This assay 
is to demonstrate the ability of ‘Test compound’ to inhibit HIV-1 replication. The 
activity of ‘Test compound’ is compared with drug control (e.g. AZT). 
In Britelite Assay, Luciferase activity is measured using Britelite plus 
substrate. The results are expressed in terms of Relative Luminescence Units (RLU) 
and then the IC50 value is calculated for each virus. (Concentration of compound at 
which 50% virus is inhibited). Also, the inhibition of virus growth is monitored and 
compared with virus growth in absence of drug. Additionally, respective ‘Drug control’ 
is tested in each assay to compare the IC50 value of ‘Test compound’. Finally, the 
‘Therapeutic index’ (TI), is calculated and compared with the TI of Control drug.  
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Only the compounds showing promising activity at primary testing will be 
taken further for “Confirmatory Testing” wherein, activated Peripheral Blood 
Mononuclear Cells (PBMCs) will be used.  
5.4.7. Statistical analysis 
Data were exhibited  as mean (±) standard deviation and statistical analysis 
was performed employing the Student’ t test using Graphpad software. A value of 
P<0.05 was considered statistically significant. 
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6. RESULTS AND ANALYSIS 
The present study was undertaken to formulate pronoisome carrier system for 
antiviral drug abacavir sulphate by slurry method using commonly available 
surfactants like span 20, span 40, span 60, span 80, tween 20, tween 40, tween 60 and 
tween 80. Maltodextrin was used as carrier, cholesterol was used as membrane 
stabilizer and DCP was used as negative charge inducer. Conventional niosomes also 
prepared and the results of the evaluation parameters were compared with proniosome 
derived niosomes. Preformulation studies were carried out before the formulation in 
which certain parameters were evaluated. A total of sixty four formulations were 
prepared to achieve the encapsulation of abacavir sulphate in vesicular carrier system. 
In which 32 formulations were conventional noisome formulations and remaining 32 
formulations were proniosome formulations. 
In each noisome as well as proniosome formulations sixteen trials were drug 
loaded formulations and sixteen trials were blank formulations. In sixteen drug loaded 
formulations, eight formulations were formulated with charge inducer dicetyl 
phosphate and remaining eight formulations were prepared without adding dicetyl 
phosphate. The prepared formulations were evaluated for various.  
The outcome of the research was presented as follows, 
6.1. Preformulation studies 
6.1.1.Screening of drugs: 
Based on the solubility, dosage frequency, half life, suitability to controlled 
release and adverse drug reaction of various antiretroviral drugs comparative table 
was prepared. 
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Table 6.1: Comparative table of selected drugs 
Drugs Solubility 
Dosage 
frequency 
Half 
Life 
Suitability 
to 
controlled 
release 
Adverse Drug reaction 
Abacavir 
77 mg/ml in water 
at 25°C 
Twice daily 
1 to 1.5 
hr 
Suitable 
Disorder of cardiovascular system, Hepatomegaly, 
Hepatotoxicity, Hypersensitivity reaction, Lactic 
acidosis, Myocardial infarction, Steatosis of liver, 
Stevens-Johnson syndrome, Toxic epidermal 
necrolysis. 
Zidovudine 
In water at 25°C: 
20.1 mg/ml., 
in ethanol 750 g/l. 
5 to 6 times a 
day 
0.5 to 3 
hr 
Suitable 
Anemia, Disorder of muscle, Granulocytopenic 
disorder, Hepatomegaly, Lactic acidosis, Neutropenia, 
Steatosis of liver. 
 
Tenofovir 
 
13.4mg/mL in 
distilled water at 
25°C 
 
 
 
Once daily 
Oral: 
17 hr, 
IV: 
4 - 8 hr 
Not 
suitable 
Acute renal failure, Angioedema, Fanconi syndrome, 
Hepatitis B, Hepatomegaly, With steatosis, Lactic 
acidosis, Nephrogenic diabetes insipidus, Osteopenia, 
Renal impairment, Tubular necrosis. 
 
Efairenz 
 
Practically 
insoluble in water 
less than 10 µg/mL 
 
Once daily 
 
52 to 76 
hr 
 
Not 
suitable 
At risk for suicide, Severe depression, Erythema 
multiforme, Liver failure, Prolonged QT interval, 
Psychotic disorder, Rash, Grade 4 Stevens-Johnson 
syndrome, Suicidal thoughts, Torsades de pointes. 
 
Lamividine 
Soluble in water; 
sparingly soluble 
in methanol. 
 
150 mg BD 
orally or 300 
mg OD orally. 
 
 
3 to 7 hr 
 
Suitable 
 
Fat maldistribution, Hepatomegaly, Lactic acidosis, 
Pancreatitis, Relapsing type B viral hepatitis. 
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Staudine 
83 mg/mL in water 
and 30 mg/mL in 
propylene glycol at 
23° C 
 
 
Every 12 hours 
 
 
1.6 hr 
 
 
Suitable 
Anemia, Hepatomegaly, Lactic acidosis, Liver 
function tests abnormal, Neurological muscle 
weakness, Neutropenia, Pancreatic enzyme level above 
reference range, Pancreatitis, Steatosis of liver, 
Thrombocytopenia. 
 
6.1.2. Calibration of standard curve: 
Standard graph of abacavir sulphate in phosphate buffer pH 7.4: 
Table 6.2: Standard graph data of abacavir sulphate in phosphate buffer pH 7.4 
Sl. No 
Concentration 
µg/ml 
Absorbance at 
285 nm 
1 2 0.115 
2 4 0.244 
3 6 0.346 
4 8 0.444 
5 10 0.550 
6 12 0.659 
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Figure 6.1: Standard graph of abacavir sulphate in phosphate buffer pH 7.4 
Standard graph of abacavir sulphate in phosphate buffer pH 6.8: 
Table 6.3: Standard graph data of abacavir sulphate in phosphate buffer pH 6.8 
Sl. No 
Concentration 
µg/ml 
Absorbance at 
285 nm 
1 2 0.112 
2 4 0.222 
3 6 0.333 
4 8 0.432 
5 10 0.525 
 
 
Figure 6.2: Standard graph of abacavir sulphate in phosphate buffer pH 6.8 
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Standard graph of abacavir sulphate in 0.1N hyrdrochloric acid: 
Table 6.4: Standard graph data of abacavir sulphate in 0.1N hyrdrochloric acid 
Sl.No 
Concentration 
µg/ml 
Absorbance at 
295 nm 
1 2 0.094 
2 4 0.188 
3 6 0.275 
4 8 0.375 
5 10 0.474 
6 12 0.573 
 
 
Figure 6.3: Standard graph of abacavir sulphate in 0.1N hyrdrochloric acid 
6.1.3. Organoleptic properties: 
The organoleptic properties like color, odor, and taste of the API were 
evaluated. The color of abacavir sulphate was found to be white to off white powder, 
no characteristic odor was observed in the study and the taste was found to be bland. 
6.1.4.Particle size: 
Preweighed abacavir sulphate powder was passed through the series of sieve 
numbers 20, 30,40,60,80,100 and 120.  No particles were retained in any sieve. All 
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the drug particles completely passed through the sieves. Thus the particle size of the 
API was found to be less than 125 microns. 
6.1.5.Solubility studies of abacavir sulphate: 
The outcome of abacavir sulphate solubility in various solvents are 
summarized in Table 6.5. 
Table 6.5: Solubility studies data of abacavir sulphate. 
S.No 
Solvent 
system ml 
Solubility 
Abacavir 
mg/ml 
Abacavir Sulphate 
mg/ml 
Solubility description 
1 0.1N HCl 72.03 84.33 Soluble 
2 PBS pH 6.8 70.47 82.54 Soluble 
3 Water 64.41 75.44 Soluble 
4 PBS pH 7.4 60.16 70.47 Soluble 
5 Methanol 3.67 4.30 slightly soluble 
6 Ethanol 0.769 0.901 very slightly soluble 
7 Chloroform 0.539 0.631 very slightly soluble 
8 n-butanol 0.104 0.122 very slightly soluble 
 
 
Figure 6.4:Solubility of abacavir sulphate in various solvents 
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The results suggest that the drug abacavir sulphate was soluble in aqueous 
solvents such as  0.1N hydrochloric acid, phosphate buffer pH 6.8, water and 
phosphate buffer pH 7.4, slightly soluble in methanol and very slightly soluble in 
ethanol, chloroform and n-butanol. 
6.16.IR spectrum of pure Abacavir sulphate: 
 
 Figure 6.5: FT-IR Spectra of pure abacavir sulphate 
Table 6.6: FT-IR Spectra observations of pure abacavir sulphate 
Range Observed Functional group 
3200-3400 3220.54 NH2 group 
2900-2950 2918.73 OH-Stretching 
1400-1450 1405.85 C=N Stretching 
1340-1380 1369.21 C=C Stretching 
1100-1150 1105.98 CH2 group 
1010-1040 1028.80 C-H Stretching 
 
The characteristic peaks of IR spectrum which is taken for the obtained drug 
abacavir sulphate was found to be similar with IR spectrum of abacavir sulphate 
published in Indian Pharmacopoeia. 
6.1.7.Partition Co-efficient Of Pure Drug: 
Partition co-efficient of abacavir sulphate was determined using organic 
solvent n-butanol with pH 7.4 phosphate buffer and the result was found to be 0.065. 
The Result revealed that the pure abacavir sulphate exhibits highy hydrophilic nature. 
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6.1.8.Drug – excipients compatability studies: 
Compatibility studies were carried out by preparing physical mixture of 
different pronoisome excipients with abacavir sulphate and stored at 40°C/75%RH for 
a week. The presence and possible interactions were evaluated by FT-IR analysis and 
by observing the changes of physical mixture visually. The results are given in table 
6.7 -6.9 and figure 6.6-6.27.  
Table 6.7:  Drug excipient compatibility studies report 
Sl.No Composition Initial period After 7 days 
1 
Abacavir sulphate White to off white powder 
with no characteristic odor 
No characteristic 
change 
2 
Abacavir sulphate + 
Cholesterol 
White to off white powder 
with no characteristic odor 
No characteristic 
Change 
3 
Abacavir sulphate+ 
Maltodextrin 
White to off white powder 
with no characteristic odor 
No characteristic 
change 
4 
Abacavir sulphate+ 
Span 20 
Brownish white semisolid 
with no characteristic odor 
No characteristic 
change 
5 
Abacavir sulphate + 
Span40 
Off white granular mass 
with no characteristic odor 
No characteristic 
change 
6 
Abacavir sulphate + 
Span60 
White to off white granules 
with no characteristic odor 
No characteristic 
change 
7 
Abacavir sulphate + 
Span 80 
Off white semisolid with no 
characteristic odor 
No characteristic 
change 
8 
Abacavir sulphate + 
Tween 20 
White to off white 
semisolid with no 
characteristic odor 
No characteristic 
change 
9 
Abacavir sulphate + 
Tween 40 
Off white semisolid with no 
characteristic odor 
No characteristic 
change 
10 
Abacavir sulphate + 
Tween 60 
Brownish white semisolid 
with no characteristic odor 
No characteristic 
change 
11 
Abacavir sulphate + 
Tween 80 
Brownish white semisolid 
with no characteristic odor 
No characteristic 
change 
12 
Abacavir sulphate + 
Dicetyl Phosphate 
White to off white powder 
No characteristic 
change 
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6.1.9.FTIR spectrum of abacavir sulphate with different formulation excipients: 
 
Figure 6.6: FT-IR Spectra of abacavir sulphate with cholesterol 
 
Figure 6.7: FT-IR Spectra of abacavir sulphate with maltodextrin 
 
Figure 6.8: FT-IR Spectra of abacavir sulphate with span 20 
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Figure 6.9: FT-IR Spectra of abacavir sulphate with span 40 
 
Figure 6.10: FT-IR Spectra of abacavir sulphate with span 60 
 
Figure 6.11: FT-IR Spectra of abacavir sulphate with span 80 
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Figure 6.12: FT-IR Spectra of abacavir sulphate with tween 20 
te with Figure 6.13: FT-IR Spectra of abacavir sulphate tween 40 
 
Figure 6.14: FT-IR Spectra of abacavir sulphate with tween 60 
 
Figure 6.15: FT-IR Spectra of abacavir sulphate with tween 80 
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Figure 6.16: FT-IR Spectra of abacavir sulphate with DCP 
 
Figure6.17: FT-IR Spectra of pure cholesterol 
 
Figure 6.18: FT-IR Spectra of pure maltodextrin 
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Figure 6.19: FT-IR Spectra of pure span 20 
 
Figure 6.20: FT-IR Spectra of pure span 40 
 
Figure 6.21: FT-IR Spectra of pure span 60 
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Figure 6.22: FT-IR Spectra of pure span 80 
 
Figure 6.23: FT-IR Spectra of pure tween 20 
 
Figure 6.24: FT-IR Spectra of pure tween 40 
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Figure 6.25: FT-IR Spectra of pure tween 60 
 
Figure 6.26: FT-IR Spectra of pure tween 80 
 
Figure 6.27: FT-IR Spectra of pure Dicetyl phosphate 
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Table 6.8: FTIR data of drug excipient compatibility study. 
 
Functional group Range 
Blend with 
cholesterol 
Blend with  
maltodextrin 
Blend with 
span 20 
Blend with 
span 40 
Blend with 
span 60 
Blend with span 
80 
NH2 group 3200-3400 3284.18 3277.43 3344.93 3287.07 3319.88 3287.07 
OH-Stretching 2900-2950 2932.23 2920.66 2937.41 2921.63 2919.70 2919.69 
C=N Stretching 1400-1450 1406.82 1406.82 1463.71 1400.07 1404.80 1404.07 
C=C Stretching 1340-1380 1347.03 1345.11 1381.75 1344.14 1340.28 1352.82 
CH2 group 1100-1150 1109.83 1110.80 1107.90 1110.80 1111.70 1118.51 
C-H Stretching 1010-1040 1025.94 1024.98 1035.59 1027.87 1028.84 1028.84 
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Table 6.9: FTIR data of drug excipient compatibility study.  
Functional group Range 
Blend with 
tween 20 
Blend with  
tween 40 
Blend with 
tween 60 
Blend with 
tween 80 
Blend with 
DCP 
NH2 group 3200-3400 3322.75 3285.14 3336.25 3286.11 3200.82 
OH-Stretching 2900-2950 2928.38 2921.63 2921.09 2921.63 2921.63 
C=N Stretching 1400-1450 1402.96 1404.83 1402.96 1404.89 1405.85 
C=C Stretching 1340-1380 1342.21 1350.89 1349.93 1351.86 1346.07 
CH2 group 1100-1150 1108.87 1107.90 1108.87 1106.94 1120.12 
C-H Stretching 1010-1040 1027.87 1032.69 1033.66 1034.62 1018.50 
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6.2.Characterization of abacavir sulphate noisome and proniosome formulations 
6.2.1.Optical microscopy: 
The morphology of prepared abacavir sulphate noisome and proniosome 
formulations were studied using optical microscopy and the images are illustrated in 
figure 6.28.and 6.29.  
 
Figure 6.28: Optical photomicrograph of various batches of niosomes. 
CDPF2 CDPF6
CDPF3 CDPF7
 
Figure 6.29: Optical photomicrograph of various batches of proniosome derived 
niosomes. 
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6.2.2.Vesicle size, size distribution and zeta potential determination of niosomes 
and proniosome derived niosomes: 
Mean zeta potential, vesicle size, and PDI data of different abacavir sulphate 
niosomal and proniosomal formulations prepared using different surfactants were 
determined by zetasizer and the data are given in Table  and Table . 
Table 6.10:Vesicle size, size distribution and zeta potential of various niosomal  
formulations. 
S.No 
Formulation 
code 
Zeta potential 
mV 
Vesicle Size nm PDI 
1 BNF1 -30.7 ±1.375 150.9 ±11.260 0.326 ±0.027 
2 BNF2 -28.9±1.569 145.9 ±14.363 0.432 ±0.029 
3 BNF3 -33.6±0.611 138.8 ±12.095 0.349 ±0.033 
4 BNF4 -30.6±1.217 135.0 ±8.837 0.182 ±0.016 
5 BNF5 -2.04 ±0.477 172.8 ±8.361 0. 253±0.013 
6 BNF6 -3.69 ±0.539 181.1 ±10.617 0.332 ±0.026 
7 BNF7 -3.53 ±0.601 174.4 ±13.712 0.414 ±0.031 
8 BNF8 -3.57 ±0.465 169.3 ±12.106 0.406 ±0.027 
9 DNF1 -26.5 ±1.401 152.8 ±7.159 0.332 ±0.023 
10 DNF2 -28.3 ±0.850 149.2 ±9.611 0.384 ±0.032 
11 DNF3 -32.9 ±0.954 141.1 ±11.849 0.439 ±0.057 
12 DNF4 -29.5±1.464 137.0 ±7.753 0.314 ±0.033 
13 DNF5 -2.11 ±0.252 176.2 ±10.018 0.368 ±0.049 
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14 DNF6 -2.89 ±0.506 183.2 ±13.390 0.347 ±0.042 
15 DNF7 -2.72 ±0.733 179.4 ±7.619 0.277 ±0.039 
16 DNF8 -2.65 ±0.671 173.2 ±14.853 0.435 ±0.043 
17 CBNF1 -41.7 ±1.305 153.2 ±13.453 0.402 ±0.066 
18 CBNF2 -41.8 ±1.206 148.3±10.553 0.361 ±0.036 
19 CBNF3 -42.4 ±0.833 141.5±13.403 0.373 ±0.023 
20 CBNF4 -41.8 ±1.192 137.4±7.267 0.382 ±0.030 
21 CBNF5 -36.6 ±1.137 175.2±12.217 0.369 ±0.055 
22 CBNF6 -38.5 ±0.751 183.3 ±9.340 0.385 ±0.063 
23 CBNF7 -38.2±1.106 179.1 ±7.427 0.377 ±0.047 
24 CBNF8 -38.3 ±0.802 173.2 ±10.352 0.384 ±0.075 
25 CDNF1 -43.6 ±1.550 155.8 ±11.920 0.377 ±0.048 
26 CDNF2 -44.1 ±0.656 151.9 ±10.007 0.347 ±0.045 
27 CDNF3 -44.6 ±1.464 144.2 ±9.304 0.344 ±0.042 
28 CDNF4 -44.8 ±1.206 139.9 ±7.251 0.362 ±0.024 
29 CDNF5 -34.2 ±0.656 179.3 ±13.892 0.411 ±0.034 
30 CDNF6 -36.6 ±0.954 185.0 ±13.402 0.371 ±0.028 
31 CDNF7 -37.2 ±0.757 182.1 ±16.690 0.469 ±0.045 
32 CDNF8 -36.6 ±1.200 176.8 ±15.222 0.415 ±0.054 
 
 
 
Chapter 6                                                                                                    Results and Analysis 
 
Department of Pharmaceutics                           147        J.K.K Nattraja College of Pharmacy 
 
Table 6.11: Vesicle size, size distribution and zeta potential of proniosome 
derived niosomes 
S.No 
Formulation 
code 
Zeta potential 
mV 
Vesicle Size nm PDI 
1 BPF1 -30.1 ±1.801 143.8 ±11.581 0.377 ±0.045 
2 BPF2 -29.0±1.153 138.6 ±14.076 0.404 ±0.061 
3 BPF3 -32.5±0.833 133.1 ±15.982 0.397±0.056 
4 BPF4 -30.5±0.985 124.7 ±11.351 0.361±0.049 
5 BPF5 -2.23±0.521 166.7 ±12.354 0.341±0.022 
6 BPF6 -3.27±0.297 172.7 ±8.046 0.355±0.037 
7 BPF7 -3.48±0.546 169.3 ±10.157 0.399±0.037 
8 BPF8 -2.97±0.476 161.8 ±10.523 0.359±0.012 
9 DPF1 -26.5±0.862 147.8±9.592 0.398±0.043 
10 DPF2 -28.2±1.079 141.6±10.159 0.379±0.016 
11 DPF3 -31.6±1.007 135.5±10.977 0.371±0.036 
12 DPF4 -28.9±1.500 129.1±15.808 0.379±0.059 
13 DPF5 -2.81±0.105 169.9±14.479 0.352±0.023 
14 DPF6 -2.91±0.792 176.2±9.735 0.393±0.042 
15 DPF7 -2.83±0.387 172.7±10.797 0.331±0.046 
16 DPF8 -3.26±0.569 165.2±11.927 0.363±0.069 
17 CBPF1 -40.5±1.082 146.9±7.475 0.395±0.064 
Chapter 6                                                                                                    Results and Analysis 
 
Department of Pharmaceutics                           148        J.K.K Nattraja College of Pharmacy 
 
18 CBPF2 -40.9±1.343 141.3±8.773 0.372±0.016 
19 CBPF3 -42.1±0.985 136.0±6.354 0.350±0.028 
20 CBPF4 -41.8±0.896 128.6±10.792 0.359±0.029 
21 CBPF5 -35.7±1.124 168.1±7.790 0.368±0.013 
22 CBPF6 -37.5±1.026 175.8±9.943 0.351±0.027 
23 CBPF7 -37.6±0.802 171.4±6.047 0.362±0.055 
24 CBPF8 -38.1±1.039 164.5±8.054 0.369±0.012 
25 CDPF1 -42.1±0.519 149.2±8.864 0.359±0.036 
26 CDPF2 -43.2±1.365 144.5±7.436 0.342±0.015 
27 CDPF3 -44.3±1.735 138.5±6.548 0.390±0.035 
28 CDPF4 -43.4±0.954 131.8±8.450 0.371±0.056 
29 CDPF5 -33.0±1.172 172.2±6.396 0.397±0.029 
30 CDPF6 -35.5±1.137 178.8±6.872 0.398±0.066 
31 CDPF7 -34.4±1.159 175.0±5.122 0.372 ±0.046 
32 CDPF8 -34.5±1.114 168.8±8.435 0.375±0.051 
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Vesicle size, size distribution reports of optimized noisome and proniosome 
derived niosome: 
 
Figure 6.30: Vesicle size, size distribution report of optimized noisome Trial 1 
 
Figure 6.31: Vesicle size, size distribution report of optimized noisome Trial 2 
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Figure 6.32: Vesicle size, size distribution report of optimized noisome Trial 3 
 
Figure 6.33: Vesicle size, size distribution report of optimized proniosome 
derived noisome Trial 1 
 
Figure 6.34: Vesicle size, size distribution report of optimized proniosome 
derived noisome Trial 2 
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Figure 6.35: Vesicle size, size distribution report of optimized proniosome 
derived noisome Trial 3 
Zeta potential reports of optimized noisome and proniosome derived niosome: 
 
Figure 6.36: Zeta potential reports of optimized noisome Trial 1 
 
Figure 6.37: Zeta potential reports of optimized noisome Trial 2 
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Figure 6.38: Zeta potential reports of optimized noisome Trial 3 
 
Figure 6.39:Zeta potential reports of optimized proniosome derived noisome 
Trial 1 
 
Figure 6.40: Zeta potential reports of optimized proniosome derived noisome 
Trial 2 
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Figure 6.41: Zeta potential reports of optimized proniosome derived noisome 
Trial 3 
6.2.3.Encapsulation Efficiency: 
Table 6.12: Encapsulation efficiency of various noisome formulations. 
Formulation 
code 
% Drug 
Encapsulated 
Formulation 
code 
%Drug 
Encapsulated 
DNF1 34.10 ±2.352 CDNF1 38.73 ±1.518 
DNF2 58.23 ±0.777 CDNF2 61.93 ±1.793 
DNF3 66.85 ±1.232 CDNF3 68.67 ±0.666 
DNF4 29.43 ±1.692 CDNF4 32.12 ±2.535 
DNF5 61.87 ±2.715 CDNF5 65.78 ±1.650 
DNF6 70.77 ±1.644 CDNF6 76.57 ±0.839 
DNF7 77.81 ±2.837 CDNF7 83.02 ±1.085 
DNF8 47.9 ±2.007 CDNF8 54.98 ±2.628 
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Figure 6.42: Encapsulation efficiency of niosomal formulations. 
Table 6.13: Encapsulation efficiency of various pronoisome formulations. 
Formulation 
code 
% Drug 
Encapsulated 
Formulation 
code 
%Drug 
Encapsulated 
DPF1 42.72 ±2.727 CDPF1 45.38 ±1.924 
DPF2 61.02 ±2.555 CDPF2 63.62 ±1.541 
DPF3 68.73 ±1.740 CDPF3 70.72 ±2.479 
DPF4 33.49 ±0.978 CDPF4 35.13 ±1.404 
DPF5 64.80 ±2.807 CDPF5 68.38 ±2.395 
DPF6 72.27 ±2.491 CDPF6 77.32 ±2.113 
DPF7 80.24 ±1.886 CDPF7 85.02 ±1.560 
DPF8 49.47 ±0.919 CDPF8 57.59 ±2.025 
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Figure 6.43: Encapsulation efficiency of proniosomal formulations. 
6.2.4.Drug content: 
Table 6.14: Drug content of abacavir sulphate niosomal formulations 
Formulation code Drug content Formulation code Drug content 
DNF1 99.3±0.794 CDNF1 99.64 ±0.922 
DNF2 98.75 ±1.073 CDNF2 98.86 ±1.332 
DNF3 98.85±1.283 CDNF3 99.54 ±1.082 
DNF4 99.16 ±0.661 CDNF4 99.97 ±0.740 
DNF5 99.72 ±0.940 CDNF5 98.62 ±0.863 
DNF6 98.99 ±1.610 CDNF6 98.72 ±0.927 
DNF7 99.91 ±0.986 CDNF7 99.25 ±0.708 
DNF8 99.02 ±1.226 CDNF8 99.62 ±1.063 
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Table 6.15: Drug content of abacavir sulphate proniosomal formulations 
Formulation code Drug content Formulation code Drug content 
DPF1 100.17 ±0.766 CDPF1 99.03 ±0.245 
DPF2 99.58 ±0.474 CDPF2 99.94 ±0.652 
DPF3 99.32 ±1.082 CDPF3 99.19 ±0.854 
DPF4 99.95 ±0.578 CDPF4 100.13 ±1.234 
DPF5 99.16 ±1.524 CDPF5 99.04 ±0.573 
DPF6 99.93 ±0.541 CDPF6 99.01 ±0.949 
DPF7 99.54 ±1.125 CDPF7 99.67 ±0.963 
DPF8 100.04 ±0.769 CDPF8 99.03 ±0.245 
 
6.2.5.Transmission electron microscopy TEM 
 
Figure 6.44: TEM image of CDNF7 formulation 
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6.2.6. Invitro drug release study of noisome and proniosome formulations: 
Table 6.16: Invitro abacavir release data of niosome formulations without DCP 
in 0.1N HCl 
Time 
Hours 
DNF1 DNF2 DNF3 DNF4 DNF5 DNF6 DNF7 DNF8 
0.15 
37.80 
±1.836 
31.32 
±1.288 
25.66 
±1.330 
41.73 
±1.752 
28.21 
±1.580 
23.67 
±1.872 
13.56 
±1.013 
33.41 
±1.780 
0.45 
48.46 
±1.790 
40.53 
±1.915 
32.67 
±1.014 
57.94 
±1.745 
39.67 
±2.052 
27.95 
±1.894 
20.56 
±1.894 
41.63 
±2.040 
1 
57.43 
±1.789 
44.19 
±1.676 
33.43 
±2.222 
68.46 
±2.181 
42.22 
±1.742 
30.60 
±2.174 
21.68 
±2.160 
46.28 
±1.912 
2 
77.55 
±2.229 
50.47 
±2.173 
42.58 
±1.831 
82.47 
±2.261 
48.57 
±2.205 
37.69 
±1.948 
30.44 
±2.016 
54.58 
±1.841 
3 
79.42 
±1.863 
55.47 
±1.856 
49.47 
±2.132 
85.58 
±2.015 
52.47 
±1.770 
46.57 
±2.125 
39.51 
±1.896 
63.58 
±2.015 
4 
80.47 
±2.063 
63.55 
±2.027 
53.49 
±2.008 
86.24 
±1.709 
59.59 
±2.083 
49.64 
±1.779 
45.71 
±1.022 
65.44 
±2.246 
6 
86.64 
±2.206 
67.43 
±2.025 
61.25 
±1.720 
89.54 
±1.987 
66.53 
±1.829 
58.39 
±1.851 
55.47 
±1.842 
69.52 
±1.992 
10 
96.49 
±2.127 
72.62 
±2.195 
69.52 
±1.897 
97.27 
±1.757 
71.59 
±1.848 
68.61 
±1.955 
65.43 
±2.075 
74.47 
±1.858 
14 
97.59 
±1.793 
74.49 
±2.325 
70.58 
±2.049 
98.37 
±1.671 
72.69 
±2.130 
69.39 
±2.107 
68.43 
±2.059 
77.63 
±2.028 
16 
99.42 
±1.389 
80.53 
±1.902 
74.39 
±1.860 
99.68 
±1.046 
76.61 
±1.777 
72.52 
±1.804 
70.45 
±1.508 
83.58 
±1.993 
17 
99.80 
±1.075 
82.61 
±1.741 
76.59 
±1.926 
- 
78.50 
±1.930 
75.41 
±1.011 
73.51 
±1.685 
84.46 
±2.053 
18 - 
83.60 
±2.205 
78.62 
±2.190 
- 
80.49 
±1.981 
76.67 
±1.837 
74.54 
±2.035 
89.48 
±2.066 
20 - 
90.51 
±1.919 
84.49 
±2.098 
- 
87.53 
±2.170 
81.74 
±1.776 
79.53 
±1.969 
95.49 
±2.091 
21 - 
94.54 
±2.086 
88.54 
±2.101 
- 
92.67 
±2.017 
85.52 
±2.119 
83.61 
±2.160 
97.81 
±1.315 
24 - - - - 
99.39 
±0.834 
98.45 
±1.243 
97.45 
±2.200 
- 
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Figure 6.45:Invitro abacavir release plot of niosome formulations without DCP in 
0.1N HCl 
 
Table 6.17: Invitro abacavir release data of niosome formulations without DCP 
in PBS 6.8. 
TIME 
Hours 
DNF1 DNF2 DNF3 DNF4 DNF5 DNF6 DNF7 DNF8 
0.15 
35.33 
±0.903 
29.07 
±1.637 
24.80 
±1.231 
39.27 
±1.135 
26.36 
±1.338 
21.58 
±1.225 
12.7 
±0.945 
31.40 
±1.307 
0.45 
46.44 
±1.160 
38.51 
±1.685 
29.39 
±2.123 
54.73 
±1.479 
36.56 
±2.316 
24.73 
±0.877 
16.11 
±1.620 
39.68 
±1.167 
1 
54.28 
±0.956 
42.25 
±2.202 
30.32 
±1.049 
65.16 
±0.910 
39.54 
±1.581 
27.23 
±1.718 
18.98 
±1.188 
43.09 
±1.690 
2 
74.25 
±1.035 
47.34 
±2.050 
39.65 
±0.943 
79.28 
±1.808 
45.56 
±1.397 
34.36 
±1.673 
26.15 
±1.433 
52.64 
±2.081 
3 
76.31 
±1.92 
52.53 
±1.271 
45.57 
±1.569 
81.54 
±1.797 
49.43 
±2.450 
43.02 
±2.079 
36.45 
±1.188 
59.12 
±1.676 
4 
78.34 
±1.447 
60.24 
±1.799 
50.76 
±1.114 
83.64 
±2.124 
56.47 
±0.878 
47.51 
±2.145 
43.78 
±1.041 
62.05 
±1.685 
6 
83.55 
±1.596 
64.26 
±0.859 
58.87 
±2.091 
86.84 
±0.951 
62.23 
±1.523 
55.33 
±2.166 
51.56 
±1.301 
65.41 
±1.954 
0 
20 
40 
60 
80 
100 
120 
0 5 10 15 20 25 30 
P
er
ce
n
ta
g
e 
D
ru
g
 R
el
ea
se
d
 (
%
) 
Time (Hours) 
Niosome formulations with out DCP in 0.1N HCl 
DNF1 
DNF2 
DNF3 
DNF4 
DNF5 
DNF6 
DNF7 
DNF8 
Chapter 6                                                                                                    Results and Analysis 
 
Department of Pharmaceutics                           159        J.K.K Nattraja College of Pharmacy 
 
10 
92.29 
±1.537 
69.96 
±1.07 
65.62 
±1.560 
94.36 
±0.669 
69.36 
±0.719 
63.76 
±2.209 
62.39 
±1.917 
72.35 
±1.905 
14 
94.79 
±1.431 
71.49 
±1.291 
68.72 
±0.983 
95.63 
±1.131 
70.65 
±1.421 
66.58 
±1.935 
65.20 
±1.682 
74.49 
±1.364 
15 
95.24 
±2.046 
73.72 
±1.541 
69.97 
±0.95 
96.57 
±1.771 
71.48 
±2.330 
68.63 
±2.109 
66.66 
±0.968 
77.49 
±1.293 
16 
95.99 
±1.28 
76.16 
±1.174 
70.34 
±1.710 
97.64 
±0.789 
73.67 
±0.995 
71.12 
±1.481 
68.48 
±1.788 
80.32 
±1.722 
17 
96.63 
±1.595 
78.30 
±1.454 
71.6 7 
±0.886 
98.22 
±1.321 
75.49 
±1.233 
73.45 
±1.332 
71.24 
±1.827 
81.14 
±1.405 
18 
98.48 
±1.073 
80.63 
±1.613 
76.66 
±1.017 
99.08 
±0.867 
78.43 
±1.768 
74.48 
±1.757 
72.52 
±1.781 
86.42 
±0.959 
20 
99.77 
±0.906 
87.66 
±2.503 
81.28 
±1.396 
- 
84.36 
±1.551 
78.79 
±0.981 
75.08 
±1.381 
93.24 
±1.484 
22 - 
95.67 
±1.514 
90.66 
±1.359 
- 
92.51 
±1.640 
87.78 
±1.595 
85.39 
±1.935 
98.63 
±1.051 
24 - 
99.80 
±0.805 
99.68 
±0.994 
- 
99.27 
±1.246 
97.15 
±1.198 
96.07 
±1.605 
- 
 
 
 
Figure 6.46:Invitro abacavir release plot of niosome formulations without DCP in 
PBS 6.8 
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Table 6.18: Invitro abacavir release data of niosome formulations with DCP in 
0.1N HCl. 
TIME 
Hours 
CDNF
1 
CDNF
2 
CDNF
3 
CDNF
4 
CDNF
5 
CDNF
6 
CDNF
7 
CDNF
8 
0.15 
29.90 
±1.688 
23.80 
±1.221 
17.57 
±1.968 
31.33 
±1.769 
20.82 
±1.972 
14.75 
±1.075 
9.74 
±1.170 
27.41 
±2.171 
0.45 
33.44 
±1.376 
27.94 
±1.787 
20.69±
2.039 
44.32 
±1.955 
23.72 
±2.271 
17.43 
±1.783 
14.87 
±1.021 
30.53 
±1.801 
1 
54.52 
±1.825 
35.57 
±1.980 
26.63 
±2.046 
58.76 
±2.005 
30.43 
±1.842 
22.81 
±1.971 
17.62 
±2.222 
41.54 
±2.059 
2 
66.53 
±2.262 
43.46 
±2.321 
39.50 
±1.757 
71.23 
±1.824 
39.54 
±2.179 
24.57 
±2.305 
22.50  
±2.269 
49.47 
±2.033 
3 
70.68 
±1.893 
47.55 
±1.748 
41.45 
±2.085 
74.36 
±2.160 
43.57 
±2.242 
36.75 
±2.111 
31.68 
±2.159 
51.66 
±1.884 
4 
74.51 
±2.020 
54.63 
±2.379 
48.52 
±1.986 
79.48 
±2.222 
50.57 
±1.959 
44.55 
±1.994 
39.77 
±1.986 
59.67 
±1.775 
5 
77.60 
±1.921 
57.50 
±2.150 
53.59 
±2.195 
82.34 
±1.919 
54.72 
±2.168 
50.79 
±1.979 
46.70 
±1.506 
63.38 
±2.279 
6 
82.52 
±2.025 
61.76 
±2.011 
56.13 
±2.011 
85.52 
±2.020 
58.53 
±1.739 
54.51 
±2.215 
50.51 
±2.182 
65.35 
±2.181 
10 
88.53 
±2.363 
69.59 
±1.969 
63.55 
±2.234 
92.47 
±2.053 
66.45 
±2.285 
61.47 
±1.993 
58.58 
±2.177 
73.47 
±2.071 
12 
92.38 
±1.843 
71.36 
±1.883 
67.70 
±2.165 
94.53 
±2.007 
70.63 
±2.215 
64.59 
±2.266 
62.46 
±2.199 
75.45 
±1.982 
16 
95.61 
±1.913 
75.58 
±2.318 
70.47 
±1.925 
98.15 
±1.184 
73.54 
±2.230 
68.58 
±1.958 
65.44 
±1.815 
82.51 
±2.106 
18 
98.23 
±1.617 
80.61 
±1.875 
74.40 
±1.417 
99.94 
±1.906 
79.52 
±1.769 
71.59 
±1.975 
69.61 
±1.775 
87.46 
±2.119 
20 
99.69 
±1.236 
88.71 
±2.041 
81.57 
±1.951 
- 
85.75 
±2.155 
77.62 
±2.165 
75.36 
±1.926 
94.53 
±1.928 
22 - 
95.57 
±1.837 
90.42 
±2.094 
- 
92.55 
±2.218 
89.68 
±2.026 
85.52 
±2.281 
97.53 
±2.125 
24 
- 
99.32 
±1.908 
94.47 
±2.105 
- 
98.41 
±1.559 
92.66 
±1.778 
89.56 
±2.090 
99.58 
±1.489 
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Figure 6.47:Invitro abacavir release plot of niosome formulations with DCP in 
0.1N HCl 
 
Table 6.19: Invitro abacavir release data of niosome formulations with DCP in 
PBS 6.8. 
TIME 
Hours 
CDNF 
1 
CDNF 
2 
CDNF 
3 
CDNF 
4 
CDNF 
5 
CDNF  
6 
CDNF 
7 
CDNF 
8 
0.15 
27.62 
±1.496 
21.57 
±1.016 
15.37 
±1.210 
29.81 
±1.648 
18.93 
±1.371 
12.73 
±1.794 
8.73 
±1.367 
24.16 
±1.869 
0.45 
30.29 
±2.469 
24.84 
±0.962 
18.97 
±0.996 
41.17 
±1.061 
21.91 
±1.473 
15.18 
±1.299 
12.93 
±0.915 
27.81 
±0.993 
1 
51.48 
±1.813 
32.29 
±1.394 
23.55 
±2.017 
55.71 
±1.273 
27.18 
±1.433 
19.86 
±2.685 
14.82 
±1.505 
38.77 
±1.659 
2 
63.41 
±2.110 
40.27 
±0.662 
33.32 
±1.466 
67.38 
±0.729 
36.31 
±2.246 
21.75 
±2.304 
19.67 
±1.754 
46.73 
±1.522 
3 
67.79 
±0.771 
43.67 
±1.341 
37.12 
±1.449 
71.33 
±1.388 
39.67 
±2.673 
33.82 
±1.651 
27.91 
±2.578 
47.80 
±0.976 
4 
71.44 
±1.002 
51.81 
±1.219 
44.92 
±0.839 
76.28 
±1.723 
47.21 
±1.570 
41.87 
±1.725 
36.69 
±0.852 
56.83 
±1.587 
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6 
79.36 
±0.952 
58.85 
±0.826 
52.05 
±0.951 
82.56 
±1.014 
54.68 
±2.754 
49.55 
±1.556 
46.86 
±1.609 
62.26 
±2.192 
9 
82.34 
±1.338 
63.20 
±1.833 
57.08 
±1.726 
86.40 
±0.850 
60.56 
±2.631 
55.33 
±2.005 
51.26 
±1.473 
66.57 
±2.318 
10 
85.38 
±0.999 
65.74 
±1.757 
60.79 
±2.339 
88.68 
±1.298 
63.03 
±1.470 
58.12 
±1.558 
55.79 
±2.647 
69.65 
±1.462 
12 
89.13 
±0.917 
69.16 
±1.631 
64.87 
±0.981 
92.44 
±0.965 
67.46 
±1.897 
61.51 
±1.171 
58.18  
±2.349 
71.07 
±2.326 
16 
91.74 
±1.023 
72.72 
±1.882 
67.51 
±1.083 
95.39 
±1.333 
69.53 
±2.258 
64.38 
±1.143 
62.46 
±2.295 
79.69 
±1.279 
18 
95.33 
±1.233 
77.61 
±1.548 
72.32 
±0.942 
97.76 
±1.489 
75.38 
±2.958 
67.75 
±1.369 
65.62 
±2.192 
83.23 
±2.075 
20 
96.64 
±1.068 
84.78 
±1.038 
78.66 
±1.620 
99.26 
±1.248 
81.70 
±1.449 
73.57 
±2.469 
70.12 
±1.499 
91.73 
±1.517 
22 
99.28 
±0.651 
92.67 
±2.072 
87.19 
±1.399 
 
89.41 
±1.328 
86.74 
±1.078 
82.46  
±2.132 
94.49 
±2.158 
24 - 
96.81 
±1.153 
91.49 
±1.685 
 
94.73 
±1.935 
88.78 
±2.174 
85.59 
±1.311 
98.88 
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Figure 6.48:Invitro abacavir release plot of niosome formulations with DCP in 
PBS 6.8 
0 
20 
40 
60 
80 
100 
120 
0 5 10 15 20 25 30 
P
er
ce
n
ta
g
e 
D
ru
g
 R
el
ea
se
d
 (
%
) 
Time (Hours) 
Niosome formulations with DCP in pH 6.8 PBS 
CDNF1 
CDNF2 
CDNF3 
CDNF4 
CDNF5 
CDNF6 
CDNF7 
CDNF8 
Chapter 6                                                                                                    Results and Analysis 
 
Department of Pharmaceutics                           163        J.K.K Nattraja College of Pharmacy 
 
Table 6.20: Invitro abacavir release data of proniosome formulations of abacavir 
sulphate without DCP in 0.1N HCl 
TIME 
Hours 
DPF1 DPF2 DPF3 DPF4 DPF5 DPF6 DPF7 DPF8 
0.15 
15.38 
±1.215 
11.19 
±1.687 
8.20 
±1.731 
16.44 
±1.259 
10.46 
±1.147 
7.75 
±1.645 
5.71 
±1.657 
13.04 
±1.669 
0.45 
18.08 
±1.708 
13.51 
±1.344 
11.32 
±1.746 
22.52 
±2.133 
12.77 
±1.103 
9.70 
±2.083 
6.49 
±1.116 
15.24 
±1.754 
1 
26.58 
±1.330 
15.42 
±1.411 
12.50 
±1.899 
30.24 
±1.966 
14.63 
±1.340 
11.89 
±1.859 
10.57 
±1.771 
21.52 
±0.996 
2 
36.37 
±2.056 
24.49 
±2.120 
17.54 
±2.212 
43.49 
±2.173 
22.46 
±2.224 
15.46 
±1.851 
13.63 
±2.042 
26.68 
±1.839 
3 
50.18 
±1.609 
37.58 
±1.958 
30.82 
±1.950 
53.61 
±2.003 
34.64 
±2.018 
27.52 
±2.055 
22.64 
±1.759 
45.73 
±2.123 
4 
61.75 
±2.103 
44.59 
±2.035 
37.52 
±2.140 
72.40 
±2.170 
41.68 
±1.952 
33.52 
±1.909 
25.58 
±1.992 
56.68 
±2.121 
5 
70.63 
±2.207 
58.90 
±1.639 
51.25 
±2.031 
81.08 
±1.466 
56.62 
±2.180 
45.67 
±1.964 
41.66 
±1.950 
64.45 
±1.462 
6 
77.82 
±1.631 
64.45 
±2.116 
57.52 
±2.125 
87.58 
±2.171 
62.52 
±1.798 
50.69 
±2.106 
45.60 
±2.086 
72.43 
±2.088 
9 
84.67 
±2.154 
74.59 
±2.061 
63.41 
±1.735 
91.46 
±2.200 
69.68 
±1.427 
59.52 
±1.785 
54.42 
±1.997 
79.29 
±1.676 
10 
89.55 
±2.218 
81.40 
±2.275 
72.57 
±2.053 
95.68 
±1.338 
78.35 
±2.101 
65.57 
±2.016 
60.51 
±2.308 
85.37 
±1.936 
12 
94.44 
±2.198 
86.55 
±2.337 
75.40 
±1.825 
97.13 
±1.791 
81.50 
±1.733 
71.47 
±1.880 
68.29 
±1.709 
92.42 
±1.821 
16 
97.79 
±1.711 
90.30 
±2.521 
81.57 
±1.825 
99.68 
±1.031 
85.51 
±2.160 
77.42 
±2.001 
72.58 
±2.216 
96.01 
±2.607 
18 
99.69 
±1.221 
93.40 
±2.180 
86.64 
±2.097 
- 
90.53 
±1.911 
83.68 
±1.969 
79.59 
±1.733 
98.56 
±1.313 
20 - 
98.56 
±1.669 
92.44 
±1.864 
- 
95.39 
±2.158 
89.31 
±1.733 
85.62 
±2.134 
100.31 
±0.799 
22 - 
98.88 
±1.567 
96.40 
±2.190 
- 
97.40 
±2.112 
95.54 
±2.135 
93.51 
±2.021 
- 
24 - 
99.69 
±1.360 
98.53 
±1.908 
- 
99.59 
±1.225 
97.56 
±1.949 
96.56 
±2.075 
- 
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Figure 6.49:Invitro abacavir release plot of proniosome formulations without 
DCP in 0.1N HCl 
Table 6.21: Invitro abacavir release data of proniosome formulations of abacavir 
sulphate without DCP in PBS 6.8 
Time 
Hours 
DPF1 DPF2 DPF3 DPF4 DPF5 DPF6 DPF7 DPF8 
0.15 
12.71 
±1.669 
8.28 
±1.171 
6.37 
±1.315 
14.13 
±1.629 
7.17 
±1.681 
5.17 
±1.681 
3.33 
±1.365 
11.29 
±1.084 
0.45 
16.20 
±1.658 
10.25 
±1.367 
7.78 
±1.504 
20.40 
±2.252 
8.67 
±1.905 
6.82 
±1.569 
4.31 
±1.307 
13.38 
±1.423 
1 
23.56 
±1.936 
16.36 
±2.198 
9.66 
±1.469 
28.30 
±1.992 
12.62 
±1.878 
8.45 
±1.989 
7.52 
±2.128 
18.35 
±1.248 
2 
32.45 
±1.988 
22.52 
±1.097 
15.05 
±1.451 
39.22 
±1.617 
19.22 
±1.502 
12.51 
±2.073 
10.38 
±1.952 
26.97 
±1.879 
3 
47.68 
±2.175 
34.37 
±1.829 
27.79 
±1.593 
51.48 
±1.843 
31.52 
±2.138 
24.48 
±2.263 
19.19 
±1.668 
42.46 
±1.957 
4 
59.62 
±2.065 
40.19 
±1.658 
33.47 
±2.017 
69.38 
±2.606 
38.78 
±1.805 
29.14 
±1.619 
22.33 
±2.011 
53.43 
±2.182 
5 
67.52 
±2.001 
55.58 
±2.019 
48.07 
±1.731 
78.40 
±2.154 
53.64 
±2.095 
42.52 
±2.007 
37.67 
±2.072 
61.36 
±2.197 
6 
74.35 
±1.326 
62.54 
±2.132 
54.35 
±1.854 
85.65 
±1.361 
59.40 
±1.804 
47.51 
±2.214 
43.30 
±2.082 
69.29 
±1.966 
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9 
81.52 
±1.996 
71.42 
±1.935 
61.42 
±2.082 
89.41 
±2.071 
66.89 
±1.777 
56.37 
±1.853 
51.32 
±1.797 
76.36 
±2.068 
10 
87.41 
±2.041 
78.42 
±1.831 
69.44 
±1.967 
93.25 
±2.101 
74.30 
±1.977 
63.49 
±2.192 
57.37 
±1.853 
82.29 
±2.066 
12 
91.12 
±1.444 
83.43 
±2.319 
72.43 
±2.157 
95.06 
±1.626 
79.38 
±2.308 
68.44 
±2.144 
64.58 
±1.080 
89.37 
±2.307 
16 
95.31 
±1.809 
88.37 
±1.991 
78.42 
±1.827 
97.45 
±2.225 
82.49 
±2.044 
74.50 
±2.115 
69.39 
±2.029 
92.29 
±1.867 
18 
97.08 
±2.401 
91.44 
±2.061 
83.33 
±2.243 
99.14 
±1.679 
87.60 
±2.134 
80.37 
±1.961 
77.46 
±2.153 
96.81 
±1.567 
20 
99.30 
±1.072 
95.38 
±1.973 
89.31 
±1.894 
- 
93.52 
±2.099 
86.55 
±2.057 
83.39 
±2.311 
98.32 
±1.482 
22 - 
97.55 
±1.867 
93.41 
±2.032 
- 
95.29 
±1.739 
92.51 
±2.077 
89.42 
±2.186 
99.02 
±1.450 
24 - 
99.08 
±1.701 
96.32 
±1.915 
- 
98.59 
±2.011 
95.42 
±2.082 
94.55 
±1.249 
- 
 
 
Figure 6.50:Invitro abacavir release plot of proniosome formulations without 
DCP in PBS 6.8 
 
0 
20 
40 
60 
80 
100 
120 
0 5 10 15 20 25 30 
P
er
ce
n
ta
g
e 
D
ru
g
 R
el
ea
se
d
 (
%
) 
 
Time (Hours) 
 
Proniosome formulations without DCP in PBS 6.8 
 
DPF1 
DPF2 
DPF3 
DPF4 
DPF5 
DPF6 
DPF7 
DPF8 
Chapter 6                                                                                                    Results and Analysis 
 
Department of Pharmaceutics                           166        J.K.K Nattraja College of Pharmacy 
 
Table 6.22: Invitro abacavir release data of proniosome formulations of abacavir 
sulphate with DCP in 0.1N HCl 
Time 
Hour
s 
CDPF
1 
CDPF
2 
CDPF
3 
CDPF
4 
CDPF
5 
CDPF
6 
CDPF
7 
CDPF
8 
0.15 
12.03 
±1.533 
9.18 
±1.363 
6.45 
±1.349 
14.68 
±1.091 
7.72 
±1.165 
5.45   
±1.228 
3.66 
±1.108 
11.52 
±2.235 
0.45 
17.28 
±1.632 
11.08 
±1.531 
8.47 
±1.419 
20.45 
±1.876 
9.55 
±2.106 
7.44   
±1.318 
5.53 
±1.293 
13.78 
±1.508 
1 
24.56 
±1.945 
14.79 
±1.578 
10.46 
±2.031 
29.66 
±2.121 
12.51 
±1.300 
9.44  
±1.885 
7.77 
±1.710 
19.37 
±1.471 
2 
33.47 
±2.105 
22.59 
±2.053 
16.61 
±2.121 
38.5 
±2.215 
19.56 
±2.120 
13.45 
±1.477 
11.41 
±2.122 
25.51 
±2.005 
3 
48.53 
±1.285 
34.67 
±1.964 
27.78 
±1.401 
50.49 
±2.170 
31.44 
±1.796 
24.50 
±2.144 
16.63 
±2.101 
42.54 
±1.356 
4 
59.64 
±1.766 
40.49 
±1.905 
34.42 
±2.067 
69.56 
±2.241 
37.57 
±1.832 
27.63 
±2.103 
20.39 
±2.171 
49.50 
±2.291 
5 
67.51 
±2.311 
56.65 
±2.015 
48.56 
±2.215 
77.61 
±2.281 
50.50 
±2.097 
43.21 
±1.580 
38.43 
±1.783 
62.36 
±2.081 
6 
75.66 
±2.064 
60.56 
±1.935 
54.44 
±2.090 
84.72 
±2.085 
57.47 
±1.354 
48.37 
±1.981 
43.46 
±2.245 
70.49 
±2.078 
10 
87.49 
±1.735 
77.61 
±2.092 
70.44 
±1.893 
92.52 
±2.330 
75.41 
±2.110 
63.42 
±2.150 
57.59 
±2.140 
82.49 
±1.982 
12 
91.53 
±1.946 
83.55 
±2.178 
73.74 
±2.549 
96.39 
±1.872 
78.61 
±1.937 
69.52 
±2.163 
65.59 
±1.687 
89.21 
±1.625 
16 
96.44 
±1.425 
88.53 
±2.111 
78.38 
±2.141 
98.24 
±1.661 
82.50 
±2.080 
75.04 
±1.579 
70.43 
±2.153 
93.54 
±2.138 
18 
98.11 
±1.646 
91.52 
±1.994 
84.67 
±1.991 
99.51 
±1.300 
88.33 
±1.775 
80.23 
±2.058 
77.44 
±1.463 
96.58 
±2.134 
20 
99.77 
±1.014 
94.55 
±2.020 
90.31 
±2.154 
- 
94.36 
±2.059 
86.48 
±2.262 
83.49 
±2.113 
98.64 
±1.391 
22 - 
96.50 
±2.166 
93.49 
±2.329 
- 
97.78 
±1.427 
91.12 
±1.399 
90.61 
±1.931 
99.56 
±1.276 
24 - 
99.04 
±0.570 
97.57 
±2.066  
- 
98.39 
±1.355 
95.36 
±1.896 
94.46 
±1.396 
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Figure 6.51:Invitro abacavir release plot of proniosome formulations with DCP 
in 0.1 N HCl 
Table 6.23: Invitro abacavir release data of proniosome formulations of abacavir 
sulphate with DCP in pH 6.8 phosphate buffer 
 
 
Time 
Hours 
CDPF 
1 
CDPF 
2 
CDPF 
3 
CDPF 
4 
CDPF 
5 
CDPF 
6 
CDPF 
7 
CDPF 
8 
0.15 
10.37 
±1.311 
7.39   
±1.728 
5.16 
±1.885 
12.38 
±2.234 
6.59 
±1.935 
4.21 
±1.511 
2.43 
±1.334 
9.35 
±1.875 
0.45 
14.45 
±1.356 
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6.35 
±1.363 
17.37 
±2.094 
7.13 
±1.395 
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±1.705 
3.32 
±1.501 
11.21 
±2.058 
1 
21.55 
±1.421 
13.37 
±1.956 
8.37 
±2.193 
26.48 
±1.916 
10.37 
±2.084 
7.39 
±1.929 
5.14 
±1.809 
16.42 
±2.289 
2 
30.44 
±2.227 
19.47 
±2.026 
13.27 
±1.632 
35.51 
±2.102 
16.39 
±1.793 
10.35 
±2.335 
8.52 
±2.132 
23.56 
±1.365 
3 
45.30 
±2.180 
31.52 
±2.007 
24.57 
±2.226 
47.47 
±2.159 
27.39 
±1.801 
21.28 
±2.184 
13.45 
±2.189 
39.60 
±2.082 
4 
55.72 
±1.448 
37.49 
±2.161 
31.22 
±1.974 
66.37 
±1.863 
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5 
64.42 
±2.165 
52.48 
±1.955 
44.56 
±2.185 
74.55 
±1.987 
47.31 
±1.702 
40.22 
±1.859 
34.32 
±1.816 
58.30 
±2.195 
6 
72.52 
±1.484 
57.56 
±2.014 
51.39 
±2.113 
81.55 
±2.203 
54.35 
±1.875 
47.44 
±1.967 
40.41 
±2.228 
67.22 
±2.054 
9 
79.53 
±2.022 
68.25 
±1.897 
58.80 
±1.731 
86.40 
±1.696 
62.57 
±2.021 
53.38 
±1.751 
48.29 
±2.140 
73.29 
±1.976 
10 
84.46 
±2.137 
74.31 
±2.127 
66.32 
±2.124 
90.53 
±2.135 
71.42 
±2.092 
60.41 
±1.889 
54.29 
±2.279 
79.30 
±1.848 
12 
88.46 
±2.251 
80.42 
±2.107 
69.26 
±1.715 
93.49 
±2.157 
75.31 
±1.789 
65.16 
±2.219 
61.21 
±1.959 
86.25 
±2.002 
16 
93.44 
±1.864 
85.23 
±1.860 
74.29 
±1.872 
96.18 
±1.912 
79.49 
±2.192 
72.29 
±1.862 
67.30 
±2.081 
90.42 
±2.195 
18 
95.18 
±2.001 
88.37 
±2.381 
81.42 
±2.038 
98.02 
±1.265 
84.55 
±1.919 
77.10 
±2.127 
74.34 
±2.363 
93.36 
±2.276 
20 
98.49 
±2.083 
93.51 
±2.190 
87.03 
±2.065 
99.52 
±1.263 
91.13 
±1.589 
82.38 
±2.131 
79.35 
±1.864 
94.95 
±2.550 
22 
99.21 
±1.214 
95.41 
±2.224 
91.34 
±1.780 
- 
94.36 
±1.856 
89.24 
±1.559 
87.56 
±2.179 
97.52 
±2.050 
24 - 
98.55 
±1.987 
95.48 
±2.184 
- 
97.16 
±2.229 
93.19 
±2.002 
92.12 
±1.429 
99.13 
±1.444 
 
 
Figure 6.52: Invitro abacavir release plot of proniosome formulations with DCP 
in PBS pH 6.8 
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 Figure 6.53: Comparitive invitro release of optimized proniosome and niosome formulations in 0.1N HCl 
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6.2.7. Release kinetics: 
Table 6.24: Release kinetics data of selected noisome formulations 
Formulation 
code 
Zero order First order R
2
 
Higuchi’ 
Model R
2
 
Hixson Crowell 
Korsmeyer & Peppas 
equation 
0.1N 
HCl 
pH 6.8 
PBS 
0.1N 
HCl 
pH 6.8 
PBS 
0.1N 
HCl 
pH 6.8 
PBS 
0.1N HCl 
pH 6.8 
PBS 
0.1N HCl pH 6.8 PBS 
DNF5 0.818 0.840 0.734 0.713 0.921 0.931 0.866 0.856 
0.974 
n=0.226 
0.971 n=0.238 
DNF6 0.874 0.876 0.781 0.816 0.960 0.967 0.892 0.903 
0.971 
n=0.290 
0.971 n=0.306 
DNF7 0.889 0.900 0.819 0.830 0.972 0.973 0.908 0.908 
0.981 
n=0.379 
0.976 n=0.411 
CDNF5 0.868 0.857 0.831 0.906 0.973 0.976 0.925 0.940 
0.983 
n=0.314 
0.980 n=0.327 
CDNF6 0.882 0.893 0.910 0.923 0.973 0.971 0.935 0.939 
0.965 
n=0.383 
0.964 n=0.406 
CDNF7 0.900 0.909 0.939 0.944 0.982 0.981 0.951 0.951 
0.981 
n=0.446 
0.975 n=0.467 
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Table 6.25: Release kinetics data of selected proniosome formulations 
Formulation 
code 
Zero order First order Higuchi’ model Hixson Crowel 
Korsmeyer & Peppas 
equation 
0.1N 
HCl 
pH 6.8 
PBS 
0.1N 
HCl 
pH 6.8 
PBS 
0.1N 
HCl 
pH 6.8 
PBS 
0.1N 
HCl 
pH 6.8 
PBS 
0.1N HCl pH 6.8 PBS 
DPF5 0.871 0.882 0.906 0.946 0.973 0.975 0.980 0.980 
0.956 
n=0.515 
0.965 
n=0.590 
DPF6 0.932 0.937 0.935 0.959 0.986 0.982 0.984 0.986 
0.958 
n=0.571 
0.960 
n=0.655 
DPF7 0.950 0.955 0.928 0.949 0.981 0.977 0.979 0.984 
0.965 
n=0.634 
0.971 
n=0.738 
CDPF5 0.896 0.907 0.949 0.963 0.979 0.979 0.984 0.959 
0.966 
n=0.576 
0.959 
n=0.621 
CDPF6 0.933 0.938 0.962 0.967 0.981 0.976 0.986 0.984 
0.963 
n=0.636 
0.956 
n=0.701 
CDPF7 0.953 0.960 0.952 0.958 0.973 0.965 0.984 0.984 
0.959 
n=0.733 
0.962 
n=0.812 
 
  
Chapter 6                                                                                                    Results and Analysis 
 
Department of Pharmaceutics                           172        J.K.K Nattraja College of Pharmacy 
 
Release kinetics calculation details: 
Table 6.26: Drug release kinetic computation of noisome formulation DNF5 in 
0.1 N HCl 
Time 
Hours 
Cumulative 
% drug 
released 
Log 
cum % 
drug 
release 
% 
drug 
remain
ing 
Log % 
drug 
remain
ing 
Sq.Rt
.  
Time 
Log 
Time 
Cub. Rt. 
Unreleased 
drug 
fraction 
0 0 - 100 2.0 0 - 4.64 
0.15 28.21 1.45 71.79 1.86 0.39 -0.82 4.16 
0.45 39.67 1.59 60.33 1.78 0.67 -0.35 3.92 
1 42.22 1.63 57.78 1.76 1.0 0 3.87 
2 48.57 1.69 51.43 1.71 1.41 0.30 3.72 
3 52.47 1.72 47.53 1.68 1.73 0.48 3.62 
4 59.59 1.78 40.41 1.61 2.0 0.60 3.43 
5 63.91 1.81 36.09 1.56 2.24 0.70 3.30 
6 66.53 1.82 33.47 1.52 2.45 0.78 3.22 
10 71.59 1.85 28.41 1.45 3.16 1.0 3.05 
14 72.69 1.86 27.31 1.44 3.74 1.15 3.01 
15 74.53 1.87 25.47 1.41 3.87 1.18 2.94 
16 76.61 1.88 23.39 1.37 4.0 1.20 2.86 
17 78.5 1.89 21.5 1.33 4.12 1.23 2.78 
18 80.49 1.91 19.51 1.29 4.24 1.26 2.69 
20 87.53 1.94 12.47 1.09 4.47 1.30 2.32 
21 92.67 1.97 7.33 0.87 4.58 1.32 1.94 
24 99.39 1.99 0.61 -0.21 4.89 1.38 0.85 
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y = -0.0513x + 1.8993 
R² = 0.7342 
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Figure 6.55: First order plot 
(DNF5) in 0.1N HCl 
y = 2.5721x + 38.971 
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Figure 6.54: Zero order plot 
(DNF5) in 0.1N HCl 
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Figure 6.56: Higuchi model 
plot (DNF5) in 0.1N HCl 
y = -0.0996x + 4.0623 
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Figure 6.57: Hixon Crowell 
model plot (DNF5) in 0.1N HCl 
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Figure 6.58: Kosmeyer & Pepas plot (DNF5) in 0.1N 
HCl 
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Table 6.27: Drug release kinetics computation of noisome formulation DNF5 in 
PBS pH 6.8 
Time 
Hours 
Cumulative 
% drug 
released 
Log 
cum % 
drug 
release 
% 
drug 
rema
ining 
Log % 
drug 
remaining 
Sq.Rt
.  
Time 
Log 
Time 
Cub. Rt. 
Unreleased 
drug 
fraction 
0 0 - 100 2 0 - 4.64 
0.15 26.36 1.42 73.64 1.87 0.39 -0.82 4.19 
0.45 36.56 1.563 63.44 1.80 0.67 -0.35 3.99 
1 39.54 1.60 60.46 1.78 1.0 0 3.92 
2 45.56 1.66 54.44 1.74 1.41 0.30 3.79 
3 49.43 1.69 50.57 1.70 1.73 0.48 3.69 
4 56.47 1.75 43.53 1.64 2.0 0.60 3.52 
5 60.37 1.78 39.63 1.59 2.24 0.69 3.41 
6 62.23 1.79 37.77 1.58 2.45 0.78 3.36 
10 69.36 1.84 30.64 1.49 3.16 1.0 3.13 
14 70.65 1.85 29.35 1.47 3.74 1.15 3.08 
15 71.48 1.85 28.52 1.46 3.87 1.18 3.06 
16 73.67 1.87 26.33 1.40 4.0 1.20 2.97 
17 75.49 1.88 24.51 1.39 4.12 1.23 2.90 
18 78.43 1.89 21.57 1.33 4.24 1.26 2.78 
20 84.36 1.93 15.64 1.19 4.47 1.30 2.50 
22 92.51 1.97 7.49 0.87 4.69 1.34 1.96 
24 99.27 1.99 0.73 -0.14 4.89 1.38 0.90 
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y = 2.6028x + 36.116 
R² = 0.8407 
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Figure 6.59: Zero order plot 
(DNF5) in PBS pH 6.8 
y = -0.0474x + 1.9105 
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Figure 6.60: First order  plot 
(DNF5in PBS pH 6.8 
y = 14.609x + 21.751 
R² = 0.9313 
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Figure 6.61: Higuchi model 
plot (DNF5) in PBS pH 6.8 
y = -0.0956x + 4.1197 
R² = 0.8567 
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Figure 6.62: Hixon Crowell 
model plot (DNF5) in PBS pH 
6.8 
y = 0.2382x + 1.61 
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Figure 6.63: Kosmeyer & Pepas plot (DNF5) in PBS 
6.8 
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Table 6.28: Drug release kinetics computation of noisome formulation DNF6 in 
0.1 N HCl 
Time 
Hours 
Cumulative 
% drug 
released 
Log 
cum % 
drug 
release 
% 
drug 
rema
ining 
Log % 
drug 
remaining 
Sq.Rt.  
Time 
Log 
Time 
Cub. Rt. 
Unreleased 
drug 
fraction 
0 0 - 100 2.0 0 - 4.64 
0.15 23.67 1.37 76.33 1.88 0.39 -0.82 4.24 
0.45 27.95 1.45 72.05 1.86 0.67 -0.35 4.16 
1 30.6 1.49 69.4 1.84 1.0 0 4.11 
2 37.69 1.58 62.31 1.79 1.41 0.30 3.96 
3 46.57 1.67 53.43 1.73 1.73 0.48 3.77 
4 49.64 1.69 50.36 1.70 2.0 0.60 3.69 
5 54.79 1.74 45.21 1.66 2.24 0.69 3.56 
6 58.39 1.77 41.61 1.62 2.45 0.78 3.47 
10 68.61 1.84 31.39 1.49 3.16 1.0 3.15 
14 69.39 1.84 30.61 1.48 3.74 1.15 3.13 
15 70.53 1.85 29.47 1.47 3.87 1.18 3.09 
16 72.52 1.86 27.48 1.44 4.0 1.20 3.02 
17 75.41 1.88 24.59 1.39 4.12 1.23 2.91 
18 76.67 1.88 23.33 1.37 4.24 1.26 2.86 
20 81.74 1.91 18.26 1.26 4.47 1.30 2.63 
21 85.52 1.93 14.48 1.16 4.58 1.32 2.44 
24 98.45 1.99 1.55 0.19 4.89 1.38 1.16 
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y = 2.8177x + 30.54 
R² = 0.8742 
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Figure 6.64: Zero order plot 
(DNF6) in 0.1N HCl  
y = -0.0426x + 1.9229 
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Figure 6.65: First order plot 
(DNF6) in 0.1N HCl 
y = 15.752x + 15.166 
R² = 0.9607 
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Figure 6.66: Higuchi model 
plot (DNF6) in 0.1N HCl 
y = -0.0937x + 4.215 
R² = 0.8923 
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Figure 6.67:Hixon Crowell 
model plot (DNF6) in 0.1N HCl 
y = 0.2904x + 1.5358 
R² = 0.9713 
0 
0.5 
1 
1.5 
2 
2.5 
-1 -0.5 0 0.5 1 1.5 
L
o
g
 c
u
m
. 
%
 d
ru
g
 r
el
ea
se
 
Log Time 
Figure 6.68:Kosmeyer & Pepas plot (DNF6) in 0.1N 
HCl 
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Table 6.29: Drug release kinetics computation of noisome formulation DNF6 in 
PBS pH 6.8 
Time 
Hours 
Cumulative 
% drug 
released 
Log 
cum % 
drug 
release 
% 
drug 
remain 
Log % 
drug 
remain 
Sq.Rt.  
Time 
Log 
Time 
Cub. Rt. 
Unrelease
d drug 
fraction 
0 0 - 100 2.0 0 - 4.64 
0.15 21.58 1.33 78.42 1.89 0.39 -0.82 4.28 
0.45 24.73 1.39 75.27 1.88 0.67 -0.35 4.22 
1 27.23 1.44 72.77 1.86 1.0 0 4.17 
2 34.36 1.54 65.64 1.82 1.41 0.30 4.03 
3 43.02 1.63 56.98 1.76 1.73 0.48 3.85 
4 47.51 1.68 52.49 1.72 2.0 0.60 3.74 
5 51.63 1.71 48.37 1.68 2.24 0.69 3.64 
6 55.33 1.74 44.67 1.65 2.45 0.78 3.55 
10 63.76 1.80 36.24 1.56 3.16 1.0 3.31 
14 66.58 1.82 33.42 1.52 3.74 1.15 3.22 
15 68.63 1.84 31.37 1.49 3.87 1.18 3.15 
16 71.12 1.85 28.88 1.46 4.0 1.20 3.07 
17 73.45 1.87 26.55 1.42 4.12 1.23 2.98 
18 74.48 1.87 25.52 1.41 4.24 1.26 2.94 
20 78.79 1.89 21.21 1.33 4.47 1.30 2.77 
21 82.19 1.91 17.81 1.25 4.58 1.32 2.61 
24 97.15 1.99 2.85 0.45 4.89 1.38 1.42 
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Figure 6.69: Zero order plot 
(DNF6) in PBS pH 6.8 
y = -0.0377x + 1.9229 
R² = 0.8167 
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Figure 6.70: First order plot 
(DNF6) in PBS pH 6.8 
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Figure 6.71:Higuchi model plot 
(DNF6) in PBS pH 6.8 
y = -0.0877x + 4.253 
R² = 0.9038 
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Figure 6.72: Hixon Crowell 
model plot (DNF6) in PBS pH 
6.8 
y = 0.3067x + 1.4998 
R² = 0.9715 
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Figure 6.73: Kosmeyer & Pepas plot (DNF6) in PBS 
pH 6.8 
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Table 6.30: Drug release kinetics computation of noisome formulation DNF7 in 
0.1 N HCl 
Time 
Hours 
Cumulative 
% drug 
released 
Log 
cum % 
drug 
release 
% 
drug 
rema
ining 
Log 
% 
drug 
remai
ning 
Sq.Rt.  
Time 
Log 
Time 
Cub. Rt. 
Unreleased 
drug 
fraction 
0 0 - 100 2.0 0 - 4.64 
0.15 13.56 1.13 86.44 1.94 0.39 -0.82 4.42 
0.45 20.56 1.31 79.44 1.90 0.67 -0.34 4.29 
1 21.68 1.34 78.32 1.89 1.0 0 4.28 
2 30.44 1.48 69.56 1.84 1.41 0.30 4.11 
3 39.51 1.59 60.49 1.78 1.73 0.48 3.93 
4 45.71 1.66 54.29 1.73 2.0 0.60 3.79 
5 51.53 1.71 48.47 1.69 2.24 0.69 3.65 
6 55.47 1.74 44.53 1.65 2.45 0.78 3.54 
10 65.43 1.82 34.57 1.54 3.16 1.0 3.26 
14 68.43 1.84 31.57 1.49 3.74 1.15 3.16 
15 69.69 1.84 30.31 1.48 3.87 1.18 3.12 
16 70.45 1.85 29.55 1.47 4.0 1.20 3.09 
17 73.51 1.87 26.49 1.42 4.12 1.23 2.98 
18 74.54 1.87 25.46 1.41 4.24 1.26 2.94 
20 79.53 1.90 20.47 1.31 4.472 1.30 2.74 
21 83.61 1.92 16.39 1.21 4.58 1.32 2.54 
24 97.45 1.99 2.55 0.41 4.89 1.38 1.37 
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y = 3.0413x + 24.623 
R² = 0.8893 
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Figure 6.74: Zero order plot 
(DNF7) in 0.1N HCl 
y = -0.0403x + 1.9472 
R² = 0.8194 
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Figure 6.75: First order plot 
(DNF7) in 0.1N HCl 
y = 16.961x + 8.144 
R² = 0.9726 
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Figure 6.76: Higuchi model 
plot (DNF7) in 0.1N HCl 
y = -0.0936x + 4.3202 
R² = 0.9081 
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Figure 6.77: Hixon Crowell 
model plot (DNF7) in 0.1N HCl 
y = 0.3799x + 1.4205 
R² = 0.9811 
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Figure 6.78: Kosmeyer & Pepas plot (DNF7) in 0.1N 
HCl 
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Table 6.31: Drug release kinetics computation of noisome formulation DNF7 in 
PBS pH 6.8 
Time 
Hours 
Cumulative 
% drug 
released 
Log 
cum % 
drug 
release 
% 
drug 
remain 
Log % 
drug 
remain 
Sq.Rt.  
Time 
Log 
Time 
Cub. Rt. 
Unreleased 
drug 
fraction 
0 0 - 100 2 0 - 4.64 
0.15 12.7 1.10 87.3 1.94 0.39 -0.82 4.44 
0.45 16.11 1.21 83.89 1.92 0.68 -0.35 4.38 
1 18.98 1.28 81.02 1.91 1.0 0 4.33 
2 26.15 1.42 73.85 1.87 1.41 0.30 4.19 
3 36.45 1.56 63.55 1.80 1.73 0.48 3.99 
4 43.78 1.64 56.22 1.75 2.0 0.60 3.83 
5 48.37 1.68 51.63 1.71 2.24 0.69 3.72 
6 51.56 1.71 48.44 1.69 2.45 0.78 3.65 
10 62.39 1.79 37.61 1.58 3.16 1.0 3.35 
14 65.2 1.81 34.8 1.54 3.74 1.15 3.26 
15 66.66 1.82 33.34 1.52 3.87 1.18 3.22 
16 68.48 1.84 31.52 1.49 4.0 1.20 3.16 
17 71.24 1.85 28.76 1.46 4.12 1.23 3.06 
18 72.52 1.86 27.48 1.44 4.24 1.26 3.02 
20 75.08 1.88 24.92 1.39 4.47 1.30 2.92 
22 85.39 1.93 14.61 1.16 4.69 1.34 2.44 
24 96.07 1.98 3.93 0.59 4.89 1.38 1.58 
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y = 3.0594x + 21.518 
R² = 0.9008 
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Figure 6.79: Zero order plot 
(DNF7) in PBS pH 6.8 
y = -0.0368x + 1.9554 
R² = 0.8308 
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Figure 6.80: First order plot 
(DNF7) in PBS pH 6.8 
y = 16.961x + 5.2248 
R² = 0.9735 
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Figure 6.81: Higuchi model 
plot (DNF7) in PBS 6.8 
y = -0.0891x + 4.3699 
R² = 0.9084 
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Figure 6.82: Hixon Crowell 
model plot (DNF7) in PBS pH 
6.8 
y = 0.4117x + 1.364 
R² = 0.9766 
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Figure 6.83: Kosmeyer & Pepas plot(DNF7) in PBS pH 
6.8 
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Table 6.32: Drug release kinetics computation of noisome formulation CDNF5 in 
0.1 N HCl 
Time 
Hours 
Cumulative 
% drug 
released 
Log 
cum % 
drug 
release 
% 
drug 
remai
ning 
Log % 
drug 
remaini
ng 
Sq.Rt.  
Time 
Log 
Time 
Cub. Rt. 
Unreleased 
drug 
fraction 
0 0 - 100 2.0 0 - 4.64 
0.15 20.82 1.32 79.18 1.89 0.39 -0.82 4.29 
0.45 23.72 1.38 76.28 1.88 0.67 -0.35 4.24 
1 30.43 1.48 69.57 1.84 1.0 0 4.11 
2 39.54 1.59 60.46 1.78 1.41 0.30 3.92 
3 43.57 1.64 56.43 1.75 1.73 0.48 3.84 
4 50.57 1.70 49.43 1.69 2.0 0.60 3.67 
5 54.72 1.74 45.28 1.66 2.24 0.69 3.56 
6 58.53 1.77 41.47 1.62 2.45 0.78 3.46 
10 66.45 1.82 33.55 1.53 3.16 1.0 3.23 
12 70.63 1.85 29.37 1.47 3.46 1.08 3.09 
16 73.54 1.87 26.46 1.42 4.0 1.20 2.98 
18 79.52 1.90 20.48 1.31 4.24 1.26 2.74 
20 85.75 1.93 14.25 1.15 4.47 1.30 2.42 
22 92.55 1.97 7.45 0.87 4.69 1.34 1.95 
24 98.41 1.99 1.59 0.20 4.89 1.38 1.17 
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y = 3.0723x + 28.501 
R² = 0.8683 
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Figure 6.84: Zero order plot 
(CDNF5) in 0.1N HCl 
y = -0.049x + 1.9473 
R² = 0.8314 
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Figure 6.85: First order plot 
(CDNF5) in 0.1N HCl  
y = 17.027x + 12.188 
R² = 0.9733 
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Figure 6.86: Higuchi model 
plot (CDNF5) in 0.1N HCl 
y = -0.1045x + 4.2677 
R² = 0.925 
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Figure 6.87: Hixon Crowell 
model plot (CDNF5) in 0.1N 
HCl 
y = 0.3146x + 1.515 
R² = 0.9831 
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Figure 6.88: Kosmeyer & Pepas plot (CDNF5) in 0.1N 
HCl 
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Table 6.33: Drug release kinetics computation of noisome formulation CDNF5 in 
PBS pH 6.8 
Time 
Hours 
Cumulative 
% drug 
released 
Log 
cum % 
drug 
release 
% drug 
remain 
Log % 
drug 
remain 
Sq.Rt.  
Time 
Log 
Time 
Cub. Rt. 
Unreleas
ed drug 
fraction 
0 0 - 100 2 0 - 4.64 
0.15 18.93 1.28 81.07 1.91 0.39 -0.82 4.33 
0.45 21.91 1.34 78.09 1.89 0.67 -0.35 4.27 
1 27.18 1.43 72.82 1.86 1.0 0 4.18 
2 36.31 1.56 63.69 1.80 1.41 0.30 3.99 
3 39.67 1.59 60.33 1.78 1.73 0.48 3.92 
4 47.21 1.67 52.79 1.72 2.0 0.60 3.75 
5 51.86 1.71 48.14 1.68 2.24 0.69 3.64 
6 54.68 1.74 45.32 1.66 2.45 0.78 3.57 
10 63.03 1.79 36.97 1.57 3.16 1.0 3.33 
12 67.46 1.83 32.54 1.51 3.46 1.08 3.19 
16 69.53 1.84 30.47 1.48 4.0 1.20 3.12 
18 75.38 1.88 24.62 1.39 4.24 1.26 2.91 
20 81.7 1.91 18.3 1.26 4.47 1.30 2.64 
22 89.41 1.95 10.59 1.02 4.69 1.34 2.20 
24 94.73 1.98 5.27 0.72 4.89 1.38 1.74 
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y = 3.0642x + 25.672 
R² = 0.8575 
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Figure 6.89: Zero order plot 
(CDNF5) in PBS pH 6.8 
y = -0.0386x + 1.9269 
R² = 0.9062 
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Figure 6.90: First order plot 
(CDNF5) in PBS pH 6.8 
 
y = 16.554x + 10.244 
R² = 0.9762 
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Figure 6.91: Higuchi model 
plot (CDNF5) in PBS pH 6.8 
y = -0.0916x + 4.2826 
R² = 0.9408 
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Figure 6.92: Hixon Crowell 
model plot (CDNF5) in PBS 
pH 6.8 
y = 0.327x + 1.4777 
R² = 0.9803 
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Figure 6.93: Kosmeyer & Pepas plot (CDNF5) inPBS 
pH 6.8  
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Table 6.34: Drug release kinetics computation of noisome formulation CDNF6 in 
0.1 N HCl 
Time 
Hours 
Cumulative 
% drug 
released 
Log 
cum % 
drug 
release 
% 
drug 
remain 
Log % 
drug 
remain 
Sq.Rt.  
Time 
Log 
Time 
Cub. Rt. 
Unreleased 
drug 
fraction 
0 0 - 100 2.0 0 - 4.64 
0.15 14.75 1.17 85.25 1.93 0.39 -0.82 4.40 
0.45 17.43 1.24 82.57 1.92 0.67 -0.35 4.35 
1 22.81 1.36 77.19 1.89 1.0 0 4.26 
2 24.57 1.39 75.43 1.88 1.41 0.30 4.23 
3 36.75 1.57 63.25 1.80 1.73 0.48 3.98 
4 44.55 1.65 55.45 1.74 2.0 0.60 3.81 
5 50.79 1.71 49.21 1.69 2.24 0.69 3.66 
6 54.51 1.74 45.49 1.66 2.45 0.78 3.56 
10 61.47 1.79 38.53 1.59 3.16 1.0 3.38 
12 64.59 1.81 35.41 1.55 3.46 1.08 3.28 
16 68.58 1.84 31.42 1.49 4.0 1.20 3.16 
18 71.59 1.85 28.41 1.45 4.24 1.26 3.05 
20 77.62 1.89 22.38 1.35 4.47 1.30 2.82 
22 89.68 1.95 10.32 1.01 4.69 1.34 2.18 
24 92.66 1.97 7.34 0.87 4.89 1.38 1.94 
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y = 3.0976x + 22.297 
R² = 0.8822 
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Figure 6.94: Zero order plot 
(CDNF6) in 0.1N HCl  
y = -0.0364x + 1.9402 
R² = 0.9107 
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Figure 6.95: First order plot 
(CDNF6) in 0.1N HCl 
y = 17.035x + 6.1916 
R² = 0.9736 
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Figure 6.96: Higuchi model 
plot (CDNF6) in 0.1 N HCl 
y = -0.0895x + 4.3424 
R² = 0.9359 
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Figure 6.97: Hixon Crowell 
model plot (CDNF6) in 0.1N 
HCl 
y = 0.3837x + 1.3994 
R² = 0.9651 
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Figure 6.98: Kosmeyer & Pepas plot (CDNF6) in 0.1N 
HCl 
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Table 6.35: Drug release kinetics computation of noisome formulation CDNF6 in 
PBS pH 6.8 
Time 
Hours 
Cumulativ
e % drug 
released 
Log 
cum % 
drug 
release 
% 
drug 
remain 
Log % 
drug 
remain 
Sq.Rt.  
Time 
Log 
Time 
Cub. Rt. 
Unreleased 
drug 
fraction 
0 0 - 100 2.0 0 - 4.64 
0.15 12.73 1.10 87.27 1.94 0.39 -0.82 4.44 
0.45 15.18 1.18 84.82 1.93 0.67 -0.35 4.39 
1 19.86 1.29 80.14 1.90 1.0 0 4.31 
2 21.75 1.34 78.25 1.89 1.41 0.30 4.28 
3 33.82 1.53 66.18 1.82 1.73 0.48 4.04 
4 41.87 1.62 58.13 1.76 2.0 0.60 3.87 
5 46.56 1.67 53.44 1.73 2.24 0.69 3.77 
6 49.55 1.69 50.45 1.70 2.45 0.78 3.69 
10 58.12 1.76 41.88 1.62 3.16 1.0 3.47 
12 61.51 1.79 38.49 1.59 3.46 1.08 3.38 
16 64.38 1.81 35.62 1.55 4.0 1.20 3.29 
18 67.75 1.83 32.25 1.51 4.24 1.26 3.18 
20 73.57 1.87 26.43 1.42 4.47 1.30 2.98 
22 86.74 1.94 13.26 1.12 4.69 1.34 2.37 
24 88.78 1.95 11.22 1.05 4.89 1.38 2.24 
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y = 3.028x + 19.731 
R² = 0.8939 
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Figure 6.99: Zero order plot 
(CDNF6) in PBS  pH 6.8 
y = -0.0317x + 1.9432 
R² = 0.9234 
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Figure 6.100: First order plot 
(CDNF6) in PBS pH 6.8 
 
y = 16.203x + 5.4683 
R² = 0.9715 
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Figure 6.101: Higuchi model 
plot (CDNF6) in PBS pH 6.8 
y = -0.0819x + 4.3759 
R² = 0.9391 
0 
2 
4 
6 
0 10 20 30 
C
u
b
. 
R
t.
 U
n
re
le
a
se
d
 d
ru
g
 
fr
a
ct
io
n
 
Time in hours 
 
Figure 6.102: Hixon Crowell 
model plot (CDNF6) in PBS 
pH 6.8 
 
y = 0.4069x + 1.3479 
R² = 0.9646 
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Figure 6.103: Kosmeyer & Pepas plot (CDNF6) in PBS 
pH 6.8 
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Table 6.36: Drug release kinetics calculation of noisome formulation CDNF7 in 
0.1 N HCl 
Time 
Hours 
Cumulative 
% drug 
released 
Log 
cum % 
drug 
release 
% 
drug 
remain 
Log % 
drug 
remain 
Sq.Rt.  
Time 
Log 
Time 
Cub. Rt. 
Unreleased 
drug 
fraction 
0 0 - 100 2 0 - 4.64 
0.15 9.74 0.99 90.26 1.96 0.39 -0.82 4.49 
0.45 14.87 1.17 85.13 1.93 0.67 -0.35 4.39 
1 17.62 1.25 82.38 1.92 1.0 0 4.35 
2 22.5 1.35 77.5 1.89 1.41 0.30 4.26 
3 31.68 1.50 68.32 1.83 1.73 0.48 4.09 
4 39.77 1.59 60.23 1.78 2.0 0.60 3.92 
5 46.7 1.67 53.3 1.73 2.24 0.69 3.76 
6 50.51 1.70 49.49 1.69 2.45 0.78 3.67 
10 58.58 1.77 41.42 1.62 3.16 1.0 3.46 
12 62.46 1.79 37.54 1.57 3.46 1.08 3.35 
16 65.44 1.82 34.56 1.54 4.0 1.20 3.26 
18 69.61 1.84 30.39 1.48 4.24 1.26 3.12 
20 75.36 1.88 24.64 1.39 4.47 1.30 2.91 
22 85.52 1.93 14.48 1.16 4.69 1.34 2.44 
24 89.56 1.95 10.44 1.02 4.90 1.38 2.19 
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y = 3.1243x + 18.687 
R² = 0.9009 
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Figure 6.104: Zero order plot 
(CDNF7) in 0.1N HCl 
y = -0.0326x + 1.9499 
R² = 0.9394 
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Figure 6.105: First order plot 
(CDNF7) in 0.1N HCl 
y = 17.079x + 2.7075 
R² = 0.9824 
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Figure 6.106:Higuchi model 
plot  (CDNF7) in 0.1N HCl 
y = -0.0843x + 4.3965 
R² = 0.9516 
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Figure6.107: Hixon Crowell 
model plot (CDNF7) in 0.1N 
HCl 
y = 0.446x + 1.3097 
R² = 0.9813 
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Figure 6.108: Kosmeyer & Pepas plot (CDNF7) in 0.1N 
HCl 
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Table 6.37: Drug release kinetics computation of noisome formulation CDNF7 in 
PBS pH 6.8 
Time 
Hours 
Cumulativ
e % drug 
released 
Log 
cum % 
drug 
release 
% 
drug 
remain 
Log % 
drug 
remain 
Sq.Rt.  
Time 
Log 
Time 
Cub. Rt. 
Unreleased 
drug 
fraction 
0 0 - 100 2.0 0 - 4.64 
0.15 8.73 0.94 91.27 1.96 0.39 -0.82 4.50 
0.45 12.93 1.11 87.07 1.94 0.67 -0.35 4.43 
1 14.82 1.17 85.18 1.93 1 0 4.39 
2 19.67 1.29 80.33 1.90 1.41 0.30 4.31 
3 27.91 1.45 72.09 1.86 1.73 0.48 4.16 
4 36.69 1.56 63.31 1.80 2 0.60 3.99 
5 42.55 1.62 57.45 1.76 2.24 0.69 3.86 
6 46.86 1.67 53.14 1.73 2.45 0.78 3.76 
10 55.79 1.75 44.21 1.65 3.16 1.0 3.54 
12 58.18 1.76 41.82 1.62 3.46 1.08 3.47 
16 62.46 1.79 37.54 1.57 4.0 1.20 3.35 
18 65.62 1.82 34.38 1.54 4.24 1.26 3.25 
20 70.12 1.85 29.88 1.48 4.47 1.30 3.10 
22 82.46 1.92 17.54 1.24 4.69 1.34 2.59 
24 85.59 1.93 14.41 1.16 4.89 1.38 2.43 
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y = 3.0347x + 16.385 
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Figure 6.109: Zero order plot 
(CDNF7) in PBS pH 6.8 
 
y = -0.0288x + 1.9538 
R² = 0.9443 
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Figure 6.110: First order plot 
(CDNF7) in PBS pH 6.8 
 
y = 16.504x + 1.0851 
R² = 0.9815 
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Figure 6.111: Higuchi model 
plot (CDNF7) in PBS pH 6.8 
 
y = -0.0773x + 4.4263 
R² = 0.9516 
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Figure 6.112: Hixon Crowell 
model plot (CDNF7) in PBS 
pH 6.8 
 
y = 0.4674x + 1.2574 
R² = 0.9758 
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Figure 6.113: Kosmeyer & Pepas plot (CDNF7) in PBS 
pH 6.8 
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Table 6.38:Drug release kinetics computation of pronoisome formulation DPF5 
in 0.1 N HCl 
Time 
Hours 
Cumulative 
% drug 
released 
Log 
cum % 
drug 
release 
% 
drug 
remain 
Log % 
drug 
remain 
Sq.Rt.  
Time 
Log 
Time 
Cub. Rt. 
Unreleased 
drug 
fraction 
0 0 - 100 2 0 - 4.64 
0.15 10.46 1.02 89.54 1.95 0.39 -0.82 4.47 
0.45 12.77 1.11 87.23 1.94 0.67 -0.35 4.43 
1 14.63 1.17 85.37 1.93 1.0 0 4.40 
2 22.46 1.35 77.54 1.88 1.41 0.30 4.26 
3 34.64 1.54 65.36 1.82 1.73 0.48 4.03 
4 41.68 1.62 58.32 1.77 2 0.60 3.88 
5 56.62 1.75 43.38 1.64 2.24 0.69 3.51 
6 62.52 1.79 37.48 1.57 2.49 0.78 3.35 
10 78.35 1.89 21.65 1.34 3.16 1.0 2.79 
12 81.5 1.91 18.5 1.27 3.46 
1.07
92 
2.64 
16 85.51 1.93 14.49 1.16 4.0 1.20 2.43 
18 90.53 1.96 9.47 0.98 4.24 1.26 2.11 
20 95.39 1.98 4.61 0.66 4.47 
1.30
103 
1.66 
22 97.4 1.99 2.6 0.41 4.69 1.34 1.38 
24 99.59 1.99 0.41 -0.39 4.89 1.38 0.74 
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y = 3.9227x + 20.89 
R² = 0.8714 
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Figure 6.114: Zero order plot 
(DPF5) in 0.1N HCl 
y = -0.0755x + 2.0555 
R² = 0.9066 
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Figure 6.115: First order plot 
(DPF5) in 0.1N HCl 
 
y = 21.7x + 0.166 
R² = 0.9731 
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Figure 6.116: Higuchi model 
plot (DPF5) in 0.1N HCl 
 
y = -0.1441x + 4.4627 
R² = 0.9804 
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Figure 6.117: Hixon Crowell 
model plot (DPF5) in 0.1N HCl 
 
y = 0.5158x + 1.3172 
R² = 0.9567 
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Figure 6.118: Kosmeyer & Pepas plot (DPF5) in 0.1N 
HCl 
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Table 6.39: Drug release kinetics computation of proniosome formulation DPF5 
in PBS pH 6.8 
Time 
Hours 
Cumulative 
% drug 
released 
Log 
cum % 
drug 
release 
% 
drug 
remain 
Log % 
drug 
remain 
Sq.Rt.  
Time 
Log 
Time 
Cub. Rt. 
Unreleased 
drug 
fraction 
0 0 - 100 2 0 - 4.64 
0.15 7.17 0.86 92.83 1.97 0.39 -0.82 4.53 
0.45 8.67 0.94 91.33 1.96 0.67 -0.35 4.50 
1 12.62 1.10 87.38 1.94 1.0 0 4.44 
2 19.22 1.28 80.78 1.91 1.41 0.30 4.32 
3 31.52 1.49 68.48 1.84 1.73 0.48 4.09 
4 38.78 1.59 61.22 1.79 2.0 0.60 3.94 
5 53.64 1.73 46.36 1.67 2.24 0.69 3.59 
6 59.4 1.77 40.6 1.61 2.45 0.78 3.44 
10 74.3 1.87 25.7 1.41 3.16 1.0 2.95 
12 79.38 1.89 20.62 1.31 3.46 1.08 2.74 
16 82.49 1.92 17.51 1.24 4.0 1.20 2.59 
18 87.6 1.94 12.4 1.09 4.24 1.26 2.31 
20 93.52 1.97 6.48 0.81 4.47 1.30 1.86 
22 95.29 1.98 4.71 0.67 4.69 1.34 1.68 
24 98.59 1.99 1.41 0.15 4.89 1.38 1.12 
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y = 3.9553x + 17.97 
R² = 0.8822 
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Figure 6.119: Zero order plot 
(DPF5) in PBS pH 6.8 
y = -0.0627x + 2.0267 
R² = 0.9464 
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Figure 6.120: First order plot 
(DPF5) in PBS pH 6.8 
 
y = 21.77x - 2.6409 
R² = 0.9753 
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Figure 6.121: Higuchi model 
plot (DPF5) in PBS pH 6.8 
 
y = -0.1329x + 4.4858 
R² = 0.9802 
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Figure 6.122: Hixon Crowell 
model plot (DPF5) in PBS pH 
6.8 
 
y = 0.5901x + 1.2223 
R² = 0.9656 
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Figure 6.123: Kosmeyer & Pepas plot (DPF5) in PBS 
pH 6.8 
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Table 6.40: Drug release kinetics computation of pronoisome formulation DPF6 
in 0.1 N HCl 
Time 
Hours 
Cumulative 
% drug 
released 
Log 
cum % 
drug 
release 
% 
drug 
remain 
Log % 
drug 
remain 
Sq.Rt.  
Time 
Log 
Time 
Cub. Rt. 
Unreleased 
drug 
fraction 
0 0 - 100 2.0 0 - 4.64 
0.15 7.75 0.89 92.25 1.96 0.39 -0.82 4.52 
0.45 9.7 0.99 90.3 1.96 0.67 -0.35 4.49 
1 11.89 1.08 88.11 1.95 1.0 0 4.45 
2 15.46 1.19 84.54 1.93 1.41 0.30 4.39 
3 27.52 1.44 72.48 1.86 1.73 0.48 4.17 
4 33.52 1.53 66.48 1.82 2.0 0.60 4.05 
5 45.67 1.66 54.33 1.74 2.24 0.69 3.79 
6 50.69 1.70 49.31 1.69 2.45 0.78 3.67 
10 65.57 1.82 34.43 1.54 3.16 1.0 3.25 
12 71.47 1.85 28.53 1.456 3.46 1.08 3.06 
16 77.42 1.89 22.58 1.35 4.0 1.20 2.83 
18 83.68 1.92 16.32 1.21 4.24 1.26 2.54 
20 89.31 1.9509 10.69 1.03 4.47 1.30 2.20 
22 95.54 1.98 4.46 0.65 4.69 1.34 1.65 
24 97.56 1.99 2.44 0.39 4.90 1.38 1.35 
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y = 3.9215x + 14.344 
R² = 0.9329 
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Figure 6.124: Zero order plot 
(DPF6) in 0.1N HCl 
y = -0.0561x + 2.0412 
R² = 0.9353 
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Figure 6.125: First order plot 
(DPF6) in 0.1N HCl 
 
y = 21.108x - 4.864 
R² = 0.9863 
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Figure 6.126: Higuchi model 
plot (DPF6) in 0.1N HCl 
 
y = -0.1248x + 4.5595 
R² = 0.984 
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Figure 6.127: Hixon Crowell 
model plot (DPF6) in 0.1N HCl 
 
y = 0.5711x + 1.2031 
R² = 0.9585 
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Figure 6.128: Kosmeyer & Pepas plot (DPF6) in 0.1N 
HCl 
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Table 6.41: Drug release kinetics computation of pronoisome formulation DPF6 
in PBS pH 6.8 
Time 
Hours 
Cumulativ
e % drug 
released 
Log 
cum % 
drug 
release 
% 
drug 
remain 
Log % 
drug 
remain 
Sq.Rt.  
Time 
Log 
Time 
Cub. Rt. 
Unreleased 
drug 
fraction 
0 0 - 100 2.0 0 - 4.64 
0.15 5.17 0.71 94.83 1.98 0.39 -0.82 4.56 
0.45 6.82 0.83 93.18 1.97 0.67 -0.34 4.53 
1 8.45 0.93 91.55 1.96 1.0 0 4.51 
2 12.51 1.09 87.49 1.94 1.41 0.30 4.44 
3 24.48 1.39 75.52 1.88 1.73 0.48 4.23 
4 29.14 1.46 70.86 1.85 2.0 0.60 4.14 
5 42.52 1.63 57.48 1.76 2.24 0.70 3.86 
6 47.51 1.68 52.49 1.72 2.45 0.78 3.74 
10 63.49 1.80 36.51 1.56 3.16 1.0 3.32 
12 68.44 1.84 31.56 1.49 3.46 1.08 3.16 
16 74.5 1.87 25.5 1.41 4.0 1.20 2.94 
18 80.37 1.91 19.63 1.29 4.24 1.26 2.69 
20 86.55 1.94 13.45 1.13 4.47 1.30 2.38 
22 92.51 1.97 7.49 0.87 4.69 1.34 1.96 
24 95.42 1.98 4.58 0.66 4.89 1.38 1.66 
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y = 3.9155x + 11.573 
R² = 0.9377 
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Figure 6.129: Zero order plot 
(DPF6) in PBS pH 6.8 
y = -0.0483x + 2.0289 
R² = 0.9592 
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Figure 6.130: First order 
plot(DPF6) in PBS pH 6.8 
y = 20.984x - 7.3697 
R² = 0.9828 
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Figure 6.131: Higuchi model 
plot (DPF6) in PBS pH 6.8 
y = -0.1152x + 4.5801 
R² = 0.9869 
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Figure 6.132: Hixon Crowell 
model plot (DPF6) in PBS pH 
6.8 
y = 0.6553x + 1.0899 
R² = 0.9606 
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Figure 6.133: Kosmeyer & Pepas plot (DPF6) in PBS 
pH 6.8 
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Table 6.42: Drug release kinetics computation of pronoisome formulation DPF7 
in 0.1 N HCl 
Time 
Hours 
Cumulative 
% drug 
released 
Log 
cum % 
drug 
release 
% 
drug 
remain 
Log % 
drug 
remain 
Sq.Rt.  
Time 
Log 
Time 
Cub. Rt. 
Unreleased 
drug 
fraction 
0 0 - 100 2 0 - 4.64 
0.15 5.71 0.76 94.29 1.97 0.39 -0.82 4.55 
0.45 6.49 0.81 93.51 1.97 0.67 -0.35 4.54 
1 10.57 1.02 89.43 1.95 1.0 0 4.47 
2 13.63 1.13 86.37 1.94 1.41 0.30 4.42 
3 22.64 1.35 77.36 1.89 1.73 0.48 4.26 
4 25.58 1.41 74.42 1.87 2.0 0.60 4.21 
5 41.66 1.62 58.34 1.77 2.24 0.69 3.88 
6 45.6 1.66 54.4 1.74 2.45 0.78 3.79 
10 60.51 1.78 39.49 1.59 3.16 1.0 3.41 
12 68.29 1.83 31.71 1.50 3.46 1.08 3.17 
16 72.58 1.86 27.42 1.44 4 1.20 3.02 
18 79.59 1.90 20.41 1.31 4.24 1.26 2.73 
20 85.62 1.93 14.38 1.16 4.47 1.30 2.43 
22 93.51 1.97 6.49 0.81 4.69 1.34 1.87 
24 96.56 1.98 3.44 0.54 4.90 1.38 1.51 
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y = 3.9219x + 10.851 
R² = 0.9505 
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Figure 6.134: Zero order plot 
(DPF7) in 0.1N HCl 
y = -0.0502x + 2.0449 
R² = 0.9281 
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Figure 6.135: First order plot 
(DPF7) in 0.1N HCl 
y = 20.864x - 7.7229 
R² = 0.9815 
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Figure 6.136: Higuchi model 
plot (DPF7) in 0.1N HCl 
y = -0.1173x + 4.6088 
R² = 0.9791 
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Figure 6.137: Hixon Crowell 
model  plot (DPF7) in 0.1N 
HCl 
y = 0.6345x + 1.1039 
R² = 0.9651 
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Figure 6.138: Kosmeyer & Pepas plot (DPF7) in 0.1N 
HCl 
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Table 6.43: Drug release kinetics computation of pronoisome formulation DPF7 
in PBS pH 6.8 
Time 
Hours 
Cumulative 
% drug 
released 
Log 
cum % 
drug 
release 
% 
drug 
remain 
Log % 
drug 
remain 
Sq.Rt.  
Time 
Log 
Time 
Cub. Rt. 
Unreleased 
drug 
fraction 
0 0 - 100 2 0 - 4.64 
0.15 3.33 0.52 96.67 1.99 0.39 -0.82 4.59 
0.45 4.31 0.63 95.69 1.98 0.67 -0.35 4.57 
1 7.52 0.88 92.48 1.97 1.0 0 4.52 
2 10.38 1.02 89.62 1.95 1.41 0.30 4.48 
3 19.19 1.28 80.81 1.91 1.73 0.48 4.32 
4 22.33 1.35 77.67 1.89 2.0 0.60 4.27 
5 37.67 1.58 62.33 1.79 2.24 0.69 3.96 
6 43.3 1.64 56.7 1.75 2.45 0.78 3.84 
10 57.37 1.76 42.63 1.63 3.16 1.0 3.49 
12 64.58 1.81 35.42 1.55 3.46 1.08 3.28 
16 69.39 1.84 30.61 1.49 4.0 1.20 3.13 
18 77.46 1.89 22.54 1.35 4.24 1.26 2.82 
20 83.39 1.92 16.61 1.22 4.47 1.30 2.55 
22 89.42 1.95 10.58 1.02 4.69 1.34 2.19 
24 94.55 1.98 5.45 0.74 4.89 1.38 1.76 
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y = 3.9053x + 8.2095 
R² = 0.9559 
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Figure 6.139: Zero order plot 
(DPF7) in PBS pH 6.8 
y = -0.0441x + 2.0383 
R² = 0.9493 
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Figure 6.140: First order plot 
(DPF7) in PBS pH 6.8 
 
y = 20.671x - 10.018 
R² = 0.9773 
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Figure 6.141: Higuchi model 
plot (DPF7) in PBS pH 6.8 
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Figure 6.142: Hixon Crowell 
model plot (DPF7) in PBS pH 
6.8 
 
y = 0.7388x + 0.9672 
R² = 0.9712 
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Figure 6.143: Kosmeyer & Pepas plot (DPF7) in PBS 
pH 6.8 
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Table 6.44: Drug release kinetics computation of pronoisome formulation 
CDPF5 in 0.1 N HCl 
Time 
Hours 
Cumulative 
% drug 
released 
Log 
cum % 
drug 
release 
% 
drug 
remain 
Log % 
drug 
remain 
Sq.Rt.  
Time 
Log 
Time 
Cub. Rt. 
Unreleased 
drug 
fraction 
0 0 - 100 2.0 0 - 4.64 
0.15 7.72 0.89 92.28 1.97 0.39 -0.82 4.52 
0.45 9.55 0.98 90.45 1.96 0.67 -0.35 4.49 
1 12.51 1.09 87.49 1.94 1.0 0 4.44 
2 19.56 1.29 80.44 1.91 1.41 0.30 4.32 
3 31.44 1.49 68.56 1.84 1.73 0.48 4.09 
4 37.57 1.57 62.43 1.79 2.0 0.60 3.97 
5 50.5 1.70 49.5 1.69 2.24 0.69 3.67 
6 57.47 1.76 42.53 1.63 2.45 0.78 3.49 
10 75.41 1.88 24.59 1.39 3.16 1.0 2.91 
12 78.61 1.89 21.39 1.33 3.46 1.08 2.78 
16 82.5 1.92 17.5 1.24 4.0 1.20 2.59 
18 88.33 1.95 11.67 1.07 4.24 1.26 2.27 
20 94.36 1.97 5.64 0.75 4.47 1.30 1.78 
22 97.78 1.99 2.22 0.35 4.69 1.34 1.30 
24 98.39 1.99 1.61 0.21 4.89 1.38 1.17 
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y = 4.006x + 17.409 
R² = 0.8967 
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Figure 6.144: Zero order plot 
(CDPF5) in 0.1N HCl 
y = -0.0667x + 2.046 
R² = 0.949 
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Figure 6.145: First order plot 
(CDPF5) in 0.1N HCl 
 
y = 21.922x - 3.1384 
R² = 0.9799 
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Figure 6.146:Higuchi model 
plot (CDPF5) in 0.1N HCl 
 
y = -0.1382x + 4.5165 
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Figure 6.147: Hixon Crowell 
model plot (CDPF5) in 0.1N 
HCl 
 
y = 0.5766x + 1.2338 
R² = 0.9668 
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Figure 6.148: Kosmeyer & Pepas plot (CDPF5) 
in 0.1N HCl 
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Table 6.45: Drug release kinetics computation of pronoisome formulation 
CDPF5 in PBS pH 6.8 
Time 
Hours 
Cumulative 
% drug 
released 
Log 
cum % 
drug 
release 
% 
drug 
remain 
Log % 
drug 
remain 
Sq.Rt.  
Time 
Log 
Time 
Cub. Rt. 
Unreleased 
drug 
fraction 
0 0 - 100 2.0 0 - 4.64 
0.15 6.59 0.82 93.41 1.97 0.39 -0.82 4.54 
0.45 7.13 0.85 92.87 1.97 0.67 -0.35 4.53 
1 10.37 1.02 89.63 1.95 1.0 0 4.48 
2 16.39 1.21 83.61 1.92 1.41 0.30 4.37 
3 27.39 1.44 72.61 1.86 1.73 0.48 4.17 
4 33.39 1.52 66.61 1.82 2.0 0.60 4.05 
5 47.31 1.67 52.69 1.72 2.24 0.69 3.75 
6 54.35 1.74 45.65 1.66 2.45 0.78 3.57 
10 71.42 1.85 28.58 1.46 3.16 1.0 3.06 
12 75.31 1.88 24.69 1.39 3.46 1.08 2.91 
16 79.49 1.90 20.51 1.31 4.0 1.20 2.74 
18 84.55 1.93 15.45 1.19 4.24 1.26 2.49 
20 91.13 1.96 8.87 0.95 4.47 1.30 2.07 
22 94.36 1.97 5.64 0.75 4.69 1.34 1.78 
24 97.16 1.99 2.84 0.45 4.89 1.38 1.42 
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y = 3.9772x + 14.823 
R² = 0.9076 
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Figure 6.149: Zero order plot 
(CDPF5) in PBS pH 6.8 
y = -0.0556x + 2.0255 
R² = 0.9631 
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Figure 6.150: First order plot 
(CDPF5) in PBS pH 6.8 
 
y = 21.624x - 5.2145 
R² = 0.979 
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Figure 6.151: Higuchi model 
plot (CDPF5) in PBS pH 6.8 
 
y = 0.6218x + 1.1615 
R² = 0.9593 
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Figure 6.152: Hixon Crowell 
model plot (CDPF5) in PBS pH 
6.8 
 
y = 0.6218x + 1.1615 
R² = 0.9593 
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Figure 6.153: Kosmeyer & Pepas plot (CDPF5) in PBS 
pH 6.8 
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Table 6.46: Drug release kinetics computation of pronoisome formulation 
CDPF6 in 0.1 N HCl 
Time 
Hours 
Cumulative 
% drug 
released 
Log 
cum % 
drug 
release 
% 
drug 
remain 
Log % 
drug 
remain 
Sq.Rt.  
Time 
Log 
Time 
Cub. Rt. 
Unreleased 
drug 
fraction 
0 0 - 100 2.0 0 - 4.64 
0.15 5.45 0.74 94.55 1.98 0.39 -0.82 4.56 
0.45 7.44 0.87 92.56 1.97 0.67 -0.35 4.52 
1 9.44 0.97 90.56 1.96 1.0 0 4.49 
2 13.45 1.13 86.55 1.94 1.41 0.30 4.42 
3 24.5 1.39 75.5 1.88 1.73 0.48 4.23 
4 27.63 1.44 72.37 1.86 2.0 0.60 4.17 
5 43.21 1.64 56.79 1.75 2.24 0.69 3.84 
6 48.37 1.68 51.63 1.71 2.45 0.78 3.72 
10 63.42 1.80 36.58 1.56 3.16 1.0 3.32 
12 69.52 1.84 30.48 1.48 3.46 1.08 3.12 
16 75.04 1.88 24.96 1.39 4.0 1.20 2.92 
18 80.23 1.90 19.77 1.29 4.24 1.26 2.70 
20 86.48 1.94 13.52 1.13 4.47 1.30 2.38 
22 91.12 1.95 8.88 0.95 4.69 1.34 2.07 
24 95.36 1.98 4.64 0.67 4.89 1.38 1.67 
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y = 3.8841x + 12.105 
R² = 0.9332 
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Figure 6.154: Zero order plot 
(CDPF6) in 0.1N HCl 
y = -0.0473x + 2.0216 
R² = 0.9629 
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Figure 6.155: First order plot 
(CDPF6) in 0.1N HCl 
y = 20.856x - 6.7898 
R² = 0.9819 
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Figure 6.156: Higuchi model 
plot (CDPF6) in 0.1N HCl 
y = -0.1135x + 4.5643 
R² = 0.9866 
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Figure 6.157: Hixon Crowell 
model plot (CDPF6) in 0.1N 
HCl 
y = 0.6366x + 1.112 
R² = 0.9639 
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Figure 6.158: Kosmeyer & Pepas plot (CDPF6) in 0.1N 
HCl 
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Table 6.47: Drug release kinetics computation of pronoisome formulation 
CDPF6 in PBS pH 6.8 
Time 
Hours 
Cumulative 
% drug 
released 
Log 
cum % 
drug 
release 
% 
drug 
remain 
Log % 
drug 
remain 
Sq.Rt.  
Time 
Log 
Time 
Cub. Rt. 
Unreleased 
drug 
fraction 
0 0 - 100 2 0 - 4.641589 
0.15 4.21 0.62 95.79 1.98 0.39 -0.82 4.58 
0.45 5.22 0.72 94.78 1.98 0.67 -0.35 4.56 
1 7.39 0.87 92.61 1.97 1.0 0 4.52 
2 10.35 1.01 89.65 1.95 1.41 0.30 4.48 
3 21.28 1.33 78.72 1.89 1.73 0.48 4.29 
4 23.36 1.37 76.64 1.88 2.0 0.60 4.25 
5 40.22 1.60 59.78 1.78 2.24 0.70 3.91 
6 47.44 1.68 52.56 1.72 2.45 0.78 3.75 
10 60.41 1.78 39.59 1.59 3.16 1.0 3.49 
12 65.16 1.81 34.84 1.54 3.46 1.08 3.27 
16 72.29 1.86 27.71 1.44 4.0 1.20 3.03 
18 77.1 1.89 22.90 1.36 4.24 1.26 2.84 
20 82.38 1.92 17.62 1.25 4.47 1.30 2.60 
22 89.24 1.95 10.76 1.03 4.69 1.34 2.21 
24 93.19 1.97 6.81 0.83 4.90 1.38 1.89 
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y = 3.8443x + 9.7633 
R² = 0.9388 
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Figure 6.159: Zero order plot 
(CDPF6) in PBS pH 6.8                                                                                                        
y = -0.0424x + 2.0205 
R² = 0.9671 
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Figure 6.160: First order plot 
(CDPF6) in PBS pH 6.8
y = 20.521x - 8.6244 
R² = 0.9761 
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Figure 6.161: Higuchi model 
plot (CDPF6) in PBS pH 6.8 
y = -0.1063x + 4.5898 
R² = 0.9847 
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Figure 6.162: Hixon Crowell 
model plot (CDPF6) in PBS 
pH 6.8 
y = 0.7014x + 1.0156 
R² = 0.9561 
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Figure 6.163: Kosmeyer & Pepas plot (CDPF6) in PBS 
pH 6.8 
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Table 6.48: Drug release kinetics computation of pronoisome formulation 
CDPF7 in 0.1 N HCl 
Time 
Hours 
Cumulative 
% drug 
released 
Log 
cum % 
drug 
release 
% drug 
remain 
Log % 
drug 
remain 
Sq.Rt.  
Time 
Log 
Time 
Cub. Rt. 
Unreleased 
drug 
fraction 
0 0 - 100 2.0 0 - 4.64 
0.15 3.66 0.56 96.34 1.98 0.39 -0.82 4.58 
0.45 5.53 0.74 94.47 1.98 0.87 -0.12 4.55 
1 7.77 0.89 92.23 1.96 1.0 0 4.51 
2 11.41 1.06 88.59 1.95 1.41 0.30 4.46 
3 16.63 1.22 83.37 1.92 1.73 0.48 4.37 
4 20.39 1.31 79.61 1.90 2.0 0.60 4.30 
5 38.43 1.58 61.57 1.79 2.24 0.69 3.95 
6 43.46 1.64 56.54 1.76 2.45 0.78 3.84 
10 57.59 1.76 42.41 1.63 3.16 1.0 3.49 
12 65.59 1.82 34.41 1.54 3.46 1.08 3.25 
16 70.43 1.85 29.57 1.47 4.0 1.20 3.09 
18 77.44 1.89 22.56 1.35 4.24 1.26 2.83 
20 83.49 1.92 16.51 1.22 4.47 1.30 2.55 
22 90.61 1.96 9.39 0.97 4.69 1.34 2.11 
24 94.46 1.98 5.54 0.74 4.89 1.38 1.77 
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y = 3.9357x + 8.097 
R² = 0.9534 
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Figure 6.164: Zero order plot 
(CDPF7) in 0.1N HCl 
y = -0.0449x + 2.0413 
R² = 0.952 
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Figure 6.165: First order plot 
(CDPF7) in 0.1N HCl 
 
y = 20.955x - 10.762 
R² = 0.9731 
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Figure 6.166: Higuchi model 
plot (CDPF7) in 0.1N HCl 
 
y = -0.1106x + 4.6372 
R² = 0.9842 
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Figure 6.167: Hixon Crowell 
model plot (CDPF7) in 0.1N 
HCl 
 
y = 0.7337x + 0.9695 
R² = 0.9599 
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Figure 6.168:Kosmeyer & Pepas plot (CDPF7) in 
0.1N HCl 
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Table 6.49: Drug release kinetics computation of pronoisome formulation 
CDPF7 in PBS pH 6.8 
Time 
Hours 
Cumulativ
e % drug 
released 
Log 
cum % 
drug 
release 
% Drug 
remain 
Log % 
drug 
remain 
Sq.Rt.  
Time 
Log 
Time 
Cub. Rt. 
Unreleased 
drug 
fraction 
0 0 - 100 2.0 0 - 4.64 
0.15 2.43 0.39 97.57 1.99 0.39 -0.82 4.60 
0.45 3.32 0.52 96.68 1.99 0.67 -0.35 4.59 
1 5.14 0.71 94.86 1.98 1.0 0 4.56 
2 8.52 0.93 91.48 1.96 1.41 0.30 4.51 
3 13.45 1.13 86.55 1.94 1.73 0.48 4.42 
4 16.14 1.21 83.86 1.92 2.0 0.60 4.38 
5 34.32 1.54 65.68 1.82 2.24 0.69 4.03 
6 40.41 1.61 59.59 1.78 2.45 0.78 3.91 
10 54.29 1.73 45.71 1.66 3.16 1.0 3.58 
12 61.21 1.79 38.79 1.59 3.46 1.08 3.39 
16 67.3 1.83 32.7 1.51 4.0 1.20 3.19 
18 74.34 1.87 25.66 1.41 4.24 1.26 2.95 
20 79.35 1.90 20.65 1.31 4.47 1.30 2.74 
22 87.56 1.94 12.44 1.09 4.69 1.34 2.32 
24 92.12 1.96 7.88 0.90 4.89 1.38 1.99 
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y = 3.8812x + 5.6419 
R² = 0.9604 
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Figure 6.169:Zero order plot 
(CDPF7) in PBS pH 6.8 
y = -0.04x + 2.0388 
R² = 0.9582 
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Figure 6.170: First order plot 
(CDPF7) in PBS pH 6.8 
y = 20.375x - 12.038 
R² = 0.9659 
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Figure 6.171: Higuchi model 
plot (CDPF7) in PBS pH 6.8 
y = -0.1029x + 4.6603 
R² = 0.9843 
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Figure 6.172: Hixon Crowell 
model plot (CDPF7) in PBS pH 
6.8 
y = 0.8122x + 0.8524 
R² = 0.9623 
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Figure 6.173:Kosmeyer & Pepas plot (CDPF7) in 
PBS pH 6.8 
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6.2.8. Lyophilization of optimized noisome formulations: 
CDNF7 formulation with tween 60 as surfactant and dicetyl phosphate as 
charge inducer was lyophilized for promoting the stability during storage and 
forthermalanalysis using differential scanning calorimetry. But after Lyophilization 
the freeze dried niosome was found to be not flowing and sticky. 
6.2.9. Fourier transform infrared FTIR spectroscopy 
 
Figure 6.174 : FT-IR Spectra of optimized niosome formulation CDNF7 
 
Figure 6.175 : FT-IR Spectra of optimized proniosome formulation CDPF7 
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Table 6.50: FTIR data of optimized noisome and proniosome formulation. 
Functional group Region 
Wave numbers in CM
-1
 
CDNF7 CDPF7 
NH2 group 3200-3400 3391.03 3421.10 
OH-Stretching 2900-2950 2927.41 2923.56 
C=N Stretching 1400-1450 1452.74 1460.81 
C=C Stretching 1340-1380 1360.53 1355.71 
CH2 group 1100-1150 1148.4 1103.08 
C-H Stretching 1010-1040 1044.26 1035.59 
 
6.2.10.Differential scanning calorimetry reports of optimized noisome and 
proniosome formulation: 
 
Figure 6.176: DSC spectrum of pure drug abacavir sulphate 
 
Figure6.177: DSC spectrum of optimized proniosome formulation 
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Figure 6.178: DSC spectrum of maltodextrin 
 
Figure 6.179: DSC spectrum of Cholesterol 
 
 Figure 6.180: DSC spectrum of Tween 60 
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Figure 6.181: DSC spectrum of optimized niosome formulation 
 
Figure6.182: DSC spectrum of blank niosome formulation 
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6.2.11. X-ray diffractometry spectrum of niosome, proniosome formulations and 
excipients: 
 
Figure 6.183: X-ray diffractometry spectrum of niosome, proniosome 
formulations and excipients 
 
6.2.12. Osmotic shock studies  
Table 6.51: Effect of osmotic shock on abacavir sulphate niosome formulations.. 
Formulation 
Average Vesicle size 
PBS pH 7.4 
Hypertonic      
1 mol/L NaI 
Isotonic 0.9% 
NaCl 
Hypotonic 
0.5%NaCl 
BNF7 174.4 ±13.712 Shrunk 181.7±10.347 207.8 ±16.579 
DNF7 179.4 ±7.619 Shrunk 188.8 ±8.302 214.7 ±23.232 
CBNF7 179.1 ±7.427 Shrunk 185.7 ±9.493 208.3±19.354 
CDNF7 182.1 ±16.690 Shrunk 189.4±12.646 212.5±15.989 
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Table 6.52: Effect of osmotic shock on abacavir sulphate proniosome 
formulations 
Formulation 
Average Vesicle size 
PBS pH 7.4 
Hypertonic      
1 mol/L NaI 
Isotonic 0.9% 
NaCl 
Hypotonic 
0.5%NaCl 
BPF7 169.3 ±10.157 Shrunk 176.5 ±10.950 200.9 ±18.551 
DPF7 172.7 ±10.797 Shrunk 81.3 ±12.482 206.9 ±16.151 
CBPF7 171.4 ±6.047 Shrunk 176.2 ±10.627 197.4 ±15.615 
CDPF7 175.0 ±5.122 Shrunk 182.7 ±8.059 203.0 ±10.104 
 
6.2.13. Micromeritic properties: 
Table 6.53: Micromeritic properties of proniosome formulations 
Formulation Angle of repose CI HR 
Abacavir 
Sulphate 
56.88 ±0.265 35.23 ±0.914 1.54 ±0.022 
Maltodextrin 38.23 ±1.589 16.95 ±0.619 1.20 ±0.009 
DPF1 32.09 ±1.906 13.59 ±1.259 1.16 ±0.017 
DPF2 29.8 ±1.419 7.86 ±1.247 1.09 ±0.002 
DPF3 27.91±1.183 7.15 ±0.170 1.08 ±0.002 
DPF4 31.01±0.572 13.87 ±0.681 1.16 ±0.009 
DPF5 32.66 ±1.040 13.85 ±0.183 1.16 ±0.003 
DPF6 32.63 ±1.392 12.62 ±1.506 1.14 ±0.019 
DPF7 31.42 ±1.136 14.29 ±0.340 1.17 ±0.005 
DPF8 31.92 ±1.141 12.68 ±1.109 1.15 ±0.015 
CDPF1 32.31±1.649 13.29 ±1.448 1.15 ±0.019 
CDPF2 28.36±0.849 8.47 ±1.434 1.09 ±0.017 
CDPF3 28.51±1.054 7.92 ±1.199 1.09 ±0.014 
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CDPF4 31.84 ±0.787 12.61 ±1.461 1.14 ±0.019 
CDPF5 32.09 ±1.426 12.87 ±1.083 1.15 ±0.014 
CDPF6 33.33 ±1.296 13.07 ±1.261 1.15 ±0.017 
CDPF7 32.43 ±0.866 13.44 ±0.465 1.16 ±0.006 
CDPF8 31.66 ±1.363 11.84 ±1.050 1.13 ±0.014 
 
6.2.14. Scanning electron microscopy SEM: 
 
Figure 6.184: SEM image of maltodextrin  
 
Figure 6.185: SEM image of optimized proniosome formulation CDPF7 
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6.2.15. Stability study: 
Table 6.54: Stability study data of optimized noisome formulation 
Temperature Refrigeration temperature Room Temperature 
Sampling 
period 
Initial 
1
st
  
month 
2
nd
  
month 
3
rd
 
month 
1
st
  
month 
2
nd
  
month 
3
rd
 
month 
Percentage 
Drug 
retained 
99.25 
±0.708 
98.23 
±1.854 
97.70 
±1.268 
96.91 
±1.591 
97.90 
±1.078 
95.67 
±1.297 
93.75 
±0.972 
Percentage 
drug 
Encapsulated 
83.02 
±1.085 
80.97 
±1.325 
79.54 
±0.891 
78.65 
±1.532 
74.75 
±1.311 
65.52 
±1.925 
53.42 
±1.565 
Vesicle Size 
182.1 
±16.69 
187.03 
±11.83 
192.11 
±14.512 
200.29 
±17.045 
198.31 
±17.788 
215.71 
±16.691 
229.22 
±21.746 
 
Table 6.55: Stability study data of optimized proniosome formulation 
Temperature 
Refrigerator 
Temperature 2-8°C 
Room Temperature 
25±2°C 
Elevated Temperature 
45°±2°C 
Sampling 
period 
1 
month 
2 
months 
3 
months 
1 
month 
2 
months 
3 
months 
1 
month 
2 
months 
3 
months 
Percentage 
Drug 
retained 
99.23 
±0.89 
98.71 
±0.80 
98.55 
±1.17 
98.56 
±0.81 
98.12 
±0.72 
97.69 
±0.98 
98.66 
±0.92 
95.13 
 ± 1.35 
90.98 
±1.45 
Percentage 
drug 
Encapsulated 
84.69 
±1.14 
84.07 
±1.45 
83.16 
±1.24 
83.39 
±0.81 
81.89 
±1.18 
80.08 
±1.40 
80.52 
±1.57 
73.42 
±1.63 
68.02 
±2.03 
 
Vesicle Size 
178.63 
±7.16 
182.5 
±8.18 
188.97 
±8.91 
182.97 
±8.91 
189.67 
±7.83 
196.83 
±11.95 
189.67 
±12.24 
202.63 
±17.38 
224.4 
±18.04 
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6.3. Pharmacokinetics studies: 
Construction of calibration curve of abacavir sulphate for pharmacokinetic 
study by HPLC method. 
 
Figure 6.186: HPLC peak for 1 µg/ml concentration abacavir sulphate. 
 
Figure 6.187: HPLC peak for 2 µg/ml concentration abacavir sulphate. 
 
Figure 6.188: HPLC peak for 5 µg/ml concentration abacavir sulphate. 
Chapter 6                                                                                                    Results and Analysis 
 
Department of Pharmaceutics                           229        J.K.K Nattraja College of Pharmacy 
 
 
Figure 6.189: HPLC peak for 10 µg/ml concentration abacavir sulphate. 
 
 
Figure 6.190: HPLC peak for 25 µg/ml concentration abacavir sulphate. 
 
Figure 6.191: HPLC peak for 50 µg/ml concentration abacavir sulphate. 
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Table 6.56: Calibration curve data of abacavir sulphate for pharmacokinetic 
study 
Std code Conc µg/ml Peak area mAU*Sec 
CS1 1 16.6 
CS2 2 34.59 
CS3 5 80.73 
CS4 10 157.47 
CS5 25 385.41 
CS6 50 763.55 
 
 
Figure 6. 192: Calibration curve of abacavir sulphate for pharmacokinetic study 
Table6.57: Plasma concentration of abacavir sulphate 
Time 
Hours 
Pure drug CBPF7 CDNF7 CDPF7 
0 0 0 0 0 
0.5 0.028±0.008 0.008±0.002 0.043±0.003 0.025±0.008 
1 0.086±0.004 0.003±0.003 0.175±0.008 0.061±0.008 
2 0.399±0.008 0.001±0.001 0.899±0.007 0.358±0.009 
4 0.058±0.007 0.005±0.002 1.288±0.006 1.499±0.013 
8 0.053±0.005 0.005±0.006 0.246±0.005 0.653±0.007 
12 0.015±0.004 0.001±0.001 0.227±0.006 0.363±0.005 
24 0.003±0.001 0.002±0.001 0.025±0.004 0.071±0.008 
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 Figure 6.193: Pharmacokinetic study: Plasma concentration – time curve 
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Table 6.58: Mean pharmacokinetic parameters of abacavir sulphate 
Parameters Unit Pure drug CDNF7 CDPF7 
t1/2 H 1.441051851 2.41129389 3.441993904 
Tmax H 2.034284745 3.400322544 4.884667892 
Cmax μg/ml 0.211671717 0.894528953 0.889805815 
AUC 0-t μg/ml*h 1.170654405 8.212713148 11.3023605 
AUC 0-inf μg/ml*h 1.17076833 8.270296644 11.81634851 
AUMC μg/ml*h^2 4.764842792 56.26270954 115.4586208 
MRT H 4.069842574 6.802985669 9.771091354 
 
6.4. Anti HIV and cytotoxicity assay: 
Table 6.59: Anti HIV and cytotoxicity assay report 
Formulation  
Cytotoxicity 
assayCC50 
TZMbl Screening 
AssayIC50 
TZMbl Screening 
AssayIC50 
CA with HIV1         
X4 tropic 
CA with HIV1               
R5 tropic  
CDPF7 22.6 27.05 0.95 
Pure abacavir sulphate 172 23.18 0.795 
 
 
Chapter 7                                                                                                                    Discussion 
 
Department of Pharmaceutics                           233        J.K.K Nattraja College of Pharmacy 
 
7. DISCUSSION 
7.1. Preformulation studies: 
From the prepared comparative table 6.1, the drugs such as abacavir, 
zidoudine, lamividine and staudine were found to be suitable drug for proniosome 
formulations. But noisome formulations were already formulated for zidoudine, 
lamividine and staudine. Hence the challenge was taken to encapsulate hydrophililic 
antiretroviral drug abacavir sulphate in maltodextrin based novel proniosome 
formulations. 
Calibration curve was constructed by plotting 2-12µg/ml standard 
concentration of abacavir sulphate against absorbance in phosphate buffer pH 7.4, 
phosphate buffer pH 6.8 and 0.1N HCl at λ max of 285nm, 285nm and 295nm 
respectively using UV- visible spectrophotometer. Straight lines generated were 
facilitated to determine the concentration of drug by Y=mx+c equation (Y- 
absorbance, m-slope, x-concentration). The calibration curve showed the linearity 
with R
2
 value of 0.998 in phosphate buffer pH 7.4 & pH 6.8 and 0.999 in 0.1N 
Hydrochloric acid.  The values of R
2 
evidenced that it obeys Beer-Lamberts law. 
The results of preformulation studies like organoleptic properties, particle size 
analysis, solubility studies, partition coefficient and FT-IR spectrum were proved the 
characteristics of pure antiretroviral drug abacavir sulphate. 
From the result of drug excipient compatibility study, the chosen excipients 
did not show any characteristic changes. The FT-IR spectrum of all physical mixtures 
showed the characteristic peaks of abacavir sulphate, thus confirming that no reaction 
of drug occurred with the excipients of the physical mixture. Accordingly it was 
proved that the excipients selected for noisome formulations were compatible with 
abacavir sulphate. 
7.2. Formulation of Abacavir sulphate noisome and proniosome formulations: 
The present study was undertaken to formulate noisome formulations for 
antiviral drug abacavir sulphate by thin film hydration method and to formulate 
pronoisome carrier system by slurry method using commonly available surfactants 
like spans and tweens. From preformulation studies, 250:250μM ratio concentration 
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of surfactant:cholesterol was fixed for present formulations. The proniosome 
formulation by slurry method was found to be convenient method than the 
conventional noisome formulations prepared by thin film hydration method. 
The major difficulty found in thin film hydration method in the preparation of 
conventional noisome is requirement of additional time for the entire hydration and 
prevent the loss of surfactant-lipid film still after the hydration period of 1 hour at 
60°C. This problem is due to the conversion of thin film to viscous and adhere to the 
surface of the round bottom flask after the initial hydration.  
The formulation of proniosomes by slurry method was found to be more 
convenient and the hydration of proniosome to niosome had taken short period of 
time (2 minutes at 80°C) in vortex mixture. The convenience during hydration of 
proniosome is due to the more surface area of the surfactant–lipid film that occurs 
over t-he water soluble carrier particle maltodextrin. 
7.3. Characterization of abacavir sulphate noisome and proniosome formulations 
Most of the optical microscopy images of noisome and proniosome derived 
niosome vesicles are multilamellar, discrete and spherical with sharp boundaries 
without much aggregation. Some irregularities of noisome vesicles that monitored 
under the microscopic study may be due to drying process under ordinary 
environmental condition. 
The size of noisome and proniosome derived vesicles were found to be in 
acceptable limit. The vesicle size of conventional niosomes formulated using tween as 
surfactant was larger while compared with that of span,this is due to higher 
hydrophobicity of spans than tweens. It showed that increasing in hydrophobicity 
reduces surface energy of surfactants ensuing in smaller vesicle size. The size range 
was found to be 135.0±8.837 to 183.2±13.390 (without DCP) and from 137.4±7.267 
to 185.0±13.402 (with DCP) formulations. Vesicle size increases in the following 
manner Span 80<Span60<Span40<Span20<Tween80<Tween20<Tween60<Tween40. 
This might be explained on the basis of HLB value and alkyl chain length of 
surfactants incorporated in formulation. In span based niosomes HLB value dominate 
the alkyl chain length of surfactant and the vesicle size was increased with HLB value 
because hydrophilicity of niosomes increased with HLB value. While increased the 
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hydrophilicity, the water intake of noisome bilayer will increased and resulting in 
larger vesicles.
202 
In tween based niosomes, due to the least difference between the 
HLB values of surfactance, the length of the alkyl chain also contributed their role in 
the size of the vesicle. Thus tween 60 (HLB 14.9) formulations exhibited larger 
vesicles than that of tween 20 (HLB 16.7) formulations. As seen on table 6.10, the 
presence of DCP in formulation was found to be considerably efficient on increasing 
the noisome vesicle size (P=0.81). Incorporation of a anionic surfactant such as DCP 
into the niosome membrane leads water efflux into the bilayer and increases 
separation between bilayers.
68
 
The mean vesicle size of proniosome derived vesicles is presented in table 
6.11. The niosomes formed from blank formulations were smaller (not statistically 
significant P=0.62>0.05) in size than niosomes formed from drug loaded 
formulations. In case of charge inducer incorporated formulations the size of blank 
formulations and the drug loaded formulations were in the range of 128.6 ±10.79 to 
175.8 ±9.94 and 131.8 ±8.45 to 178.8 ±6.87 respectively. In case of the formulations 
without charge inducer the size of blank and drug loaded formulations were in the 
range of 124.7±11.351 to 172.7±8.046 and 129.1±15.808 to 176.2±9.735 respectively. 
The liaison observed between blank and drug loaded formulations has been attributed 
the role of drug encapsulation in vesicle size. The noisome vesicles produced from 
span proniosomes were extremely statistically significant (P=0.0001<0.05) smaller in 
size than the vesicles produced from tween proniosomes. Among the 32 proniosome 
formulations smallest mean size (124.7±11.35) was observed in the case of span 80 
based blank formulation without charge inducer whereas niosomes were of bigger 
size (178.8 nm ± 6.87) in the case of tween 40 based charge inducer incorporated 
proniosomes. The smaller vesicles produced from span formulations might be due to 
low HLB value, higher hydrophobicity, and low surfaceenergy of span series 
surfactants. Furthermore increasing alkyl chain length and hydrophilicity of 
surfactants may be increase the vesicle size of proniosome derived niosomes. 
Vesicle size analysis of abacavir sulphate niosome and proniosome 
preparations showed that the conventionally prepared niosomes are not statistically 
significant (P=0.1105>0.05) larger in vesicle size than the proniosome derived 
niosomes. 
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The values of zeta potential for all noisome formulations were found in range 
of -2.04 ±0.477 to -44.8 ±1.206. The vesicles formulated with tween formulations 
were found to have the less zeta values, ranging from -2.04 ±0.477 to -3.69 ±0.539 
(without DCP) and -34.2 ±0.656 to-38.5 ±0.751 (with DCP) compared to the noisome 
vesicles formulated with span, showing elevated zeta values ranging from -26.5 
±1.401 to -33.6±0.611 (without DCP) and -41.7 ±1.305 to -44.8 ±1.206 (with DCP). 
The charges of the noisome vesicles were found to be more negative (> -30 mV) in 
the presence of DCP as it is frequently used negative charge inducer. Statistically 
significant changes were observed between DCP incorporated formulations and the 
formulations without DCP (P=0.0001<0.05) The values of zeta potential showed that 
the noisomes prepared with charge inducer have sufficient charge to inhibit 
aggregation of vesicles due to electric repulsion and these outcome proved the 
effectual stability of noisome vesicles. 
The data of zeta potential of the proniosomal   formulations were found in 
range of -33.0 ±1.17 to -44.3 ±1.74 for charge inducer incorporated formulations and 
it was found in the range of -2.23±0.521 to 32.5±0.833 in the formulations without 
charge inducer. The vesicles formulated with span formulations were found to have 
the more zeta values, ranging from -26.5±0.862 to -44.3 ±1.74 compared to the 
pronoisome vesicles formulated with tween, showing extremely statistically 
significant (P=0.0010<0.05) low zeta values ranging from 2.23 ±0.52 to -38.1±1.04. 
The charges of the pronoisome derived vesicles were found to be more negative (> -
30 mV) in charge inducer added formulations due to the presence of anionic charge 
inducer DCP. It indicates the stability of vesicles with sufficient electric repulsion. 
The zeta potential values were not shown statistically significant difference 
(P=0.88>0.05) between noisome and proniosome formulations. 
Uniformity of noisome and proniosome vesicle sizes were analysed by 
determining poly dispersity index. As shown in table 6.10 and table 6.11, PDI of the 
noisome formulations ranged from 0.182 ±0.016 to 0.469 ±0.045 and proniosome 
formulation from 0.331±0.046 to 0.404±0.061. These results implied that the vesicles 
were comparatively homogenous in both noisome and proniosome formulations.  
The ratio of the mass of noisome associated abacavir sulphate to the total mass 
of abacavir sulphate was expressed as percentage in percentage encapsulation 
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efficacy. Encapsulation efficiency was analyzed for all the noisome and  proniosome 
formulations to identify the most excellent in terms of encapsulation efficiency after 
subtracting blank interference and the data are presented in tables 6.12 & 6.13 and 
figures 6.42 & 6.43. 
Encapsulation efficacy of two categories of formulations such as formulations 
with charge inducer and the formulations without charge inducer in equimolar (1:1) 
concentration of surfactant/cholesterol in both noisome and proniosome systems were 
compared. 
The data shows that the encapsulation efficiency of abacavir sulphate was 
higher in the charge inducer incorporated formulations. The EE of DCP added 
noisome formulation (CDNF7) was significantly differing (p=0.04<0.05)) from the 
formulation without DCP (DNF7) and the proniosome formulation containing DCP 
(CDPF7) was significantly differing (p=0.03<0.05) from the formulation not 
containing DCP (DPF7). This may be due to the reality that cholesterol in the 
existence of DCP more effectively able to stabilize the organization of the niosomal 
vesicular membrane in 1:1 molar ratio of non-ionic surfactant and cholesterol, 
(coinside the result of gentamycin)
85 
and  also due to the two cetyl chains present in 
the dicetyl phosphate.
203 
Surfactant is an important element in the construction of noisome vesicles and 
the variation in the surfactants may affect the encapsulation efficiency. Niosome  and 
proniosome formulations formulated with non-ionic surfactants of alkyl esters 
including tween (polyoxy ethylene sorbitan esters) and span (sorbitan esters) were 
used to evaluate the encapsulation of abacavir sulphate. Hence the encapsulation 
efficiency data also shows the effect of various sorbitan fatty acid esters and polyoxy 
ethylene sorbitan fatty acid esters on the encapsulation of abacavir sulphate in 
niosomal vesicular system.Encapsulation efficiency of niosome and proniosome 
formulations formed from tween series were exhibited high value than that of from 
span series because of larger vesicle size and highly hydrophilic drugs like abacavir 
sulphate are encapsulated mostly within the polar head facing hydrophilic region. The 
surfactant tween is the framework of span molecule with 20 molecules of ethylene 
oxide. Accordingly the tween molecules showing more hydrophilicity and larger 
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hydrophilic head region than span molecule.
148
 Thus water soluble drug abacavir 
sulphate greatly encapsulated in the polar head facing hydrophilic region.  
The results of encapsulation efficiency determination indicated that 
formulations containing tween-60 with DCP (CDNF7: 83.02 ±1.085) and (CDPF7: 
85.02% ±1.560) had efficient encapsulation efficiency than those formulations 
containing other surfactants. This is may be due to the presence of larger hydrophilic 
head region as well as longer hydrophobic alkyl chain. This longer alkyl chain 
prevents the leakage of encapsulated drug from the noisome and proniosome derived 
niosome vesicles. In the same time the noisome vesicles prepared with span 80 
showed least encapsulation efficiency (DNF4:29.43±1.692) and (DPF4: 33.49 
±0.978) even the presence of same head group in all span series surfactants. This may 
be due to the lowest HLB value, presence of unsaturated, bended alkyl chain and 
absence of DCP. Lowest HLB value leads to small vesicle size and bended, double 
bonded alkyl chain prevent the tight binding of adjacent molecules during the 
membrane of noisome vesicle formation. 
Furthermore the abacavir sulphate proniosome formulations had shown 
statistically non significant (P=0.62>0.05) higher encapsulation efficiency than 
noisome formulations. This may be due to the short hydration period of proniosome 
formulation than that of the time consuming hydration period of noisome 
formulations. 
Uniformity in abacavir sulphate content of niosomal dispersion (DNF1 to 
CDNF8) and proniosomal formulations (DPF1 to CDPF8) were confirmed to ensure 
uniformity in dosages. The drug content was found to be in the range of 98.62% 
(±0.863) to 99.97% (±0.740) in noisome formulations and 99.01% ±0.949 to 
100.17%±0.766 in proniosome formulattons.  The results are reported in table 6.14 
and 6.15.  The differences in drug content among CDNF7 and CDPF7 were non 
significant (P=0.37>0.05). 
The morphology of noisome vesicles investigated using Transmission electron 
microscopy. Photograph of TEM depicted in figure 6.44 reveals that the niosomal 
vesicles appear as spherical nano vesicles. 
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Invitro drug release studies are habitually performed to predict how a drug delivery 
system might work in an ideal situation as well as provide some signs of its invivo 
performance since drug release indicates the amount of drug existing for 
absorption.
204
 The release study   was carried out for all the abacavir sulphate loaded 
noisome and proniosome formulations in 0.1N HCl and phosphate buffer solution pH 
6.8 as shown in the tables 6.16 -6. 23 and graphically represented in figures 6.45-6.53. 
The invitro drug release was affected by the pH of the drug release medium. 
The drug release in 0.1N HCl was slightly higher than that in the phosphate buffer 
solution pH 6.8. The increasing drug release as the pH decrease is may be due to pH 
dependent solubility of abacavir sulphate. The release of abacavir sulphate from all 
noisome formulations was actually biphasic process where a primary rapid drug 
release phase was observed in the first 2 hours where about 19.67±1.754 to 
82.47±2.205% of the abacavir sulphate was released from various niosome 
preparations and followed by a slow drug release phase. The drug release observed in 
the first 2 hours in case of proniosome formulations was 8.52±2.132–43.49±2.173. 
The variation observed between the abacavir release from noisome and proniosme 
formulations, confirming the superiority of proniosomes than niosomes and the 
proniosome granules loaded into the capsule shell for release study and the time taken 
in the conversion of proniosome into niosomes may contribute the slow initial release 
of abacavir from proniosomes. The early rapid phase found in niosomes might be 
owing to the release of unencapsulated drug and desorption of abacavir sulphate from 
the surface of noisome vesicles while the drug release in the subsequent time 
consuming phase was limited by diffusion through the niosomal bilayers.
146,205 
This 
biphasic drug release profile approved with the formerly published studies.
14,206
 
By comparing the drug release data of abacavir sulphate noisome and 
proniosome formulations containing dicetyl phosphate (DCP) with that of drug loaded 
DCP free formulations, it is cleared that the drug release is slow down in the presence 
of DCP. This authenticates that DCP stabilizes the structure of abacavir sulphate 
loaded niosomal and proniosome derived niosomal membrane and turns into less 
permeable. The formulation with DCP (CDNF7) showed not quite statistically 
significant slow drug release (P=0.0526<0.05) with formulation without DCP 
(DNF7). As well as the proniosomal formulation with DCP CDNF7) showed non 
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statistically significant slow drug release (P=0.28<0.05) with formulation without 
DCP (DNF7) 
The impact in the abacavir sulphate release varies according to the change in 
composition of the non-ionic surfactant. The amount of abacavir sulphate released 
from different niosomal and proniosomal  formulations were found in the array of 
DNF4 > DNF1 > DNF8> DNF2 > DNF5 > DNF3> DNF6> DNF7 and DPF4 > DPF1 
> DPF8> DPF2 > DPF5 > DPF3> DPF6> DPF7 respectively.  This may be due to the 
inverse relationship between encapsulation efficiency and drug release, ie, higher 
encapsulation efficiency slower the drug release. Invitro drug release from tween 60 
formulation with DCP was found to be prolonged and span 80 formulation without 
DCP showed rapid release. In noisomal systems tween 60 formulation (CDNF7) 
showed prolonged drug release of 85.59% (±1.311) after 24 hours and span 80 
formulation (CDNF4) showed rapid release of 99.26% (±1.248) after 20 hours. In 
proniosomal system CDPF7 formulation showed prolonged drug release of 
94.46%(±1.396) after 24 hours and CDPF4 formulation showed 99.52(±1.263) after 
20 hours.  
Another suitable explanation of these results is connected to the ability of 
cholesterol to close down the gel to liquid phase transition of vesicular system and 
thus improved the encapsulation of hydrophilic drug abacavir sulphate. Furthermore it 
reduces the niosomal and proniosome derived niosomal vesicle membrane fluidity 
and improves the rigidity by compacting the packing of surfactants into the bilayer 
membranes. 
Invitro release was found to be appreciable for proniosome formulations as 
compared with noisome formulations due to their limited initial release and the 
gradual improvement in further release. The optimized proniosome formulation had 
shown the prolonged in vitro release of 94.46% ±1.396 in 0.1N HCl and optimized 
noisome formulation had shown the release of 85.59% (±1.311) in the same pH. 
The in-vitro drug release data was applied to different kinetic models to 
predict the drug release kinetic mechanism. Out of 16 drug loaded noisomal and  16 
proniosomal formulations 12 desired formulations (DNF5, DNF6, DNF7, CDNF5, 
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CDNF6 and CDNF7) and  (DPF5, DPF6, DPF7, CDPF5, CDPF6 and CDPF7) were 
selected and taken forward for drug release kinetics study. 
For all the selected formulations, zero order (cumulative per cent drug release 
vs time), first (log percentage drug remaining vs time), Higuchi plot (cumulative per 
cent drug release vs square root of time), Hixson Crowell (cubic root of the 
unreleased fraction of the drug vs time) and Korsmeyer and Peppas model (log 
cumulative percentage of drug released vs. log time) were plotted separately. In each 
models, R
2
 value was determined from the graph and reported in tables 6.24 &6.25. 
While the R
2 
values of regression plots for zero order and first order were 
considered in noisome formulation, R
2
 values of zero order plots were found to be 
higher than first order plots in case of the noisome formulations without charge 
inducer and it was higher for first order plots in case of charge inducer incorporated 
formulations. Hence it is clear that the drug release from these abacavir sulphate 
niosomal formulations without and with charge inducer followed zero order kinetics 
and first order kinetics respectively. By incorporating drug release data in Higuchi as 
well as Erosion models, the R
2
 values of all the noisome formulations were found to 
be more for higuchi model. So all the abacavir sulphate noisome formulations in the 
studies were best expressed by higuchi’s classical diffusion equation. The linearity of 
graph indicated that the release model was diffusion controlled.  
To additional confirmation of the exact drug release mechanism, the data was 
incorporated in to kores meyer- peppas model and the drug release mechanism was 
indicated based on the value of exponent ‘n’. For all the niosomal formulations the 
drug release exponent ‘n’ value found near to 0.5. This shows the drug released from 
all the niosomal formulations followed fickian diffusion. 
When considered the R
2 
value of zero order and first order plots of proniosome 
formulations, the values found from the formulations DPF5, DPF6, CDPF5 and 
CDPF6 were best fit with first order kinetics. The tween 60 based formulations (DPF7 
& CDPF7) were highly fit with zero order kinetics. Thezero order plots confirmed the 
zero order abacavir release characteristics of the optimized proniosome formulation 
(CDPF7), which was proved by the R
2
 value which found to be closer to 1. By 
incorporating release data in Higuchi and Hixon  models, the R
2 
values of all the 
formulations were found to be closer to 1 in both models. Thus the plot indicated that 
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the drug release follow combined desorption and diffusion mechanism.The in vitro 
kinetic was subjected to Peppa’s model, all the n values ranged from 0.515 to 0.812 
(0.5 < n < 0.89) revealed the truth that the abacavir release mechanism from 
proniosomes  follows non – fickian. 
The optimized noisome formulation (CDNF7) was lyophilized for promoting 
the stability during storage. The solid samples are more convenient to use to identify 
the nature of the drug in formulation by differential scanning calorimetry, X-Ray 
diffraction spectroscopy and FTIR spectrocpy. Thus lyophilized niosomes are used 
for the above mentioned analytical studies to confirm the stability of drug in 
formulation. Even after lyophilization, the noisome formulation found to be not 
flowing and sticky due to the mixture of tween 60 and cholesterol.    
FT-IR Spectra of pure abacavir sulphate and optimized formulations were 
recorded. The FTIR spectra of pure abacavir sulphat, optimized noisome and 
proniosome formulation are shown in figures 6.5, 6.174 & 6.175 respectively. The 
presence of peaks at 3220.54cm
-1
 (NH2 group), 2918.73cm
-1
 (OH-stretching), 
2866.67cm-1(C-H stretching), 1405.85cm
-1
(C=N Stretching), 1369.21cm
-1
 (C=C 
stretching), 1105.98cm
-1
(CH2 group), 1028.80cm
-1
 (C-H stretching) were 
characteristic to the pure abacavir sulphate. The characteristic peaks due to pure 
abacavir sulphate have appeared in optimized noisome and proniosome formulations 
with slight shifting indicating the absence of chemical interaction between abacavir 
sulphate and excipients. It also confirmed that the stability of drug in formulation. 
Endothermic peak of pure abacavir sulphate was observed at 228
o
C in DSC 
spectrum. In the noisome and proniosome formulations the endothermic peak of 
abacavir sulphate was disappeared, indicating that drug is molecularly dispersed in 
both formulations.  
XRD diffractograms of pure abacavir sulphate, optimized abacavir sulphate 
encapsulated niosomes, optimized abacavir sulphate encapsulated proniosomes, blank 
niosomes and proniosome excipients such as tween 60, maltodextrin and cholesterol 
were  presented in figure 6.183. The diffractograms point out the loss of crystallinity 
of abacavir sulphate after encapsulation. The diffraction patterns of abacavir sulphate 
illustrated many peaks around 2 of 10-30°, whereas a high intensity peak at 2=21° 
symbolizes its crystallinity. On the other hand, these peaks have vanished in the 
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abacavir sulphate encapsulated niosomes and proniosomes. But only peaks found in 
the formulation excipients and blank formulation were appeared, proving that drug 
abacavir sulphate is molecularly dispersed or encapsulated in formulation and its 
crystal nature are not there in both noisome and proniosome formulations. 
The results of osmotic shock on optimized noisome and proniosome 
formulations of abacavir sulphate were presented in tables 6.51 & 6.52. It was found 
that shrinkage of vesicles occurred for abacavir sulphate noisome and proniosome 
formulations incubated in hypertonic solution whereas an increase in vesicle size 
occurred in hypotonic solution. When incubated in normal saline (0.9% NaCl), 
formulations showed a small increase in vesicle size. 
Angle of repose of maltodextrin and pure abacavir sulphate were compared 
with proniosome formulation of abacavir sulphate by fixed funnel method and the 
results of measurements are summarized in table 6.53. The results indicate that the 
angle of repose of dry proniosome powder is smaller than that of maltodextrin powder 
and the free flowing property of pure Abacavir sulphate was very poor. It shown the 
flow property of proniosome granules is appreciable than that of maltodextrin powder 
and pure drug. The compressibility index and hausner ratio results moreover 
supported to the angle of repose data. Thus further processing of dry proniosome 
granules as a tablets, capsules or beads is possible to provide suitable unit dosing. 
Shape and surface feature of proniosome were observed by scanning 
electronic microscopy analysis. Scanning electron microscopy of uncoated 
maltodextrin (figure 6.184) and dry best proniosome powder (figure 6.185) reveal that 
the difference in the exterior of the surfaces. The changes in surface morphology 
proved the coating of surfactant on carrier. 
From the stability study results of vesicular size, encapsulation efficiency and 
drug content of the optimised noisome and proniosome formulations it was concluded 
that the noisome formulation was stable at refrigeration temperature and proniosome 
formulation was quite stable at refrigeration temperature and room temperature as 
well. Therefore, the abacavir sulphate noisome formulation can be stored at 
refrigeration temperature and proniosomal formulations can be stored at either 
refrigeration or room temperature. Results for vesicular size, encapsulation efficiency 
and drug content are shown in tables 6.54 & 6.55. The outcome suggest that 
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proniosomes offered a more stable structure that could minimize the problems found 
about conventionally prepared niosomes like degradation by hydrolysis or 
sedimentation, oxidation, fusion and aggregation during storage. 
Pharmacokinetic parameters such as T max, C max, AUC, AUMC, MRT, t1/2, 
were determined by the software PK solver for pure drug, optimized noisome 
formulation and optimized proniosome formulation.
200,146
 All values were expressed 
in the mean ± standard deviations (SD). The obtained results were shown in the table 
6.57 and figure 6.193. The AUC of abacavir sulphate was increased from 1.171 
μg/ml*h to 8.213 μg/ml*h in niosome formulations and 11.302 μg/ml*h in 
proniosome formulations. The value of T max was shifted from 2.034 h to 3.4 h for 
noisome formulations and 4.885 h for proniosome formulations. Cmax of the abacavir 
sulphate was increased from 0.212 μg/ml to 0.895 μg/ml for noisome formulation and 
0.889 μg/ml for proniosome formulation. 
The abacavir sulphate pronisoms and abacavir sulphate solution containing 
equal concentration of active moiety abacavir were tested for determining anti-HIV 
activity against cell associated HIV using TZM-bl assay. In which, TZM-bl cells are 
infected with the pre-titrated HIV-1 UG070 & VB59 viruses. This assay is to 
demonstrate the ability of abacavir sulphate proniosome to inhibit HIV-1 replication 
and also order to qualitatively characterize abacavir intracellular delivery and the 
ability of proniosomes to be taken up by TZM-bl cell lines. 
Results showed that proniosomes of abacavir sulphate shows higher IC50 
value in TZM-bl screen assay than abacavir sulphate pure solution (table.6.59). This 
may be due to higher localization or higher delivery of abacavir sulphate inside the 
cell or HIV-target cells. The higher antiviral activity of abacavir pronisoms compared 
to abacavir sulphate pure drug may be attributed to the interactions of pronisoms with 
cells, which have been reported to enter cells by fusion or endocytosis.
207
 On the other 
hand, this higher antiviral activity might be attributed to the uptake of different 
colloidal carriers that is correlated to the membrane perturbation caused by the 
virus.
208
 
This indicates that developed systems provide a way for passive targeting, 
being particularly important due to the contribution of these cells to HIV transmission 
and infection. 
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The cell viability is determined using MTT assay using TZM-bl cell lines. The 
CC50value (the concentration of a compound at which 50% cells are viable) of 
abacavir solution and abacavir pronisoms was 22.6 µM and 172 µM respectively. 
From the results of the MTT assay, it was found that abacavir solution showed greater 
cytotoxicity of when compared to the abacavir sulphate encapsulated pronisoms. The 
cytotoxicity assay concluded that cytoxic effect of abacavir can be decreased by 
encapsulating the drug in the vesicular formulation. 
From the results of the evaluation parameters of both niosome and 
proniosome, the formulations made with Tween 60, cholesterol and DCP was found 
to be best formulation in encapsulation of abacavir sulphate and in case of better 
invitro drug release. Based on this, the formulation (CDNF7) was found to be best 
noisome formulation and (CDPF7) was found to be best pronoisome formulation than 
the other formulations. 
By comparing the proniosome formulations and niosome formulation, the 
proniosome formulation (CDPF7) was considered as the optimized formulations. 
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8. SUMMARY AND CONCLUSION 
Presently proniosomes have been studied by investigators as a preference of 
oral drug delivery system for antiretroviral drugs to provide a better oral 
bioavailability considering, targeted delivery, minimize the adverse effects, prolonged 
release of the niosome encapsulated medicaments through biological membrane and 
the stability of them.  
Acquird immune deficiency syndrome (AIDS) is the most common problem 
throughout the world because of rapid increase in the number of victims. HIV is an 
RNA retrovirus and infection occurs when a glycoprotein from HIV binds to surface 
receptors of T lymphocytes, monocytes, macrophages and dendritic cells leading to 
destruction of these cells. It causes slow progressive decrease in immune function 
resulting in opportunistic infections of various types.  
Nucleoside reverse trascriptors are the anti retoviral drugs useful in prolonging 
and improving the quality of life and postponding complications of acquired 
immunodeficiency syndrome.Abacavir sulphatewas approved in 1998 as a nucleoside 
reverse transcriptase inhibitor.This guanosine analogue is a clinically potent ARV 
drug.Rapid reduction in plasma HIV –RNA count and rapid rise in CD4 cell count has 
been noted when abacavir was given to AIDS patient. 
Proniosomes evidenced to be the potential carriers for proficient oral delivery 
of hydrophilic and lipophilic drugs. Henceforth an attempt was made toencapsulate 
the hydrophilic drug abacavir sulphate to prolong the drug release, reduce the drug 
related adverse effect and hypersensitivity reactions. Preformulation studies were 
accomplished to formulate the stable abacavir sulphate noisome and proniosome 
formulations. Abacavir sulphate loaded niosomes were formulated by thin film 
hydration method and maltodextrin based proniosomes were prepared by slurry 
method with different surfactants andcholesterol. The formulation of proniosomes by 
slurry method was found to be more convenient than the preparation of conventional 
niosomes. 
The prepared noisome formulations were evaluated for vesicle formation, 
vesicle size, size distribution, zeta potential, entrapment efficiency and drug content. 
Inviro drug release study was carried out only for drug loaded formulation. The 
optimized formulation was evaluated for vesicle morphology by transmission electron 
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microscopy, fourier transform infrared (FTIR) spectroscopy, differential scanning 
calorimetry, X ray diffraction spectroscopy, osmotic shock studies and stability study. 
The proniosome powder formulations were evaluated for angle of repose, 
scanning electron microscopy, proniosome derived niosomes were evaluated for 
optical microscopic examination, vesicle size, size distribution, zeta-potential, 
percentage encapsulation efficiency, drug content andin vitro drug release. The 
optimized formulation was evaluated for differential scanning calorimetry, fourier 
transform infrared (FT-IR) spectroscopy, X- ray diffraction spectroscopy, osmotic 
shock studies, stability studies, in vivo pharmacokinetic study, and invitro anti HIV 
activity. The drug release kinetic mechanism was determined for 6 niosome 
formulations and 6 proniosome formulations. 
Optical microscopy images confirmed the vesicle formation of prepared 
abacavir sulphate noisome and proniosome formulations. Vesicle size analysis of 
abacavir sulphate niosome and proniosome preparations showed that the 
conventionally prepared niosomes are not statistically significant (P=0.1105>0.05) 
larger in vesicle size than the proniosome derived niosomes. The charges of the 
noisome and proniosome derived noisome vesicles were found to be more negative (> 
-30 mV) in the presence of dicetyl phosphate. The polydispersity index results 
implied that the vesicles were comparatively homogenous in both noisome and 
proniosome formulations. The proniosome formulation containing Tween 60 and 
DCP (CDPF7) which showed higher entrapment efficiency (85.02±1.560) and 
prolonged invitro releases of 94.46 (±1.396)% in 0.1 N HCl and 92.12 (±1.429)% in 
pH 6.8 phosphate buffer at the end of 24 hours was found to be best among all 
noisome and proniosome formulations. Uniformity in abacavir sulphate content of 
niosomal dispersion (DNF1 to CDNF8) and proniosomal formulations (DPF1 to 
CDPF8) were confirmed to ensure uniformity in dosages. The nano sized noisome 
vesicles were confirmed by transmission electron microscopy and surfactant 
cholesterol mixture coating on maltodextrin carrier in abacavir sulphate proniosome 
formulation was confirmed by scanning electron microscopy. The optimized noisome 
formulation (CDNF7) was lyophilized for promoting the stability during storage and 
further solid state analysis. 
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Fourier transform infrared (FTIR) spectroscopy,differential scanning 
calorimetry, X-ray diffractometry spectras revealed that the stability of abacavir 
sulphate formulation in both noisome and proniosome formulations. The results of 
osmotic shock on optimized noisome and proniosome formulations of abacavir 
sulphate proved the stability of vesicle size in isotonic solution. 
The angle of repose, compressibility index and hausner ratio of dry 
proniosome powder results supported to the free flowing property of all proniosome 
formulations. The stability study data illustrated that the noisome formulation was 
stable at refrigeration temperature and proniosome formulation was quite stable at 
refrigeration temperature and room temperature as well. 
The pharmacokinetic data obtained from invivo study shows better 
bioavailability of proniosome formulation when compared with pure abacavir 
sulphate and noisome formulation.  
The abacavir sulphate pronisoms and abacavir sulphate solution containing 
equal concentration of active moiety abacavir were tested for determining anti-HIV 
activity against cell associated HIV using TZM-bl assay. Results showed that 
proniosomal formulation were able to be rapidly localized  of abacavir inside the cell 
or HIV-target cells. The cytotoxicity assay concluded that cytoxic effect of abacavir 
can be decreased by encapsulating the drug in the vesicular formulation. 
On conclusion, the abacavir sulphate novel proniosome drug delivery system 
compared with conventional niosomes, represent a significant improvement in all 
evaluation parameters. To summarize the above mentioned outcomes, water soluble 
drug abacavir sulphate was fruitfully incorporated into proniosome powders with 
agreeable flow properties.  
The optimized proniosomal powder CDPF7, composed of CH: T60: DCP in 
micromolar ratio of 250:250:5 loaded on maltodextrin, showed abacavir EE% of 
nearly 85.02 % and vesicle size of 175.0 nm after reconstitution. The hydration of dry 
proniosome powder was found to be much easier than the long shaking process 
necessary to hydrate thin film in the conventional niosome preparation. This 
formulation provided prolonged dissolution profile due to the inclusion of drug into 
the vesicles.  
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Combined with the immense advantages the vesicular drug delivery systems 
invoked, the optimized formulation represents a predominantly attractive carrier for 
abacavir sulphate due to its confirmed stability along with the established ability to 
prolong drug release, enhancing oral bioavailability, improving anti HIV activity and 
as it is dry free flowing granule form, facilitates the possibility of comfortable unit 
dosing through further processing to make tablets and beads or capsules. 
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9. IMPACT OF THE STUDY 
 The main intention of the novel drug delivery research is to help the HIV 
infected patients by developing clinically secure and valuable formulation. 
 The research is expected to give a newer and safer antiretroviral proniosome 
formulation to rectify the demerits associated with the presentlly available 
conventional formulations. 
 Since viral replication is intracellular, antiviral drug must be highly selective. 
This specificity may be possible by proniosomal approach of antiretroviral 
drugs as it is targeted to the reticuloendothelial cells. 
 Proniosomal approaches of antiviral drug abacavirsulphate may not interfere 
with normal cellular functions of the host. 
 It possible to improve patient compliance and convenience due to lesser 
frequent drug administration. 
 Abacavir sulphate loaded proniosome formulation  may maximize the benefit 
of the drug simultaneously minimizing its undesirable effects.  
 Effectual nature of antiviral drug loaded proniosome drug delivery may do 
good to the patient medically and economically by minimizing hospital stay 
and improve the quality of AIDS patient. 
 Prolonged release of antiviral drugs from proniosome formulation expected to 
maintain the plasma concentration of drugs in between minimum inhibitory 
concentration and maximum safe concentration (therapeutic concentration). 
 Reducing dose of drug by formulating proniosome to achieve the expected 
drug concentration is very useful to the patients from some developing 
countries, where drug costs can account for 20% of an already meagre health 
budget. 
 Based on the above mentioned reasons such proniosome drug delivery system 
is presently needed for successful drug delivery in severe retroviral (HIV) 
infection. 
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